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Introduction
Uveal Melanoma
Brief overview
Uveal Melanomas (UMs) arise from melanocytes. This cell type originates from neural crest cells 
and thereby uveal melanomas share their origin with pheochromocytomas, neuroblastomas, 
paragangliomas and cutaneous melanomas, other tumors that develop from neural crest 
originating cells. 1-3 Uveal melanoma is the most common primary tumor in the eye with an 
incidence of approximately 7 per million every year in the Western World. In adults, 80 percent 
of all intraocular tumors are uveal melanomas. The mean age at diagnosis is 60 years. Most uveal 
melanomas arise in the ciliary body (23%), or the choroid (72%) and a small fraction originates 
in the iris (5%).4 Predispositions for UM are a light eye color, fair skin color and ability to tan, 
which are all related with a fair phenotype. Despite advances in treatment with enucleation, pre-
enucleation radiotherapy, stereotactic radiotherapy, brachytherapy, charged particle irradiation, 
thermo therapy and local eye wall resection, the mortality rate has not changed significantly. As 
many as 50% of all newly diagnosed patients will die from distant metastases, which are mainly 
located in the liver.5
Prognostic parameters
The clinical outcome of patients with uveal melanoma depends on the development of metastases. 
A number of clinical and histopathological parameters to predict the outcome of the disease have 
been described. The most widely used prognostic parameters are tumor diameter, involvement 
of the ciliary body, cell type, nucleolar size and tumor vascular patterns. Tumor diameter 
and nucleolar size correlate negatively with prognosis and also ciliary body involvement, the 
presence of epitheloid cells and vascularization indicate a poorer prognosis. Other prognostic 
factors associated with a poor prognosis are extrascleral growth, presence of tumor-infiltrating 
lymphocytes, older age and male gender.6, 7 However, the use of these parameters only is not 
conclusive; even combined, these parameters cannot provide a sound estimation of prognosis.
Molecular Tumor Cytogenetics
Different cytogenetic techniques have been applied to uveal melanoma in the search for 
candidate regions on chromosomes and, eventually, candidate genes related with poor prognosis 
or responsible for tumor initiation and development. With conventional karyotyping larger gains, 
deletions and translocations can be detected, but for analysis of more cryptic abnormalities and 
for higher resolution delineation, molecular cytogenetic techniques are indispensable. Molecular 
cytogenetic techniques that are nowadays widely used in studies on UM and a variety of other 
types of tumors are Fluorescence In Situ Hybridization (FISH), Spectral Karyotyping (SKY), 
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Comparative Genomic Hybridization (CGH) and Loss Of Heterozygosity (LOH) analysis with 
microsatellite markers.
FISH
With FISH specific translocations and gains and losses can be detected in both metaphase spreads 
and interphase nuclei. The technique is rapid, has a high specificity and makes it possible to 
detect gains and losses that are only present in smaller sub clones of the tumor.8, 9 Thereby, this 
technique is also of value in estimating tumor heterogeneity. In spite of heterogeneity, known to 
occur in UM, it is demonstrated that FISH results in Fine Needle Aspiration Biopsies (FNABs) are 
in agreement with the results from the main tumor.10 A drawback of FISH is that it only focuses 
on a very limited number of loci analyzed in a single experiment.
SKY
With SKY DNA of all chromosomes are differentially labeled with a combination of fluorochromes. 
Hybridization of the labeled DNA to metaphase spreads of the tumor and visualization using 
spectral imaging leads to a separate color for each chromosome. In this way the origin of derivative 
chromosomes can be discerned. This technique has been used to characterize balanced and 
unbalanced complex chromosomal abnormalities in UM and UM derived cell lines.11, 12
CGH
CGH allows a complete copy number analysis across the entire genome. It involves the 
competitive hybridization of DNA of the sample of interest with a reference DNA to a target 
sequence. In case of the classic CGH this target are normal human metaphase spreads. Since 
control and sample DNA are labeled with different fluorochrome tags, imbalances caused by 
gene deletion or amplification lead to a detectable and visible difference in fluorescence signals. 
In this way a higher resolution compared to conventional karyotyping can be archived (table 1). 
However, balanced rearrangements and abnormalities that are only present in smaller sub clones 
of a tumor cannot be detected with CGH.13-15 A large CGH study on UM by Aalto et al. (2005) 
revealed concomitant loss of chromosome 3 and whole arm losses and gains of the respective 
chromosome 1, 6, and 8 in metastasizing primary uveal melanoma.16 A CGH study by White et 
al. (2006) revealed gain of 18q22.1 as the most powerful predictor of a poor prognosis in UM. 17 
However, this aberration occurs less frequent and these findings are not confirmed by other 
groups.
LOH
Microsatellites are tandem repeats of simple polymorphic sequences randomly distributed in 
non-coding regions of DNA. An extreme form of microsatellite instability (MSI), characterized 
by frequent length changes at simple tandem repeats, was first described in sporadic colon 
cancer and in HNPCC syndrome.18-20  MSI is, however, not observed in UM and in most studies 
microsatellite markers are used to detect Loss Of Heterozygosity (LOH) as an indicator for 
chromosomal loss. A drawback of this technique is that only a limited number of markers can be 
analyzed in one single experiment.
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Genomics
Micro array technology
A new era in biomedical science started with the completion of the human genome sequencing 
project and the introduction and development of DNA array technology. DNA arrays consist 
of a series of DNA segments regularly arranged on a support, to which a labeled DNA sample 
can be hybridized for copy number or expression measurements. In this way information on 
thousands of loci or expression of thousands of genes in a sample can be obtained in one single 
experiment. Although low-resolution DNA arrays already existed in the seventies as dot blots21, 
the development of gridding robots in the late 1980s made it possible to produce high-density 
filters with 10,000 spots on a filter the size of A4 page. 22, 23 To increase the number of genes 
assayed and to decrease the required amounts of sample, smaller cDNA arrays were developed, 
resulting in the first micro arrays. Competing with the cDNA arrays, oligonucleotide micro arrays 
were developed to discriminate between a perfect match and a mismatch of the oligonucleotide 
present. These types of arrays are based on sequence knowledge alone and do not require the 
laborious maintenance of cDNA libraries and PCR amplification.24-26 For DNA copy number 
approaches, arrays have been constructed with bacterial artificial chromosomes (BACs) as a 
DNA target with a length of each clone ranging from 80 to 200 kb.27 Micro-array technology can 
be used for many different genomic approaches, of which array-based CGH, SNP analysis and 
gene expression analysis are the most frequently applied techniques. Also exon arrays and micro-
RNA arrays are applied more and more frequent. A drawback of these array-based approaches 
is that the analyzed signal represents the average value of all cells in the analyzed sample. As a 
result, balanced anomalies and genomic abnormalities appearing in frequencies below 50% of 
the analyzed nuclei will not be detected. For these cases, the FISH approach is a better option. 
In table 1 the different cytogenetic approaches are compared on their detection limits.
Genomic micro array approaches
Array-CGH
The recent advances in micro array technologies offer the potential of CGH analysis with, 
compared to the classic chromosome CGH, an even higher resolution using many different highly 
specific oligonucleotides or BACs as a fixed template on a micro array slide. With array-CGH, 
regions of gain and loss as small as 10 kb can be detected. There are CGH micro arrays available 
that cover specific chromosomal regions with a resolution of approximately 1 kb, whereas other 
arrays cover the entire genome with a lower resolution. There are also tiled arrays available 
covering almost the entire genome with overlapping sequences.28 
Micro array SNP analysis
Another, even more recently developed type of micro array makes use of single-nucleotide 
polymorphisms (SNPs) in the human genome. The discovery of SNPs lead to the construction 
of increasingly dense SNP maps, allowing innovations in genotyping technologies. Today, there 
are micro arrays on the market that genotype more than 7 million SNPs in one experiment. This 
offers a mapping tool designed to identify regions of the genome linked to or associated with a 
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particular trait or phenotype. Additionally, it is useful for the determination of allele frequencies 
in various populations and for mapping regions with loss of heterozygosity. Furthermore, SNP 
arrays can be used to define copy number changes in tumors using the combined information of 
signal intensities and SNPs.29
Cytogenetics and genomics in uveal melanoma
In contrast to hematological malignancies, it is difficult to get good quality metaphase spreads 
from solid tumors. Furthermore, solid tumors are often more complex and heterogeneous. This 
makes it harder to study solid tumors cytogenetically and to determine frequently occurring 
aberrations in a tumor type. However, uveal melanoma was found to be relatively accessible to 
cytogenetical analysis. From the late eighties on, several reports on the cytogenetic analysis of uveal 
melanomas have been published. Most of the studies are based on cytogenetic and FISH analysis. 
Only a minor fraction was analyzed with CGH. The most frequently found aberrations are loss of 
1p36, loss of chromosome 3, abnormalities of chromosome 6 and gain of chromosome 8 or 8q. 
Also changes in chromosome 11, 16, loss of chromosome 2, 21 and the sex chromosomes were 
described, but those occurred less frequently.16, 33, 34 Results of these molecular (cyto) genetic 
studies result in a delineation of commonly affected regions on chromosomes 1p, 3, 6 and 8. 
These data are summarized in the following sections.
Chromosome 1
Loss of chromosomal region 1p36 is frequently observed in various tumors, including the 
neural crest derived neuroblastoma and pheochromocytoma.35-37 In neuroblastoma, loss of 
chromosome-arm 1p is known to be a predictor of unfavorable clinical outcome.38, 39 In UM loss 
of 1p has been detected predominantly in primary tumors with monosomy of chromosome 3 
and metastasizing tumors.16, 40 Loss of chromosome 1p by itself is not of prognostic significance, 
but concurrent loss of chromosomes 1p and 3 is strongly associated with decreased survival 
of UM patients (discussed further in chapter 4).41 This suggests that a tumor suppressor gene 
involved in UM is located on 1p36. 
The common deleted regions on chromosome 1 described in the literature are summarized 
in figure 1, in which also the overlap between these regions, referred to as shortest region of 
overlap (SRO) total, is indicated. The candidate tumor suppressor gene APITD1, located in this 
SRO addressed in chapter 5 of this thesis is also depicted in this figure.
Chromosome 3
In UM, monosomy of chromosome 3 is the most frequently found non-random chromosomal 
aberration. It is a constant event in UMs that are characterized by different sub-populations 
and therefore the involvement of chromosome 3 is considered to be a primary event.43 In most 
UM cases an entire copy of this chromosome is lost, although in some cases, isodisomy of this 
chromosome is acquired.16, 44, 45 Monosomy of chromosome 3 correlates highly with a poor 
prognosis.46-49 This effect becomes even stronger when besides chromosome 3, chromosome 
1p36 is also lost.41 This high incidence of monosomy of chromosome 3 is specific for UM and not 
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commonly observed in other tumor types. It is widely believed that chromosome 3 harbors tumor 
suppressor genes that play an important role typically in uveal melanoma development. Since in 
most cases of chromosome 3 losses there is a complete monosomy, only a few melanomas 
with partial deletions on chromosome 3 or translocations involving chromosome 3 have been 
described. This has hampered the mapping of putative tumor suppressor genes. Different 
candidate regions were reported on both the short arm and the long arm of this chromosome. 
These data are summarized in figure 2.
Common areas of 3p and 3q loss are observed by us (see chapter 6 and 7) and others. 44, 51-54 
Remarkably some of these chromosomal loci overlap with the regions with low gene expression 
in tumors with a short survival, a study described in chapter 2. The analysis of genes in these 
regions and their role in tumor development and progression is in progress. 
Chromosome 6
In UM abnormalities on chromosome 6 consist mostly of 6p gain and 6p loss. Aberrations, resulting 
in a relative increase of 6p material, either through an isochromosome of 6p or a deletion of 
6q, have been found to be related with both a longer survival46 or decreased survival16 in uveal 
melanoma. Deletion of the long arm of chromosome 6 is a frequent event in many neoplasms, 
including carcinomas of the prostate and breast and melanomas. This suggests the presence 
of a tumor-suppressor gene or genes on 6q. In UM deletion of 6q appears to be a late event 
resulting from tumor progression.55 Although in certain tumor types a smaller candidate region 
or regions for oncogenes on 6p and tumor suppressor genes on 6q have been identified, in UM 
only relatively large common regions of gain and loss have previously been described. Figure 3 
represents a summary of the different regions on chromosome 6 that are described in these 
papers, together with the regions demarcated in our own study as described in chapter 8.
Figure 1. Summary of previously de-
scribed common regions of deletion 
on the short arm of chromosome one 
in UM. Chromosome banding pattern is 
designated on the left according to ISCN 
(2005). On the right side of the ideogram, 
the vertical bars represent regions of de-
letion found in different studies. Letters 
under the respective bar indicate the dif-
ferent studies. A) Arrow: indicates the 
APITD1 gene (see chapter 5); Smallest 
region of deletion overlap in UMs with 
B) monosomy of chromosome 342 or 
C) disomy of chromosome 342 in micro 
satellite analysis; Common region of dele-
tion identified with D) array CGH 40 or E) 
conventional CGH. 16 
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Figure 2. Summary of previously de-
scribed common regions of deletion 
on chromosome three in UM. Chro-
mosome banding pattern is designated 
on the left according to ISCN (2005). 
On the right side of the ideogram, the 
deleted regions observed in the different 
studies are represented by vertical bars, 
the breakpoints of a translocation by an 
open circle. The different studies are in-
dicated by letters under the respective 
bar. A) Regions of loss in UM derived cell 
line Mel270 demarcated with FISH and 
micro satellite analysis (Chapter 6); B) 
SRO-region demarcated with FISH analy-
sis (chapter 7); C) Regions with significant 
lower expression of genes in tumors with 
short survival (chapter 2); D) Overlap 
found with CGH16; E, G, H and J) Com-
mon deleted region identified with micro 
satellite markers in studies from the UK44, 
USA51; Germany50 and UK52 , respectively; 
F) Translocation t(3;14)(q23;q32)53; I) 
Translocation t(3;22)(p13;p11). 54
Figure 3. Summary of previously de-
scribed common regions of gain and 
deletion on chromosome six in UM. 
Chromosome banding pattern is des-
ignated on the left according to ISCN 
(2005). On the right side of the ideogram, 
the vertical bars represent the regions of 
deletion found in different studies. The 
different studies are indicated by letters 
under the respective bar. A) Common 
regions of gain and loss identified with 
karyotyping, CGH and FISH described 
in chapter 8 of this thesis; B) Common 
regions of gain and loss identified with 
CGH16 or C) with array CGH. 40 
Chromosome 8q 
Gain of chromosome 8q is often seen as a non-random aberration. Several studies indicated 
gain of chromosome 8 as an independent prognostic marker for decreased patient survival.46, 49 
Acquisition of an isochromosome 8q seems to be a secondary event, indicated by the variable 
number of copies of chromosome 8q that is often observed in a tumor with gain of chromosome 
8. Where involvement of chromosome 3 is considered to be a primary event, variable number of 
copies of chromosome 8q can be observed in different UM sub-populations.43, 56 Chromosome 
8 abnormalities occur more often in larger tumors, which supports the hypothesis that a certain 
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gene (or a combination of genes) present on 8q, when overexpressed in these tumors, plays 
a role in the development of the metastatic phenotype.43 However, in our study described in 
chapter 3 of this thesis, the presence of chromosome 8q abnormalities correlated with largest 
tumor diameter and in univariate analysis there was no significant relation found between gain 
of 8q and the metastatic phenotype. We suggest that the acquisition of additional copies of 8q is 
related more with tumor growth than tumor aggressiveness. 57 In most cases, amplification on 
chromosome 8q involves the entire chromosome or isochromosome formation of the long arm 
of chromosome 8. Amplification of the long arm of chromosome 8 by isochromosome formation 
occurs very frequently in tumors with loss of chromosome 3 and concurrent abnormalities of 
chromosome 3 and 8 are associated with a poor outcome.16, 46, 58 Most reported partial gains of 
chromosome 8 in UM are the result of unbalanced translocations. An overview of the observed 
loss and gain of chromosome 8 in the different reports is given in figure 4. Altogether, multiple 
breakpoints are found on chromosome 8q, with a common amplified region ranging from 8q24.1 
to 8qter.
Gene expression profiling in uveal melanoma
With the emerging higher resolution views of gene expression, it became possible to classify 
human cancers based on their gene expression signature. The technique is now being used to 
predict the clinical outcome and to propose molecular targets for therapy. In melanoma research, 
gene expression profiling has already been applied in a number of studies, but in most cases the 
subject was cutaneous melanoma. In the year 2000, 31 skin melanomas were classified into 2 
subgroups, which lead to the identification of WNT5A as a new disease gene for melanoma 
progression.60 Other studies on cutaneous melanoma focused on primary tumors vs. their 
metastases and on treatment response.61, 62
Using cDNA micro array technology, highly invasive uveal melanoma tumor cells were compared 
with poorly invasive cells and a genetic reversion to a pluripotent embryonic-like genotype was 
found in the aggressive tumor cells. This suggests that aggressive uveal melanoma cells may 
Figure 4. Summary of previously de-
scribed common regions of gain and 
deletion on chromosome 8 in UM. 
Chromosome banding pattern is designat-
ed on the left according to ISCN (2005). 
On the right side of the ideogram, the re-
gions deleted in the different studies are 
represented by vertical bars. The differ-
ent studies are indicated by letters under 
the respective bar. A) Gain identified with 
array CGH40 B) Multiplex FISH analysis of 
common region of gain59; C) Gain and loss 
identified with CGH analysis; D) Gain and 
loss identified with array CGH. 40
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generate vascular channels that facilitate tumor perfusion independent of tumor angiogenesis 
in a process called vascular mimicry.63 Tschentscher et al. (2003) reported that UMs could be 
classified in groups with or without monosomy 3 with use of oligonucleotide gene expression 
arrays.64 In another study by Onken et al. (2005), uveal melanomas were found to cluster in 
two distinct entities on basis of their gene expression profile, on basis of which metastatic death 
could be predicted.65 The existence of two distinct entities was also reported by Petrausch 
et al. (2007).66 Recently a strong association was found between vascular looping patterns in 
the extra cellular matrix and the unfavorable molecular prognostic signature of the high grade 
uveal melanoma subgroup.67 This is confirmed in chapter 2 of this thesis, which describes the 
analysis of 46 uveal melanomas with gene expression profiling. Additionally, our data revealed a 
strong association between an unfavorable prognostic signature and presence of closed vascular 
patterns. This proves that gene expression profiling is a very powerful technique that can be used 
to study a broad range of variables in uveal melanoma. Data generation in expression profiling is 
enormous and can be used for clustering analysis and prognostic subtyping the data. In addition, 
the data can also be used to answer more specific questions on uveal melanoma behavior from 
a mechanistical point of view.
Aim of this thesis
The work presented in this thesis is aimed to get a better understanding of uveal melanoma 
tumor biology by delineation of chromosomal regions and identification of genes responsible for 
a poor prognosis in uveal melanoma patients. This will also help to make advances in prognostic 
screening and might provide targets for treatment. To do so, two different approaches were 
combined. The first approach was to perform gene expression profiling on a large set of uveal 
melanomas. The second approach was to further investigate the known chromosomal regions 
with prognostic significance in uveal melanomas. A combination of these approaches will lead 
to the identification of differential expressed genes located on candidate regions that function 
in tumor-related functional pathways. The use of gene expression profiling in uveal melanoma 
is described in Chapter 2. In this chapter, the creation of gene expression signatures and a 
comparison with known prognostic parameters are outlined. In chapter 3 the relations of clinical, 
histopathological and cytogenetic parameters with prognosis are outlined. A study focusing on 
the concurrent loss of chromosomes 1p and 3 is described in Chapter 4. The next section reflects 
studies on different chromosomal regions of prognostic significance in uveal melanoma. Chapter 
5 outlines a study on a possible candidate tumor suppressor gene located on 1p36, called APITD1, 
an apoptosis-inducing gene that is affected in many cases of neuroblastoma, another neural-crest 
cell-derived tumor. Delineation studies of regions of loss on chromosome 3 are described in 
Chapters 6 and 7, followed by a delineation study on chromosome 6 in Chapter 8. In Chapter 9, 
the results of the different studies are combined and discussed. In addition, different possibilities 
to use gene expression data to identify critical regions, genes and pathways in different uveal 
melanoma subgroups are discussed.
Introduction 17
References
1. Krona C, Ejeskar K, Caren H et al. A novel 1p36.2 located gene, APITD1, with tumour-suppressive 
properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours. Br J Cancer. 
2004;91:1119-1130
2. Sesterhenn AM, Folz BJ, Lippert BM, Janig U, Werner JA. Laser surgical treatment of laryngeal paraganglioma. 
J Laryngol Otol. 2003;117:641-646
3. Namiki T, Yanagawa S, Izumo T et al. Genomic alterations in primary cutaneous melanomas detected by 
metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may 
predict poor outcome. Cancer Genet Cytogenet. 2005;157:1-11
4. Zimmerman LE, McLean IW. Do growth and onset of symptoms of uveal melanomas indicate subclinical 
metastasis? Ophthalmology. 1984;91:685-691
5. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest 
Ophthalmol Vis Sci. 2003;44:4651-4659
6. Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol. 
1996;41:215-228
7. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11:255-263
8. van Dekken H, Pizzolo JG, Reuter VE, Melamed MR. Cytogenetic analysis of human solid tumors by in situ 
hybridization with a set of 12 chromosome-specific DNA probes. Cytogenet Cell Genet. 1990;54:103-107
9. Trask BJ. Fluorescence in situ hybridization: applications in cytogenetics and gene mapping. Trends Genet. 
1991;7:149-154
10. Naus NC, Verhoeven AC, van Drunen E et al. Detection of genetic prognostic markers in uveal melanoma 
biopsies using fluorescence in situ hybridization. Clin Cancer Res. 2002;8:534-539
11. Naus NC, van Drunen E, de Klein A et al. Characterization of complex chromosomal abnormalities in uveal 
melanoma by fluorescence in situ hybridization, spectral karyotyping, and comparative genomic hybridization. 
Genes Chromosomes Cancer. 2001;30:267-273.
12. White JS, Becker RL, McLean IW, Director-Myska AE, Nath J. Molecular cytogenetic evaluation of 10 uveal 
melanoma cell lines. Cancer Genet Cytogenet. 2006;168:11-21
Table 1. Overview of techniques used in (molecular) cytogenetics*
Method Resolution Detection of balanced 
anomalies? 
Detection of unbalanced 
anomalies? 
G-banding ~ 5 – 10 Mb Yes Yes
FISH ~ 0.1 Mb Yes Yes
SKY ~ 1 - 2 Mb Yes Yes
LOH  <1 kb No Yes
CGH ~ 5 – 20 Mb No Yes
MLPA ~ 1 – 40 kb No Yes
CGH array ~ 1 kb – 250 kb ** No Yes
SNP array ~ 1 kb – 250 kb ** No Yes
*Adapted from Feenstra et al., Fan et al. and Peiffer et al.30-32  ** Depending on type and number of probes (BAC, 
oligonucleotides or SNP) and/or their distribution.
Chapter 118
13. Kallioniemi A, Kallioniemi OP, Sudar D et al. Comparative genomic hybridization for molecular cytogenetic 
analysis of solid tumors. Science. 1992;258:818-821
14. Kallioniemi OP, Kallioniemi A, Sudar D et al. Comparative genomic hybridization: a rapid new method for 
detecting and mapping DNA amplification in tumors. Semin Cancer Biol. 1993;4:41-46
15. Ried T, Liyanage M, du Manoir S et al. Tumor cytogenetics revisited: comparative genomic hybridization and 
spectral karyotyping. J Mol Med. 1997;75:801-814
16. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm 
losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 
2001;42:313-317
17. White JS, McLean IW, Becker RL, Director-Myska AE, Nath J. Correlation of comparative genomic hybridization 
results of 100 archival uveal melanomas with patient survival. Cancer Genet Cytogenet. 2006;170:29-39
18. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated 
sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558-561
19. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 
1993;260:816-819
20. Aaltonen LA, Peltomaki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science. 
1993;260:812-816
21. Kafatos FC, Jones CW, Efstratiadis A. Determination of nucleic acid sequence homologies and relative 
concentrations by a dot hybridization procedure. Nucleic Acids Res. 1979;7:1541-1552
22. Hoheisel JD, Lennon GG, Zehetner G, Lehrach H. Use of high coverage reference libraries of Drosophila 
melanogaster for relational data analysis. A step towards mapping and sequencing of the genome. J Mol Biol. 
1991;220:903-914
23. Lennon GG, Lehrach H. Hybridization analyses of arrayed cDNA libraries. Trends Genet. 1991;7:314-317
24. Wodicka L, Dong H, Mittmann M, Ho MH, Lockhart DJ. Genome-wide expression monitoring in 
Saccharomyces cerevisiae. Nat Biotechnol. 1997;15:1359-1367
25. Fodor SP, Read JL, Pirrung MC et al. Light-directed, spatially addressable parallel chemical synthesis. Science. 
1991;251:767-773
26. Jordan B. Historical background and anticipated developments. Ann N Y Acad Sci. 2002;975:24-32
27. Bejjani BA, Saleki R, Ballif BC et al. Use of targeted array-based CGH for the clinical diagnosis of chromosomal 
imbalance: is less more? Am J Med Genet A. 2005;134:259-267
28. Shaffer LG, Bejjani BA. Medical applications of array CGH and the transformation of clinical cytogenetics. 
Cytogenet Genome Res. 2006;115:303-309
29. Bignell GR, Huang J, Greshock J et al. High-resolution analysis of DNA copy number using oligonucleotide 
microarrays. Genome Res. 2004;14:287-295
30. Feenstra I, Brunner HG, van Ravenswaaij CM. Cytogenetic genotype-phenotype studies: improving 
genotyping, phenotyping and data storage. Cytogenet Genome Res. 2006;115:231-239
31. Fan YS, Siu VM, Jung JH, Xu J. Sensitivity of multiple color spectral karyotyping in detecting small 
interchromosomal rearrangements. Genet Test. 2000;4:9-14
32. Peiffer DA, Le JM, Steemers FJ et al. High-resolution genomic profiling of chromosomal aberrations using 
Infinium whole-genome genotyping. Genome Res. 2006;16:1136-1148
33. Sisley K, Rennie IG, Cottam DW et al. Cytogenetic findings in six posterior uveal melanomas: involvement of 
chromosomes 3, 6, and 8. Genes Chromosomes Cancer. 1990;2:205-209
34. Sisley K, Cottam DW, Rennie IG et al. Non-random abnormalities of chromosomes 3, 6, and 8 associated with 
posterior uveal melanoma. Genes Chromosomes Cancer. 1992;5:197-200
35. Brodeur GM, Green AA, Hayes FA et al. Cytogenetic features of human neuroblastomas and cell lines. Cancer 
Res. 1981;41:4678-4686
36. Benn DE, Dwight T, Richardson AL et al. Sporadic and familial pheochromocytomas are associated with loss 
of at least two discrete intervals on chromosome 1p. Cancer Res. 2000;60:7048-7051
37. Brodeur GM, Sekhon G, Goldstein MN. Chromosomal aberrations in human neuroblastomas. Cancer. 
1977;40:2256-2263
38. Caron H, van Sluis P, de Kraker J et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome 
in patients with neuroblastoma. N Engl J Med. 1996;334:225-230
39. Casciano I, Mazzocco K, Boni L et al. Expression of DeltaNp73 is a molecular marker for adverse outcome in 
neuroblastoma patients. Cell Death Differ. 2002;9:246-251
40. Hughes S, Damato BE, Giddings I et al. Microarray comparative genomic hybridisation analysis of intraocular 
uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. Br J Cancer. 
2005;93:1191-1196
41. Kilic E, Naus NC, van Gils W et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a 
decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2005;46:2253-2257
Introduction 19
42. Hausler T, Stang A, Anastassiou G et al. Loss of heterozygosity of 1p in uveal melanomas with monosomy 3. 
Int J Cancer. 2005;116:909-913
43. Prescher G, Bornfeld N, Becher R. Two subclones in a case of uveal melanoma. Relevance of monosomy 3 
and multiplication of chromosome 8q. Cancer Genet Cytogenet. 1994;77:144-146
44. Scholes AG, Liloglou T, Maloney P et al. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including 
the retinoblastoma locus, in uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:2472-2477
45. White VA, McNeil BK, Horsman DE. Acquired homozygosity (isodisomy) of chromosome 3 in uveal 
melanoma. Cancer Genet Cytogenet. 1998;102:40-45
46. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE. Correlation of cytogenetic abnormalities 
with the outcome of patients with uveal melanoma. Cancer. 1998;83:354-359
47. Prescher G, Bornfeld N, Hirche H et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 
1996;347:1222-1225
48. Sisley K, Parsons MA, Garnham J et al. Association of specific chromosome alterations with tumour phenotype 
in posterior uveal melanoma. Br J Cancer. 2000;82:330-338
49. Sisley K, Rennie IG, Parsons MA et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma 
correlate with prognosis. Genes Chromosomes Cancer. 1997;19:22-28.
50. Tschentscher F, Prescher G, Horsman DE et al. Partial deletions of the long and short arm of chromosome 3 
point to two tumor suppressor genes in uveal melanoma. Cancer Res. 2001;61:3439-3442
51. Parrella P, Fazio VM, Gallo AP, Sidransky D, Merbs SL. Fine mapping of chromosome 3 in uveal 
melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. Cancer Res. 
2003;63:8507-8510
52. Cross NA, Ganesh A, Parpia M et al. Multiple locations on chromosome 3 are the targets of specific deletions 
in uveal melanoma. Eye. 2006;20:476-481
53. Dahlenfors R, Tornqvist G, Wettrell K, Mark J. Cytogenetical observations in nine ocular malignant melanomas. 
Anticancer Res. 1993;13:1415-1420
54. Blasi MA, Roccella F, Balestrazzi E et al. 3p13 region: a possible location of a tumor suppressor gene involved 
in uveal melanoma. Cancer Genet Cytogenet. 1999;108:81-83
55. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J 
Natl Cancer Inst. 1990;82:1765-1769
56. Horsman DE, White VA. Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and 
trisomy 8q. Cancer. 1993;71:811-819
57. Kilic E, van Gils W, Lodder E et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis 
Sci. 2006;47:3703-3707
58. Prescher G, Bornfeld N, Friedrichs W, Seeber S, Becher R. Cytogenetics of twelve cases of uveal melanoma and 
patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet. 1995;80:40-46
59. Sisley K, Tattersall N, Dyson M et al. Multiplex fluorescence in situ hybridization identifies novel rearrangements 
of chromosomes 6, 15, and 18 in primary uveal melanoma. Exp Eye Res. 2006;83:554-559
60. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene 
expression profiling. Nature. 2000;406:536-540
61. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. 
Nature. 2000;406:532-535
62. Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of melanoma metastases suggests 
classifiers of immune responsiveness. Cancer Res. 2002;62:3581-3586
63. Seftor EA, Meltzer PS, Kirschmann DA et al. Molecular determinants of human uveal melanoma invasion and 
metastasis. Clin Exp Metastasis. 2002;19:233-246
64. Tschentscher F, Husing J, Holter T et al. Tumor classification based on gene expression profiling shows that uveal 
melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63:2578-2584
65. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two 
molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205-7209
66. Petrausch U, Martus P, Tonnies H et al. Significance of gene expression analysis in uveal melanoma in 
comparison to standard risk factors for risk assessment of subsequent metastases. Eye. 2007
67. Onken MD, Lin AY, Worley LA, Folberg R, Harbour JW. Association Between Microarray Gene 
Expression Signature and Extravascular Matrix Patterns in Primary Uveal Melanomas. Am J Ophthalmol. 
2005;140:748-749

21
Chapter 2
Expression profiling in uveal melanoma provides a strong 
marker for survival and reveals two regions on
chromosome 3p related to prognosis
Part II
Gene expression profiling

23
Chapter 2
Expression profiling in uveal melanoma provides a strong 
marker for survival and reveals two regions on chromosome 
3p related to prognosis
Expression profiling in uveal melanoma provides a strong marker for survival and reveals two 
regions on chromosome 3p related to prognosis
Walter van Gils, Elisabeth M. Lodder, Hanneke W. Mensink, Emine Kiliç, Nicole C. Naus, 
Hennie T. Brüggenwirth, Wilfred van IJcken, Dion Paridaens, Gregorius P. Luyten and Annelies 
de Klein
Submitted for publication
Abstract
Introduction: Although studies on uveal melanoma (UM) revealed prognostic significance of 
chromosomal aberrations, they resulted in many classification errors in survival prediction. To 
obtain a robust prognostic classifier with strong predictive value and to gain further insight in 
genes responsible for poor prognosis, we have applied gene-expression profiling on tumors 
of UM patients of which extensive clinical, histopathological, cytogenetic and follow-up data is 
available.
Methods: Gene-expression profiles of 46 UMs were obtained using Affymetrix Hu133 2.0 Plus 
GeneChips. Data was analyzed with Omniviz and PAM software and validated with Real-Time 
PCR. The prognostic significance of UMs with specific molecular signatures was determined. 
Furthermore, LAP analysis resulted in the identification of differentially expressed chromosomal 
regions. 
Results: The primary UMs could be classified in two distinct molecular classes with a strong 
prognostic value (p<0.001; hazard ratio 7.7). Classifier gene sets for micro-array class and 
disease-free survival were validated with Real-Time PCR and the predictive value of the UM class 
marker set was validated with gene expression profiles of tumors provided by other institutions, 
showing a sensitivity of 0.93 and specificity of 1.00 for class two tumors. Using a locally adaptive 
statistical procedure two regions on chromosome-arm 3p with decreased gene-expression in 
tumors with shorter disease-free survival were identified.
Discussion: Micro-array classification outperforms known prognostic indicators for UM, such 
as clinical, histopathological and cytogenetic parameters. In addition, the identified regions with 
lower expressed genes on chromosome-arm 3p could harbor genes, responsible for the poor 
prognosis of UM patients.
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Introduction
Uveal melanoma (UM) is the most frequently occurring primary tumor in the eye, with an 
incidence of 7 per million every year in the Western world. Approximately 50% of all patients 
will die of metastatic disease. Several prognostic factors have been reported in UM of which 
the most promising are cytogenetic anomalies. Structural abnormalities on chromosomes 3, 6, 
and 8q have been linked to metastatic death 1, 2 and concurrent loss of chromosomes 1 and 
3 strongly correlates with poor survival. 3 Although these associations are rather strong, they 
are not specific or sensitive enough for the prediction of clinical outcome. Gene expression 
profiling might therefore be very helpful to improve predictive clinical testing. Tschentscher et al. 
already identified a correlation between gene expression profile and monosomy of chromosome 
3 in UMs. However, they did not investigate a direct relation between gene expression and 
patient survival. 4 Onken et al. identified two different classes in UM expression profiles that 
correlate with metastatic disease 5, but until now no gene expression classifier set has been 
identified specific for UM survival. Here, we describe gene expression analysis of a cohort of 
46 primary UMs and compared these data with extensive follow-up data, clinical, pathological 
and cytogenetic parameters. We identified gene expression signatures for array class as well as 
survival. Additionally, using locally adaptive statistical procedure (LAP analysis), we identified 
several chromosomal regions with differential gene expression.
Materials and methods
Patients and tumor samples
Ciliary body or choroidal melanomas were collected from patients who underwent enucleation 
of the tumor-containing eye at the Erasmus MC Rotterdam or Rotterdam Eye Hospital. Informed 
consent was given prior to enucleation and the study was performed according to the tenets of 
the Declaration of Helsinki. Fresh tumor material was obtained within 1 hour after enucleation 
and processed for FISH and cytogenetic analysis as described. 6 A fraction of each tumor was 
snap-frozen and stored in liquid nitrogen. The remainder of the eye was embedded in paraffin 
and sections were stained with Hematoxylin and Eosin staining (H&E) for evaluation. Patients 
(n=49) were selected from our extensive database with information on follow-up and clinical, 
cytogenetical and histopathological parameters. The selection was made such that numerical 
abnormalities of chromosomes 1, 3, 6 and 8 were all represented in at least ten patients, as well 
as UMs with no numerical chromosome anomalies.
Preparation of RNA and hybridization
From fresh frozen tumor material, a 5µm section was made for H&E staining and depending 
on the size of the tumor 5 to 8 sections of 50µm were used for RNA isolation with RNA-Bee 
(Teltest, Friendswood, TX, USA) according to the manufacturers’ instructions. RNA quantity 
(20 to 80µg in 20µl) was measured using the NanoDrop® ND-1000 Spectrophotometer 
(NanoDrop Technologies, Wilmington, Delaware USA) and quality was assayed on the 
Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA). The Affymetrix GeneChip One-Cycle Target 
Labeling and Control Reagents package (Affymetrix, Santa Clara, CA, USA) was used to create 
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biotinylated cRNA out of 5µg of total RNA. The cRNA was used for hybridization on Affymetrix 
Hu133 2.0 Plus GeneChips with the Affymetrix Fluidics 450 station and the arrays were scanned 
with the Affymetrix GeneChip Scanner 3000 (Affymetrix, Santa Clara, CA, USA), following the 
manufacturer’s instructions.
Normalization
Only gene chips with at least 30% present calls and no signs of degradation, were analyzed. 
For normalization Variance-Stabilizing Normalization (VSN) 7 was used with the Affy, VSN and 
BioConductor package in the open-source statistical language R, version 2.2.1. The MisMatch 
(MM) intensities were ignored and by doing so only the Perfect Match (PM) intensities from 
the created CEL file were taken for normalization. This strategy circumvents systematical over-
estimation of intensities by implementation of a heuristic, when PM intensities are smaller than 
MM probe intensities. For each probe set, the geometric mean of the hybridization intensities 
of all tumor samples was calculated. To reflect differential expression, the level of expression of 
each probe set in every sample was determined relative to its geometric mean and logarithmically 
transformed (on a base 2 scale) to ascribe equal weight to gene-expression levels with similar 
relative distances to the geometric mean. 
Unsupervised clustering and visualization 
The 528 annotations that had a standard deviation of at least 1.25 were selected for unsupervised 
hierarchical clustering with a K-means algorithm. Pearson’s correlation was used for unsupervised 
heat mapping cluster analysis. Probe sets that were differentially expressed in at least one patient 
were selected for further analysis. Hierarchical cluster analysis, heatmap cluster analysis and 
visualization were all performed with Omniviz software (OmniViz, Inc., Maynard, MA, USA).
PAM analysis
Supervised class-prediction analyses were performed by applying PAM (Predictive Analysis 
of Micro-arrays) software in Microsoft Excel (PAM version 2.1 Excel plug-in). This program 
uses the method of the nearest shrunken centroids to identify a subgroup of genes that best 
characterizes a predefined class. 8 The prediction error was calculated by 10-fold cross validation 
within a training set (two thirds of the patients) followed by analysis of a test set (one third of 
the patients).
Validation by Real-Time PCR
Ten RNA samples were selected from the gene expression analysis cohort. From 1.5 µg of 
total RNA cDNA was synthesized using the I-Script cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA, USA). For Real-Time assays iQ SYBR Green Supermix (Bio-Rad Laboratories, 
Hercules, CA, USA) was used. Using geNorm software and following the instructions suggested 
by Vandesompele et al. 9, we selected the three most stable reference genes from a panel of eight 
genes. Primers for the genes of interest (GOI) were selected with Primer Express Software v1.7 
(Applied Biosystems, Foster City, CA, USA) and checked for the absence of SNPs in the primer 
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sequences with the Ensembl Genome Browser, release 41. Genes and primers are listed in 
table 1. The reactions were run on the ABI PRISM™ 7300 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA) with a protocol of subsequently 95 °C for 10 min. and 40 
cycles of 95 °C for 15 s, followed by 60 °C for 1 min.
Table 1. PCR primers used in this study
Gene Forward primer sequence (5’-> 3’) Reverse primer sequence (5’-> 3’)
Ratio 
class2/
class1 P-value
4-year DFS
DKFZp434A202 CAACTTGTGATGGCCTGCCT AATTGTTCTCATCCCAACTGCC 5,7 *0,079
FDFT1 AAGGTGATGCCCAAGATGGA AGTTTTCAGGCTGCTGCTGAG 0,2 0,003
GCNT2 TGCCACGGCCACTATGTACA TTTAAGTCTCCGTTTCCATAGATACAAA 0,3 0,000
ULK4 GTTCACCACAGAAGACTTCTCCTCT GCTGACTCAGGTGTCCACTTGTAAT **0,3 0,015
SRD5A2L2 CTGATCCGCTATGGGAAAACC GAGTAAGGCACCAAAGCAGGAA 1,5 *0,316
FZD7 CTGCTTTGTTGGAAAGAGGGA ACTGCTTGACAAGCACACCG 1,9 *0,076
RIMS2 TCGACAGATGTGCATTGGTTG TGGACACAGATGGGCTTCTTTT 0,0 *0,353
FER1L3 GCTCCAGCCCCAGGACA CCAGTGTTATTTTTATGTAAGGGTCACA 2,0 *0,235
SLC1A4 TCCTGGCTGTGGACTGGATT CTTCCACATTCACCACCGTG 2,9 0,021
ZNF447 TCCCGGCACCTTCTGAGAC CTCCTCTGTTCCAGAAACAGGG 0,2 0,001
UM Class
MEGF10 GTGTGTAGCCACTGGGAAAGC TGGGTATGACTCTTGCACAGTCA 0,0 0,002
LMCD1 AAAAGATGTCCCTGGGCCAG CCAAACATGCCACACCTCTTG 0,1 0,002
ICRFp507I1077 TGCACACCGTCACACTGTTAAC GCGGAAGATACAGCACTGCC 0,2 0,024
MGC9913 TCACCTACTTCAGTGTGGTTTCAAC CCTGCACAGTGTCCAACGTT 0,0 *0,322
CUGBP2 ACCTGATGGGCTGAGTCGAG TTGCCCTTGTAGAAAATGTGACA 5,3 0,007
RaLP GTGAAGCTGTCCCCGGG TGCCAAGGACTGTTGATAGGAA 0,0 0,000
HTR2B CAAAATAACAACGAAACCAGAGGG GTTTGAACTTGCATGCCAGAGAG 55,6 0,027
PDE3A CAGTGAAAACTATACCTGTTCTGACTCTG GAGGCAAACTCCTTCTCAGGC 0,1 0,002
SORBS2 CAAATGTGGAGCTGTCACTGAGA TTTTACCTTCATACCAGTTTTGATCAA 0,1 0,005
OVOS2 ACAAGGGCCAAGTGATGAAGAC ACAAGGTTGCTCTGCTCAACAG 0,0 0,003
UM Class add.
PTGER4 TGCCGCTACAGACCCAGC AATTGACCCCGGGAGTGG 16,5 0,004
HTRA1 AATTGTTTCGCAAGCTTCCG CACTAGCCACCGGCACCT 5,0 0,002
HTATIP2 CAGCATGGCCGAAACAGAA GCATCCTGAAGTCTTCCCGA 2,7 0,028
MTUS1 CAATTGCAAGAGCAGTTTGACAA CTTAGAGGTTTCATGCGCAGC 0,1 0,002
TIMP3 CACCTGGGTTGTAACTGCAAGTC CTGCAATTAGATAACAGGCAGCA 0,1 0,023
LIMS2 CAACAGCAAGCTCACCCTGA GGCTTCATGTCGAACTCCACA 0,1 0,001
TBC1D8 GCCAAAGAAAAAGATAAAACTGAGAAA TGGATCTTCATGGAACATACTGTACAG 0,8 *0,516
RAB31 TGAGACAAGTGCAAAAAATGCTATT GGTGGGATCTGGCGGC 3,0 0,005
TNFRSF19 TGCATTCTGCAGCCAGTCTT CATCTCCCCGGCTGGG 6,9 0,006
Other genes
DDEF1 GTACCACTGCCCAGAAAAATCAA CACTCGCCTCACTTTATTTTTCC 1,9 0,011
ENPP2 ACGAGGAGAGCTGCAATAGCTC GTTCTTCTACCCATTTTGATTCGTC 0,1 0,029
CUL2 CAATGCAGAAAGACACACCACA CAACTGCACTTCTAGTCTGCTCCAT 0,6 *0,194
LAMR1 AGGTCATGCCTGATCTGTACTTCTAC GCAGCCTGCTCTTCTTTTTCA 0,2 0,001
FZD6 CCAAGAGCTTCAAAAAATCCTTCT TGAAAATGAGTCCTGGGTCAATTA 0,3 *0,128
ID2 CCTAGAGGCGGAGTGATGAACT AATCACAGCTACACGGGCG 3,2 *0,131
PHLDA1 GGGTTGTTGCAGCTCTGGA CCCTTCCTCGGTGAGGATG 0,1 0,050
VBP1 GAGGCCGTGTTTGTGGAAGA ATTCCCAGGCTGTTTCATGAA 0,7 *0,081
MITF TTGATGGATCCTGCTTTGCA ACAGGAGTTGCTGATGGTGAGG 0,4 0,043
ET2 TGAAGGGAAGGGCCAGG TGATGTCCAAGTGGCAGAAGTAGA 0,0 0,000
*=not significant; **=result contradictory to gene expression profile
The categories 4-year DFS and UM Class contain the most differential expressed genes of the respective classifier sets. 
The category of UM Class add. consists of candidate tumor genes that belong to the UM Class predictor set but with a 
less strong differential expression. The category of Other genes harbors those genes that are described in other gene 
expression profiling studies on uveal melanoma. Ratio and p-value data are derived from Real-Time PCR analysis on 10 
of the UMs in the micro-array cohort.
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The efficiency of all assays was determined with a pool of cDNA of all ten selected samples in 
dilutions of 1, 10, and 100 times. A standard curve of mean Ct for two replicates at each dilution 
versus log10 amount of cDNA was determined. The efficiency of the reaction was calculated 
from the slope of this standard curve using the formula Etarget = 10−1/slope. This efficiency value 
was included in the calculation of the relative quantity in each sample for the respective assay. 
After selection of three reference genes from a panel of eight possible reference genes and 
determination of a normalization factor for all samples in geNorm, the normalized GOI expression 
levels were calculated by dividing the raw GOI quantities for each sample by their normalization 
factor. All reference genes, assayed genes and primers are presented in table 1, together with 
the results.
Identification of differentially expressed chromosomal regions 
Differentially expressed chromosomal regions were identified with the computational tool called 
Locally Adaptive statistical Procedure (LAP) 10, which combines transcriptional data with structural 
information and estimates the differential expression of chromosomal regions accounting for 
variations in the distance between genes and gene density. LAP analysis was performed in R, 
version 2.2.1. Functions in R for implementing the LAP method were obtained from the website 
http://www.dpci.unipd.it/Bioeng/Publications/LAP.htm of the University of Padua. 
Statistical analysis
Statistical analyses were performed with SPSS software, release 11.0. Odds-ratios with 
corresponding p-values were calculated to identify associations between the different parameters. 
Actuarial probabilities of disease-free survival (DFS; with an event defined as development of 
metastatic disease or death by disease) were estimated according to the Kaplan–Meier method. 
To examine the possibility that other clinical, histopathological or chromosomal variations affected 
the prognosis, we performed Cox proportional hazard analysis for each confounding variable. An 
effect was considered significant if the p-value was 0.05 or less.
Results
Selection
Patients (n=49) were selected from the tumor database such that numerical abnormalities of 
chromosomes 1, 3, 6 and 8 were all represented in at least ten patients, as well as UMs with 
no numerical chromosome anomalies. From frozen sections RNA was isolated, labeled and 
hybridized on gene chip arrays. After scanning the expression profiles were normalized and 
analyzed using different software packages.
Unsupervised clustering
After applying a hierarchical clustering algorithm on the 528 probe sets with the highest differential 
expression, the UMs clustered into two discrete molecular classes (UM class 1: n =23; UM class 
2: n=23). This unsupervised clustering is shown in figure 1A. With Pearson’s correlation analysis 
the same two blocks of related UMs were found (fig. 1B). Next to this correlation plot cytogenetic 
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and clinical prognostic markers as status of chromosomes 1, 3, 6p, 6q, 8p and 8q, presence of 
epitheloid cells, vascular patterns, largest tumor diameter (LTD), ciliary body involvement and 
gender are shown (fig.1C). Odds ratios of UM class with the different parameters were calculated 
and the corresponding p-values are displayed in table 2. The parameters 4-year DFS, monosomy 
of chromosome 3, gain of 6p and vascular patterns correlated with UM class with the highest 
significance. To assess the prognostic significance of UM class and the other parameters, we 
performed a multivariate analysis. The parameter UM class remained significant after correction 
for possible confounders and near significant when corrected for 8q-gain (p=0.053). Also 
chromosome 3 loss, gain of 6p, 8p loss, 8q gain, ciliary body involvement and vascular patterns 
were significant when corrected for almost all confounders (table 3).
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array class 0,003 NS 0,000 0,000 NS 0,026 0,018 NS 0,003 NS 0,018 0,008
4 year-survival 0,003 NS 0,016 0,036 NS NS NS NS 0,001 NS NS NS
1p loss NS NS NS NS NS NS NS NS NS NS NS NS
3 loss 0,000 0,016 NS 0,003 NS 0,016 NS 0,025 0,002 0,001 NS NS
6p gain 0,000 0,036 NS 0,003 0,003 NS NS 0,038 0,002 NS NS NS
6q loss NS NS NS NS 0,003 NS NS NS NS NS NS NS
8q gain 0,026 NS NS 0,016 NS NS NS NS NS 0,008 NS NS
age 0,018 NS NS NS NS NS NS 0,046 0,008 NS NS NS
epitheloid present NS NS NS 0,025 0,038 NS NS 0,046 0,025 NS NS NS
vascular patterns 0,003 0,001 NS 0,002 0,002 NS NS 0,008 0,025 NS NS NS
LTD NS NS NS 0,001 NS NS 0,008 NS NS NS NS NS
involv. ciliary body 0,018 NS NS NS NS NS NS NS NS NS NS 0,030
m/f 0,008 NS NS NS NS NS NS NS NS NS NS 0,030
Table 2. Correlation between prognostic parameters for uveal melanoma in the analyzed cohort†‡
† The odds ratio’s of the parameters were calculated with Chi-square analysis based on the available data of the 46 
included uveal melanomas; correlation expressed in p-values. 
‡ Dark gray boxes/NS: Not-significant (p>0.05); light gray boxes: 0.01 < p ≤ 0.05; white boxes: p ≤ 0.01.
Gene expression signatures
To create classifier sets we applied PAM analysis for the categorical variables 4-year disease free 
survival (DFS) and UM class (table 4).The 61-gene annotation classifier set for 4-year DFS has 
a sensitivity of 0.89 and a specificity of 0.6. For UM class we selected 69 gene annotations that 
classified all samples correctly in training and cross validation. This 69 classifier set predicts with 
the maximum score of 1 for both sensitivity and specificity. 
Real-Time PCR
The 8 most differentially expressed known classifying genes for UM class and the 4-year 
DFS classifier were tested in real-time PCR together with a candidate tumor suppressor and 
oncogenes that were present in the micro-array class and other genes that were described 
to be associated with prognosis in other gene expression profiling studies on UM. Ten patient 
samples were selected from the gene expression analysis cohort, five from UM class 1 with 
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predicted DFS >4 years and five from class 2 with predicted DFS ≤4 years. The results of real-
time PCR are shown in table 1. For UM class the differential expression of the top 8 genes was 
confirmed in real-time PCR (HTATIP2 borderline-significant). For the 4-year DFS classifier, five 
out of nine assays indicated differential expression between the two different tumor groups, of 
which four were differentially expressed according to the gene expression signatures of both 
classes. One gene, ULK4, where a higher expression was expected according to the 4-year 
DFS gene expression signature, showed lower expression in the poor survival group, where a 
higher expression was expected according to the 4-year DFS gene expression signature. The 
5 other assays did not show significant differences. We further tested expression of the tumor 
suppressor genes TIMP3 and MTUS1 that were present in both classifier sets, the candidate 
tumor suppressor gene MITF that acts in the development of melanocytes and optic cup-derived 
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p-value* 0,000 0,014 0,513 0,006 0,008 0,363 0,006 0,397 0,003 0,067 0,057 0,000 0,121 0,003 0,241
array class 0,952 0,593 0,287 0,577 0,369 0,255 0,461 0,102 0,535 0,160 0,027 0,872 0,142 0,829
4-year DFS class 0,942 0,139 0,247 0,465 0,773 0,392 0,983 0,424 0,472 0,809 0,207 0,061 0,291 0,491
1p loss 0,020 0,028 0,013 0,016 0,297 0,017 0,402 0,013 0,059 0,043 0,000 0,149 0,005 0,251
3 loss 0,037 0,477 0,339 0,073 0,871 0,280 0,378 0,040 0,726 0,233 0,008 0,332 0,066 0,570
6p gain 0,021 0,253 0,701 0,023 0,056 0,055 0,648 0,020 0,035 0,214 0,026 0,531 0,077 0,525
6q loss 0,002 0,156 0,351 0,015 0,003 0,008 0,461 0,012 0,023 0,152 0,006 0,158 0,072 0,395
8p loss 0,010 0,037 0,597 0,042 0,044 0,373 0,881 0,021 0,354 0,391 0,003 0,246 0,041 0,456
8p gain 0,002 0,073 0,536 0,010 0,018 0,275 0,019 0,003 0,031 0,130 0,002 0,106 0,020 0,214
8q gain 0,053 0,111 0,854 0,053 0,051 0,939 0,111 0,048 0,258 0,074 0,016 0,895 0,048 0,947
age 0,005 0,030 0,361 0,036 0,220 0,341 0,168 0,491 0,025 0,137 0,004 0,328 0,025 0,407
epitheloid present 0,004 0,123 0,204 0,036 0,046 0,781 0,046 0,430 0,012 0,180 0,008 0,076 0,032 0,340
vascular patterns 0,017 0,096 0,061 0,048 0,203 0,594 0,013 0,295 0,023 0,292 0,389 0,075 0,047 0,383
LTD 0,030 0,911 0,598 0,023 0,025 0,730 0,019 0,398 0,014 0,147 0,058 0,001 0,029 0,351
involv. ciliary body 0,006 0,062 0,342 0,037 0,041 0,542 0,025 0,629 0,018 0,192 0,165 0,004 0,509 0,613
m/f 0,003 0,079 0,523 0,022 0,028 0,477 0,017 0,355 0,015 0,116 0,093 0,002 0,197 0,021
*Log-rank test
†Multivariate analysis using Cox proportional hazard analysis
‡Likelihood ratio test, p-value represented by color: Dark gray boxes p>0.05; light gray boxes: 0.01 < p ≤ 0.05; white 
boxes: p ≤ 0.01
Table 3. Prognostic significance of different histopathological, clinical and chromosomal aberrations in the 
uveal melanoma cohort analyzed in this study on gene expression profile†‡
retinal pigment epithelial cells 11, PTGER4 that was described in the context of tumor formation 
in cervical cancer 12, the potential tumor suppressor HTRA1 13, HTATIP2 that is associated with 
metastasis suppression 14, LIMS2 that inhibits cell spreading and migration when overexpressed 15, 
TBC1D8 that contains a TBC domain presumed to be involved in regulation of cell growth 
and differentiation 16, the ras binding protein family member RAB31 and tumor necrosis factor 
receptor superfamily member 19, TNFRSF19. The results of these genes are shown in table 1, 
referred to as UM class add.
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Table 4. Gene expression classifier sets created in this study. The list contains all different genes in the classifiers, of 
which some are represented more than one time in the respective classifier.
4-year DFS UM class UM class adjusted
236081_at 237651_x_at ARID5B
cDNA: FLJ21271 fis, clone COL01751 ARID5B Clone IMAGE:5538654, mRNA
CITED1 C10orf86 COL9A3
Clone IMAGE:5301129, mRNA C6orf149 CUGBP2
CNTN3 cDNA FLJ39164 fis, clone 
OCBBF2002656
ENPP2
DLC1 Clone IMAGE:5538654, mRNA HSD17B8
ERBB3 COL9A3 HTATIP2
FBXL7 CUGBP2 HTR2B
FDFT1 ENPP2 HTRA1
FER1L3 ENTPD1 IL12RB2
FZD7 FBXO17 ITPR2
GCNT2 FLJ25477 MID1
Hypothetical LOC389634 GALNTL4 MTUS1
JAG1 GPR27 NEDD9
MBNL2 HSD17B8 PAM
MRNA; cDNA DKFZp434A202 HTATIP2 PHLDA1
MTUS1 HTR2B PLN
RIMS2 HTRA1 PTGER4
RNF19 IL12RB2 RAB31
SEMA3C ITPR2 SDC2
SLC1A4 LIMS2 SORBS2
SLC6A6 LMCD1 TBC1D8
SNCA MEGF10 TIMP3
SRD5A2L MGC40222 ZNF11B
SULF2 MGC9913
TIMP3 MID1
ULK4 Clone ICRFp507I1077, mRNA
UQCRB MTUS1
ZNF395 NEDD9
ZNF447 OVOS2
PAM
PARP8
PCDH20
PDE3A
PHLDA1
PLN
PPM1K
PTGER4
RAB31
RaLP
ROPN1
ROPN1
ROPN1B
SDC2
SIPA1L2
SLC44A3
SORBS2
SYNPR
TBC1D8
TIMP3
TNFRSF19
ZNF11B
ZNF667
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Finally, we have analyzed a set of genes that were described to be associated with prognosis in 
other gene expression profiling studies on UM, namely DDEFF1, PHLDA1, FZD6, ENPP2, ID2, 
LAMR1, ET2, CUL2 and VBP1. 5, 17-20 Real-time PCR showed significant higher expression of 
DDEFF1 in class 2 tumors; PHLDA1, ENPP2 and LAMR1 were significantly lower expressed in 
class 2 tumors. The lower expression of CUL2 and VBP1 in class 2 tumors was not significant. 
FZD6, ID2 and ET2 were not conclusive because no expression was detected in 5 or more 
tumors. MITF showed significant lower expression in class 2 tumors.
Survival analysis
We evaluated the predictive value of the classifiers for patient survival using Kaplan-Meier life 
table analysis (data not shown). Survival analysis of all 46 patients showed that all patients in UM 
class 2 developed metastatic disease within 7 years of follow-up whereas 86% of the patients in 
class 1 did not suffer from metastatic disease in this time period (p-value 0.0004). Survival analysis 
of the groups predicted with the 4-year DFS classifier also showed no 7-year DFS survival in 
the shorter survival class versus 80% DFS of the patients in the longer survival class (p-value 
0.04). Kaplan-Meier survival analysis was also performed for the parameters chromosome 3 
loss, 6p gain, 8p loss, 8q gain, vascular patterns and ciliary body involvement, all significant after 
correcting for possible confounders. UM class outperformed all other cytogenetic, clinical and 
pathological prognostic factors (data not shown).
Analysis of other UM expression data sets
To evaluate the predictive value of the UM classifier we were able to use the expression profiles, 
kindly provided by Tschentscher et al. 4, and Onken et al. 5 All annotations in our classifier were 
present on the Affymetrix U133A and B chips that were used by the group of Onken et al., but 
on the Affymetrix U95Av2 chips that were used by Tschentscher et al., only 32 gene annotations 
of our classifier could be identified. For this reason, we have analyzed the complete data set of 
the three different research groups with an adjusted UM classifier containing the 32 annotated 
genes, present in all datasets. As a training set, we have chosen the same set of tumor samples 
that was used earlier in the UM array class prediction, the remaining samples of our dataset were 
analyzed together with the other datasets. Results are visualized in figure 2. All 62 tumors in the 
test set were classified according to the results presented by Tschentscher et al.  4 and Onken et 
al. 5 with the exception of two samples (MM27 and M18672). 
LAP analysis
The Locally Adaptive statistic Procedure (LAP analysis) was used to identify differentially 
expressed chromosomal regions for chromosome 3 status, UM class and 4-year DFS. LAP 
analysis using monosomy 3 as discriminator confirmed a lower expression of genes over the 
entire chromosome 3 in tumors with monosomy 3. These monosomy 3 tumors appear to have a 
decreased expression of genes in the telomeric 2 Mb of chromosome 1p36 and on chromosome 
8q large regions of higher expression. Other regions of higher expression in tumors with 
chromosome 3 monosomy were detected on chromosomes 1q, 7, 9, 14, 15, 17, 20 and 21 
(fig. 3A). In tumors with two copies of chromosome 3 a chromosome 6p region (15 Mb from 
6p24.3 to 6p22.2) showed a significant higher expression. 
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LAP analysis on UM class revealed lower expression of almost the entire p-arm of chromosome 
3 in class 1 tumors, whereas no significant differential expression of chromosome 3q was found 
between the two tumor classes. Additionally, a part of chromosome 6p (6 Mb from 6p24.3 to 
6p23) showed significantly higher expression in class 1 and chromosome 8q had large regions of 
higher expression in class 2. Also higher expression of 1q in the poor prognosis class and other 
smaller regions of differential expression were found (fig. 3B). 
Less differentially expressed chromosomal regions were found when comparing tumors from 
patients ≥4-year DFS with tumors from patients <4-year DFS. Remarkably, on the p-arm of 
chromosome 3, two smaller regions with lower expression in the short survival group were 
found; one region of 8 Mb ranging from the end of 3p23 to 3p25.3 and one region of 9 Mb 
ranging from 3p12 to 3p14.1. A small region of 0.5 Mb on chromosome 6p (6p23-6p24.1) 
showed significantly higher expression in tumors with a longer DFS. On chromosome 8, a large 
fraction of the p-arm showed significantly lower expression in the short DFS group whereas 
large regions on the q-arm were up regulated in this group. Additionally, regions of significantly 
higher expression in the short survival group are located on chromosome 10, 12, 13 and regions 
on chromosome 15 (fig. 3C).
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Figure 2. Test Probabilities (threshold=2) in multiplatform PAM analysis of UMs with the 32 UM class gene 
classifier. Tumors belonging to class 1, according to the literature, are placed on the left side, the tumors belonging 
to class 2 on the right side. The class 1 prediction probability of a sample with our 32-gene classifier is indicated with 
open diamonds, the class 2 probability with filled boxes. The samples were classified according to the highest prediction 
probability. Tumors: M1 numbers from data set Onken et al. [5]; MM numbers from Tschentscher et al. [4]; EOM numbers 
from our own data set. Class 1: sensitivity 1 and specificity 0,94; Class 2: sensitivity 0,93 and specificity 1.
Chapter 234
Figure 3. Whole genome plot of the differentially expressed genes in LAP analysis at a q-value of <0.05. 
The colored perpendicular lines represent the exact chromosomal locations, orientations, and up- (red) or down-
regulation (green) states of the differentially expressed genes, while the white bars indicate locations and orientations 
of all probe sets in the microarray. Positions for both the sense and antisense strands are expressed in numbers of base 
pairs measured from the p (5’ end of the sense strand) to q (3’ end of the sense strand) arms; upper and lower bars 
stand for genes on sense and antisense strands, respectively. A) Differential expression of tumors with monosomy of 
chromosome 3 compared to tumors with normal copy numbers of chromosome 3. B) Differential expression of tumors 
in class 2 compared to tumors in class 1. C) Differential expression of tumors from patients with DFS ≤ 4 years compared 
to tumors from patients with DFS >4 years.
Color figure can be found on page 141.
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Discussion
We provide results of gene expression profiling analysis of primary tumors from 46 selected 
patients with UM of all age groups and tumor sizes. Unsupervised clustering of the gene 
expression profiles grouped the tumors into two distinct classes that are strongly related with 
prognosis and 4-year DFS. Other parameters that have a strong correlation with this micro-array 
based classification are chromosome 3 loss, chromosome 6 abnormalities, vascular patterns and, 
surprisingly, gender. Chromosome 3 loss and the presence of closed vascular patterns, both more 
occurring in class 2, are known predictors of poor survival. 2, 21-23 The higher frequency of gains of 
chromosome 6p in class 1 corresponds with the earlier observed positive relation of prognosis 
with abnormalities of chromosome 6, resulting in a relative increase of 6p material compared to 
the q-arm 22. We were able to confirm these findings in our analyzed cohort using Kaplan-Meier 
survival analysis. Array class, chromosome 3 loss, 6p gain, 8p loss, 8q gain, vascular patterns and 
ciliary body involvement were strongly related with prognosis in multivariate analysis using Cox 
proportional hazard analysis. Due to the tumor selection the results differ from previous results 
by our group 24 on a larger cohort of UMs. In this latter study, chromosome 3 loss and 8q gain were 
also significant after correcting for most confounding parameters, but LTD was also significant. In 
contrast, 6p gain, 8p loss, presence of vascular patterns and ciliary body involvement were not 
significant after correcting for confounders in that study. The relatively small size of our currently 
analyzed cohort and an apparent overrepresentation of tumors with structural abnormalities on 
chromosomes 1, 3, 6 and 8 could explain this discrepancy.
Because of the very strong relation of micro-array based UM class with survival, that outperforms 
all known prognostic clinical, histopathological and cytogenetic parameters in the studied patients, 
we used PAM analysis to obtain a gene signature that accurately predicts for UM micro-array 
class. The created 69-gene classifier flawlessly predicted for UM class. We also developed a 
gene-expression signature for 4-year DFS. This 61-gene classifier set had a sensitivity of 0.89 
and a specificity value of 0.60. The low specificity value could be a result of the low number 
of patients in the poor survival group in the test set (only four patients), thereby increasing 
the influence of one misclassified patient. However, when the tumors are classified with this 
signature, this results in two groups of patients of which one has a survival rate of 80% after 
120 months of follow-up, whereas all patients in the other group suffered from metastatic 
disease in this period (p=0.014). This classification is also outperformed by UM based tumor 
classification (86% vs. 0% of the patients with DFS after 120 months; p<0.001; hazard ratio 
7.7). We confirmed differential expression in the 8 most differentially expressed genes of the 
array class classifier, indicating that the micro-array findings are truly representative for the 
UM samples. Additionally, we confirmed 7 potentially interesting tumor suppressor genes and 
oncogenes, based on literature, that were also represented by our classifier and we analyzed a 
set of genes that were previously described to be differentially expressed in micro-array analyses 
on UM. PHLDA1, FZD6 and ENPP2 form the optimal three-gene set that was used for additional 
screening of UMs with Real-time PCR by Onken et al. and loss of ID2 expression, another highly 
differentially expressed gene, has been shown to increase anchorage-independent growth in 
UM. 5, 25 DDEFF1 was described by Ehlers et al. 17  to be the gene that correlates most strongly 
with gain of chromosome 8q in their gene expression analysis. In our dataset DDEFF1, PHLDA1, 
ENPP2 and ID2 are also differentially expressed, corresponding to the data of Onken et al. and 
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Ehlers et al. The gene PHLDA1 (pleckstrin homology-like domain, family A, member 1) is of 
particular interest, since it is also represented in the gene expression classifier set Tschentscher 
et al. 4 and there is strong evidence that reduced expression of this apoptosis related gene is 
important in breast cancer progression. 26
To assess the robustness of micro array classification of UMs, we also applied our UM class 
gene-expression signature to UMs that had been analyzed by two other institutions 4, 5. Our 
UM classification was in agreement with their earlier predicted class, with the exception of two 
tumors, M18672 described by Tschentscher et al. 4  and MM27 described by Onken et al 5. In 
the original studies, both tumors differed the most from all other tumors in their respective 
tumor class and clustered to the class containing predominantly tumors with monosomy of 
chromosome 3, whereas both tumors showed retention of both alleles of this chromosome 4, 5. 
This indicates that these two tumors are difficult to classify based on unsupervised clustering 
with gene-expression profiling and that with our classifier they were classified in concordance 
with their chromosome 3 status. These data underline the robustness of micro-array based UM 
classification, that was also reported by Onken et al., Worley et al. and Petrausch et al. 5, 27, 28
LAP analysis was used to determine whether the differential expression was associated 
with specific genomic regions. We used chromosome 3 status, UM class and 4-year DFS as 
discriminatory factors in the LAP analysis. 
As could be expected, tumors with monosomy 3 showed lower expression of all the chromosome 
3 genes. The results of LAP analysis on UM class showed that only chromosome-arm 3p and not 
3q is significantly down regulated in the poor survival group.
In both these LAP analysis a large part of the genes on chromosome 8q are up-regulated and 
down-regulation of genes in a region on chromosome 6p was observed.
Interestingly, LAP analysis with 4-year DFS as discriminator revealed in the group with a shorter 
DFS two small regions of down-regulated genes on chromosome 3, one region of 8 Mb ranging 
from the end of 3p23 to 3p25.3 and one region of 9 Mb ranging from 3p12 to 3p14.1. These 
regions overlap with the two regions, 3p25-26 and 3p11-14, identified by Cross et al. 29 using 
micro satellite analysis. Surprisingly no regions on chromosome-arm 3q showed differential 
expression. The adverse effect on survival of monosomy of chromosome 3 is probably caused 
by decreased expression of tumor suppressor genes located on the identified regions on 3p. 
An interesting candidate gene in the most proximal region is MITF. This gene is located at 
3p13 translocation breakpoint of a t(3;14) reported in UM 30 and is possible disrupted by this 
translocation. Real-Time PCR analysis showed that MITF expression was significantly lower in 
class 2 tumors (table 1). MITF acts in the development of various cell types, including neural crest-
derived melanocytes and optic cup-derived retinal pigment epithelial cells. 31 It transactivates the 
tyrosinase gene, a key enzyme for melanogenesis, known to be critically involved in melanocyte 
differentiation. 11 However, no correlation between MITF-positivity and the parameters cell type, 
largest tumor diameter, sclera invasion and mitotic figures was observed in UM as reported by 
Mouriaux et al. 32. In melanoma cell lines in which the gene was repressed, induced expression 
of MITF-M showed growth-inhibitory effects and led to a change from epitheloid toward a 
spindle-cell type in vivo. 33 This suggests that decreased expression of MITF would lead to a 
more epitheloid phenotype, which is related with poor prognosis in UM. Interestingly, although 
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MITF was also significantly lower expressed in the shorter DFS group, its expression was not 
significantly lower in tumors with an epitheloid cell type (data not shown). Our data point to 
association of MITF expression and survival and it would be interesting to corroborate this in a 
larger UM cohort. Other candidate tumor suppressor genes on the proximal 3p-region are the 
Tata element Modulatory Factor 1 (TMF1) and EGF receptor antagonist leucine-rich repeats and 
immunoglobulin-like domains 1 (LRIG1). TMF is a transcription factor that likely regulates the 
expression of genes via the TATA element. 35 Down-regulation of LRIG1 increases cell-surface 
EGF receptor levels, enhances activation of downstream pathways, and stimulates epidermal 
cells proliferation. 36 The other region, ranging from 3p23 to 3p25.3, harbors multiple candidate 
TSGs, of which XPC, WNT7A, PPARG and TIMP4 are the most promising genes. XPC is a well-
described DNA repair gene that functions via nucleotide excision repair (NER) and is linked to 
type C xeroderma pigmentosum that concurs with a high incidence of malignant melanoma. 
37 WNT7A belongs to the Wnt gene family, which genes are implicated in oncogenesis and 
several developmental processes. 38 Peroxisome proliferator-activated receptor g (PPARG) is 
a nuclear hormone receptor that acts in differentiation of adipocytes in particular, although this 
gene is also expressed in other tissue types. Activation of PPARG in different cancer cell types 
induces cell growth inhibition and differentiation. 39 This inhibitory effect would be impaired by 
decreased expression of this gene. TIMP4 belongs to the tissue inhibitors of metalloproteinases 
(TIMPs) that inhibit matrix metalloproteinases (MMPs), which are involved in degradation of the 
extracellular matrix. Overexpression of recombinant TIMP4 in breast cancer cells inhibited the 
invasion potential of the cells in vitro. 40 Decreased expression of TIMP4 might therefore lead to 
an increased invasive potential. 
The selective decreased expression of genes in the two regions on chromosome 3p in poor 
prognosis uveal melanomas could, besides loss of chromosomal DNA, also be caused by 
epigenetic mechanisms like methylation of gene promoter regions. Promoter methylation has 
been identified as the mechanism responsible for lower expression of the classifier gene TIMP3 
in uveal melanoma. 20 In addition, methylation of RASSF1A has been shown to be a sensitive 
prognostic marker in uveal melanoma. 41 Lower expression of blocks of genes in those regions on 
3p in the absence of deletions could indicate epigenetics as an alternative mechanism of regulation 
of gene expression. It is therefore interesting to look at the methylation status of classifier genes 
in tumors of patients in the poor prognosis UM class without chromosome 3 aberrations. This 
could explain the presence of two UM with normal copy numbers of chromosome 3 in our UM 
class 2 group and the misclassification of the MM27 and M18672 from the Tschentscher 4 and 
Onken 5 cohorts, respectively. 
In summary, we have created a very robust gene expression signature predicting for micro-array 
class that classifies correctly tumors analyzed on different micro-array platforms. Survival analysis 
with our extensive follow-up data revealed a very strong relation between this classification 
and DFS that is superior to all other known UM prognostic classifiers. Recently, the superiority 
of this classification was confirmed by Worley et al. 27 and Petrausch et al. 28 This offers great 
perspectives for predictive screening, and prospective studies using UM biopsies as source of 
RNA are being set up. 42
Furthermore, the genes in the micro-array classifier set that are located at the plasma membrane 
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are especially potential markers for prognostic screening. There are 9 such genes in the classifier, 
of which 4 (ENPP2, ENTPD1, IL12RB2 and TBC1D8) have lower and 5 (HTR2B, PAM, PTGER4, 
SDC2 and TNFRSF19) have higher expression levels in class 2 tumors. Immunohistochemical 
studies might reveal their value for prognostic screening and their potential use in treatment 
strategies. 
Using expression profiling, we have identified two small regions on chromosome 3 of which the 
lower expression correlates with poor survival. If indeed epigenetic mechanisms as methylation 
are the cause of this decreased expression, it offers an excellent starting point for a better 
predictive, non-invasive test for the early detection of metastatic disease. 
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Abstract
Purpose: Uveal melanoma is one of the most frequent primary intraocular malignancies in the 
western world. Cytogenetically these tumors are characterized by typical chromosomal losses 
and gains, such as loss of chromosome 1p, 3, 6q and gain of chromosome 6p, and 8q. Whereas 
most studies focus on known aberrations we characterized cytogenetic changes and correlated 
them with clinical and histopathological parameters. 
Patients and methods: Karyotypes of 74 primary uveal melanomas were analyzed with respect 
to the presence or absence of chromosomal gains and losses. In the analysis classical clinical and 
histopathological parameters were analyzed together with the chromosomal aberrations. 
Results: At a median follow up of 43 months 34 patients had died or were suffering from 
metastatic disease. Clonal chromosomal abnormalities were present in 59 tumors. The most 
frequent chromosomal abnormalities involved chromosome 8 (53%), loss of chromosome 3, 
p-arm (41%) and q-arm (42%), partial loss of chromosome 1p (24%) and abnormalities of 
chromosome 6, which resulted in gain of material of 6p (18%) and/or loss of 6q (28%). Less 
frequent aberrations were abnormalities of chromosome 16, in particular loss of chromosome 
16q (16%). In the univariate analysis loss of chromosome 3, largest tumor diameter, gain of 8q 
and mixed/epithelioid cell type in the tumor compared to tumors without these chromosomal 
changes or with a spindle cell type was associated with a decreased disease free survival. 
When corrected for another confounding variable significance of gain of 8q and cell type was 
decreased, whereas the significance of loss of chromosome 3p or 3q and largest tumor diameter 
remained.
Conclusions: Monosomy 3 and largest tumor diameter are the most significant in determining 
survival for uveal melanoma patients. Abnormalities of chromosome 16q are relatively common 
in uveal melanoma, but are not associated with survival or other cytogenetic or histopathological 
parameters.
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Introduction
Uveal melanoma (UM) is the most common primary intra-ocular tumor in the western world, 
affecting approximately 7 per million people each year. Tumorigenesis and progression of cancer 
is in general preceded by the occurrence of genetic changes in normal cells. 1 In this respect 
UMs are quite homogenous with a few tumor specific cytogenetic aberrations. Some of these 
aberrations are correlated with the metastatic potential of the tumor resulting in metastatic 
disease followed by death. Recurrent aberrations in UM concern loss of chromosome 1p, 
monosomy of chromosome 3, loss of chromosome 6q and 8p, gain of chromosome 6p and 8q.
Loss of chromosome 1p was observed in metastases 2 and concurrent loss of chromosome 1p 
and 3 is associated with decreased survival. 3,4 Furthermore, monosomy 3 is considered to be an 
early event in UM and several studies have shown that it is a strong predictor for survival. 5-7 Loss 
of chromosome 3 is frequently associated with amplification of chromosome 8q, often seen as 
an isochromosome 8q. 8,9
Recently, Hoglund et al. elucidated a common genetic pathway for both uveal as cutaneous 
melanoma.10 Monosomy 3 occurs probably as an early event and loss of chromosome 1p, 8p and 
gain of 8q as secondary events.
Regions of chromosomal loss are thought to harbor tumor suppressor genes and regions of 
gain oncogenes. Previous cytogenetic analyses focus in general on the known aberrations. In 
this study we performed cytogenetic analysis on short-term cell cultures of fresh tissue from 
74 primary UMs to characterize all chromosomal changes and correlate these changes with 
clinical and histopathological parameters. Significant prognostic parameters for UM, at high-risk 
for metastases, were identified.
Material and methods
Patients and tumor samples
From March 1992 to April 2003, we collected tumor material of patients who underwent 
enucleation for ciliary body or choroidal melanoma. Informed consent was obtained prior to 
enucleation and the study was performed according to the tenets of the Declaration of Helsinki. 
Fresh tumor material was obtained within 1 hour after enucleation and processed as described 
before. 3 Conventional histopathologic examination was performed on all tumors and confirmed 
the origin of the tumor. Cytogenetic studies were also carried out on stimulated peripheral 
blood samples of each patient to exclude the presence of congenital chromosome abnormalities. 
Follow-up data from time of diagnosis till the end of the study in December 2005 were obtained 
by reviewing patient’s charts and contacting their general physician.
Cytogenetic analysis
Chromosome preparations were made according to standard procedures and stained with 
acridine orange or atebrine to obtain R or Q banding. Cytogenetic abnormalities were described 
in accordance with the ISCN (1995).11
Clinical and cytogenetic analyses in uveal melanoma 45
Data classification
Based on the cytogenetic analysis tumors were classified for gain and or loss for all chromosomal 
regions, p-arm or q-arm. When different subclones were identified, only the cytogenetic findings 
of the largest clone were classified. Chromosomal regions with loss in more than 10% of all 
tumors and gain in more than 15% of all tumors were included for analysis. Tumors were 
identified as small (<12mm) and large (> 12mm).
Statistical analysis
The primary end point for disease free survival (DFS) was the time to development of metastatic 
disease, whereby death due to other causes was treated as censored. The influence of single 
prognostic factors on DFS was assessed using the log rank test (for categorical variables) or Cox 
proportional hazard analysis (for continuous variables) and Kaplan-Meier curves were made to 
illustrate the differences in survival. To examine the possibility that other clinical, histopathological 
or chromosomal variations may affect the prognosis we performed Cox proportional hazard 
analysis for each confounding variable. An effect was considered significant if the p-value was 
0.05 or less. The odds-ratios with corresponding p-values were calculated to identify association 
between the different parameters. The statistical analyses were performed with the SPSS-11 
software.
Results
Patients
From March 1992 to April 2003 152 patients were available for this study, but chromosome 
analysis was successfully performed in 74 cases. The clinical and histopathological features of 
the 74 primary UMs are listed in the supplementary information. The median age of the patients 
at time of enucleation was 60 years (range 21-87 years), 29 women and 45 men. One patient 
was lost to follow-up after 27 months. At the end of follow-up time 31 patients had died of 
melanoma-related disease, 3 patients were diagnosed with metastases, 9 patients had died due 
to other causes and 31 patients were still alive without metastases. The median follow-up time 
was 42.8 months (range 6.4 - 164.4 months).
Histopathology
All tumors were confirmed histopathologically as UM. Based on their cell type 16 tumors were 
classified as epithelioid cell type, 24 as mixed cell type and 34 tumors as spindle cell type. The 
mean tumor diameter and thickness were 13.2 mm (range 6-19 mm) and 8.4 mm (range 2-22 
mm), respectively. Four tumors were located in the ciliary body and 70 were located in the 
choroid. From the tumors located in the choroid four showed involvement of the ciliary body.
Cytogenetic
Seventy-four UMs were analyzed for cytogenetic changes (see supplementary information) 
and classified for gain and loss for all chromosomal regions (Table 1). Clonal chromosomal 
abnormalities were present in 59 tumors. The most frequent chromosomal abnormality involved 
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chromosome 8, trisomy of chromosome 8 or gain of material from 8q, most often in the form 
of an i(8q) (53%). Other abnormalities involved loss of chromosome 3, p-arm (41%) and q-arm 
(42%). Partial loss of chromosome 1p (24%) and abnormalities of chromosome 6, resulting 
in gain of material of 6p (18%) and/or loss of 6q (28%). Other less frequent aberrations were 
abnormalities of chromosome 16, in particular loss of chromosome 16q (16%) (Figure 1).
Other chromosomal aberrations, such as loss of 6p, 9p, 15p, 15q, 21p, 22p and gain of 2p, 2q, 
7q, 9p, 11q were present but did not reach the 10%.
Statistical analysis
Univariate analysis was performed for all clinical, histopathological and cytogenetic parameters 
(Table 2, Figure 2). Univariate analysis of the single prognostic factors showed significant lower 
disease free survival (DFS) for patients with loss of chromosome 3, largest tumor diameter, gain 
of 8q and with a mixed/epithelioid cell type in the tumor compared to tumors without these 
chromosomal changes or with a spindle cell type. Other potential prognostic factors such as 
gender, age at time of diagnosis and tumor location (i.e. involvement of ciliary body) did not reach 
significance. Also chromosomal changes such as loss of chromosome 1p, gain of chromosome 6p 
and loss of chromosome 6q were not significantly associated with disease free survival. To examine 
the possibility that other clinical, histopathological or chromosomal variations may affect the 
prognosis we performed Cox proportional hazard analysis for each confounding variable (Table 2). 
Parameters presented in the columns are the investigated prognostic parameters; in the rows 
the same parameters resemble the confounders with a possible modifying effect. Significance of 
loss of chromosome 3p/3q did not alter after correcting for the possible confounders. A similar 
pattern was observed for largest tumor diameter and cell type. Odds ratios were calculated to 
identify association between the different parameters (Table 3). Associations were shown for 
loss of chromosome 3 with gain of 8q, loss of chromosome 8p, vascular patterns and largest 
tumor diameter (>12 mm), and a weak association with mixed/epithelioid cell type. Presence 
of vascular patterns and largest tumor diameter (>12 mm) showed also association with gain 
of chromosome 8q. Associations were also present for loss of chromosome 1p with loss of 16q 
and loss of chromosome 3p, and weak association with cell type, vascular patterns largest tumor 
diameter, chromosome 3q loss and 8q gain. Loss of chromosome 6q was weakly associated 
with gain of chromosome 8q. Loss of chromosome 16q was weakly associated with gain of 
chromosome 8p.
Discussion
By means of karyotyping we have analyzed chromosomal aberrations in UM. Previous reports 
have revealed that abnormalities of chromosome 1, 3, 6 and 8 occur in a nonrandom fashion in 
UM. Some of these tumor specific aberrations have been associated with the metastatic potential 
of the tumor. In this study loss of chromosome 1p, chromosome 3, aberrations of chromosome 
6, 8 and 16 are most often encountered. Furthermore, we have demonstrated that tumors with 
abnormalities of chromosome 3, gain of chromosome 8q, epithelioid/mixed cell type and a larger 
tumor diameter are strongly associated with a poor prognosis. 
In UM numerous parameters have been used to predict survival, with the conventional parameters 
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Figure 1. Karyotype of tumor 
EOM 63. This tumor showed 
chromosomal changes for UM: 
-3, i(6)(p), i(8)q (multiple copies) 
and del(16)(q21).
Table 1. Recurrent changes in karyotype of primary uveal melanoma
Loss and gain >10% of all tumors n=74
1p loss 18 (24%)
3p loss 30 (41%)
3q loss 31 (42%)
6p gain 13 (18%)
6q loss 21 (28%)
8p gain 13 (18%)
8p loss 18 (24%)
8q gain 39 (53%)
16q loss 12 (16%)
Loss and gain <10% of all tumors
2p gain 4 (5%)
2q gain 4 (5%)
6p loss 7 (9%)
7q gain 4 (5%)
9p gain 4 (5%)
9p loss 7 (9%)
11q gain 7 (9%)
15p loss 7 (9%)
15q loss 7 (9%)
21p loss 7 (9%)
22p loss 7 (9%)
being tumor size, tumor location, cell type and vascular patterns. 12 None of these factors are 
entirely solid, and there has been considerable variation in interpretation among observers. In 
contrast to some previous reports 13 we did not find chromosome 11 and 21 to occur very 
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often (Table 1) and therefore these aberrations were not included in the analysis. In addition, we 
identified loss of chromosome 16q. Chromosome 16 loss, in particular 16q, also mentioned in 
earlier reports 10,13 occurred in more than 10% of the UMs. Even though it was not significantly 
associated with disease free survival it still might be involved in tumor progression. A remarkable 
association was shown for loss of chromosome 16q with loss of chromosome 1p. Delineation 
of a region on chromosome 16q may depict a region of interest with possible candidate genes. 
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p-value* ,897 ,063 ,298 ,840 ,116 ,018 ,007 ,284 ,0009 ,0021 ,424 ,6997 ,6192 ,117 ,023 ,233
m/v ,063 ,304 ,849 ,125 ,020 ,008 ,272 ,001 ,003 ,427 ,698 ,613 ,118 ,020 ,195
age ,964 ,443 ,643 ,289 ,039 ,026 ,376 ,004 ,009 ,405 ,488 ,557 ,149 ,014 ,262
epithelioid present ,962 ,086 ,649 ,257 ,046 ,009 ,309 ,003 ,005 ,490 ,576 ,594 ,161 ,026 ,186
involv. ciliary body ,912 ,057 ,264 ,091 ,015 ,010 ,269 ,001 ,003 ,421 ,716 ,616 ,118 ,025 ,218
vascular pattern ,701 ,034 ,419 ,502 ,141 ,070 ,531 ,012 ,027 ,283 ,157 ,816 ,438 ,172 ,687
cell type ,671 ,105 ,771 ,458 ,248 ,004 ,112 ,008 ,013 ,597 ,688 ,427 ,512 ,053 ,145
LTD ,498 ,205 ,256 ,797 ,198 ,005 ,775 ,022 ,062 ,272 ,580 ,561 ,446 ,128 ,511
1p loss ,776 ,075 ,322 ,727 ,167 ,009 ,016 ,003 ,004 ,521 ,647 ,935 ,093 ,042 ,420
3p loss ,543 ,187 ,719 ,482 ,356 ,176 ,105 ,663 ,730 ,258 ,844 ,510 ,465 ,603 ,399
3q loss ,647 ,204 ,658 ,523 ,456 ,141 ,141 ,417 ,259 ,284 ,663 ,482 ,617 ,481 ,358
6p gain ,921 ,060 ,341 ,805 ,167 ,028 ,008 ,354 ,001 ,002 ,571 ,694 ,122 ,027 ,185
6q loss ,885 ,053 ,269 ,873 ,058 ,021 ,010 ,274 ,002 ,003 ,379 ,651 ,124 ,029 ,251
8p gain ,872 ,060 ,295 ,830 ,117 ,017 ,010 ,347 ,002 ,003 ,455 ,741 ,084 ,021 ,251
8p loss ,787 ,074 ,389 ,756 ,150 ,074 ,021 ,213 ,002 ,006 ,426 ,712 ,348 ,068 ,219
8q gain ,456 ,033 ,280 ,676 ,251 ,051 ,038 ,628 ,026 ,043 ,430 ,949 ,528 ,546 ,490
16q loss ,589 ,067 ,248 ,702 ,126 ,014 ,015 ,505 ,002 ,004 ,342 ,770 ,674 ,114 ,041
*Log-rank test (for categorical variables) or cox proportional hazard analysis (for continuous variables)
†Multivariate analysis using Cox proportional hazard analysis
‡Likelihood ratio test, p-value represented by color: >.10 =white, <.10 and >.05 = light shaded, < .05 = dark shaded
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m/v 0.167 0.953 0.042 0.283 0.196 0.218 0.862 0.118 0.099 0.079 0.600 0.903 0.077
involv. ciliary body 0.343 0.562 0.481 0.365 0.259 na 0.185 0.566 0.684 0.559 0.962 0.313 0.692
8p gain 1.038 1.667 0.010 0.929 0.208 0.565 0.071 0.650 0.816 na na 0.378 0.322
16q loss 0.256 1.867 0.927 0.005 0.756 0.766 0.575 0.178 0.255 0.103 0.430 0.271 0.129
1p loss 0.556 2.040 5.303 6.491 0.088 0.426 0.086 0.012 0.084 0.063 0.389 0.948 0.155
cell type 0.440 0.409 3.913 0.796 6.220 na 0.136 0.049 0.085 0.153 0.002 0.774 0.550
epithelioid present 1.889 na 1.508 0.818 1.658 na 0.003 0.048 0.076 0.418 0.173 0.324 0.161
vascular pattern 0.915 3.200 3.758 1.500 2.900 0.367 6.500 0.016 0.004 0.003 0.153 0.268 0.163
3p loss 0.467 1.538 1.321 2.374 4.222 0.316 3.148 3.600 0.000 0.000 0.000 0.798 0.866
3q loss 0.448 1.357 1.154 2.072 2.619 0.367 2.667 4.800 396.333 0.000 0.000 0.966 0.702
8q gain 0.421 1.569 na 3.200 3.000 0.424 1.513 5.042 24.000 19.727 0.002 0.047 0.603
8p loss 0.750 1.042 na 1.714 0.547 0.143 2.568 2.333 24.000 20.000 11.478 0.593 0.553
6q loss 1.066 0.329 1.758 2.054 0.962 0.838 0.583 0.523 1.143 0.978 3.021 1.367 0.126
6p gain 0.328 0.643 0.340 2.944 0.216 1.638 0.415 0.361 0.900 0.787 0.727 1.492 2.629
na = not available
The odds ratios are given below the black boxes and the corresponding p-values above. The shaded areas represent p-value <. 05.
Table 3. Relation between different histopathological, clinical and chromosomal aberations
Table 2. Prognostic significance of clinical, histopathological and chromosomal aberrations in uveal melanoma†‡
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Other tumors, s.a. breast cancer and neuro-ectodermal tumors have also shown deletion on 
16q. 14,15 In these tumors candidate genes have not yet been identified. Since UM cells are derived 
from neuro-ectodermal tissue this might be of potential interest. In many reports outcome was 
correlated with tumor location. 7,16 Since we had limited sample size in the group tumors located 
in the ciliary body we were not able to make reliable assumptions on association of outcome 
with tumor location. Largest tumor diameter in our study was histopathologically measured. 
This parameter may be used non-invasively in a clinical setting (measurement on ultrasound) 
and may be the most reliable non-invasive prognostic parameter. However, there is a variation 
between clinical and histopathological measurements. The tumor size measured on ultrasound 
is in general larger than the histopathological measurement. In contrast, the detection of specific 
chromosomal aberrations by routine FISH, CGH and karyotyping provides a more objective 
measurement of potential tumor behavior. Identification of monosomy 3 in a tumor sample 
is widely accepted as the most reliable prognostic parameter. 5-7 Monosomy of chromosome 
3 is considered as an early event, occurring before alterations of chromosome 8, 1 and 6. 5-7 
Moreover, it may cause isochromosome formation of especially isochromosome 6p and 8q. 8,9 
Table 3 may also support this hypothesis, since the odds ratios for loss of chromosome 3p 
or 3q and gain of chromosome 8q or loss of 8p were higher than the combination of loss of 
Figure 2. Kaplan-Meier survival curves for clinical, histopathological and chromosomal aberrations.
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chromosome 3p or 3q and gain of chromosome 8p. However, in our series we cannot conclude 
the same for isochromosome 6p. In addition, gain of chromosome 8q was significantly associated 
with survival in the univariate analysis (Table 2), but when corrected for confounding variables, 
s.a. vascular pattern, cell type, LTD and chromosome 3p or 3q loss, significance was absent 
implying that gain of chromosome 8q occurs together with at least one of those other variables. 
On the contrary, when this same procedure was followed for chromosome 3p or 3q loss we 
observed that the significance remained. In table 3 the odds ratios were shown for different 
chromosomal parameters. If we put the odds ratios in following order, chromosome 8q gain, and 
consequently 8p loss, follows monosomy 3, and loss of chromosome 1p and 16q occur thereafter. 
This is consistent with the findings observed by Hoglund et al. 10 Moreover, tumor diameter is 
associated with most of the chromosomal aberrations, implying that larger tumors have more 
aberrations. Our study involves patient samples from relatively large tumors that were treated 
by enucleation. Considering monosomy 3 as an early event 17 it is likely that it would be observed 
in even the smallest amount of tissue despite the heterogeneity of UM. Though, there are no 
studies to date that confirm the uniform distribution of cytogenetic abnormalities in UM, and it 
is at least theoretically possible that small amounts of tissue (s.a. used for karyotyping, FISH and 
CGH) do not contain the cytogenetic markers of interest. 
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EOM gender age localisation cell type Largest 
tumour 
diameter
vascular 
pattern
metastasis Karyotype
3 m 62 choroid mixed 12 ND no* 46,X,-Y,+5,-6,+18 
9 m 62 choroid epithelioid 15 ND yes 46,XY (6/11)/ 46,X,-Y,i(6)(p10),i(8)(q10),+i(8)
(q10),+i(8)(q10),der(13)t(13;16?)(p12;p11?),-16 (4/11)
27 m 86 ciliary body epithelioid 8 ND no* 46,XY normal
31 m 65 choroid epithelioid 7 yes yes 44,X,-Y,der(1)t(1;6)(p11;p11),add(2)(q22),-3,-6,+8
36 m 27 ciliary body epithelioid 10.5 yes yes 45,XY,-3 (37,5%)/45,XY,-3,i(8q) (62,5%) 1/16 46,XY,-
3,i(8q),+8
37 m 71 choroid mixed 7 ND yes 46, XY,del(11)(q22q25),add(15)
38 m 49 choroid mixed 5.5 ND no 45,X,-Y (79%)/46,XY (21%)
40 m 33 choroid mixed 13 ND no 47,XY,del(1)(p22),add(7)(q36),+i(8q)? 
(18%)/47,XY,del(1)(p22),del(6)(q13q24),add(7)
(q36),+i(8q) (82%). 
42 f 47 choroid mixed 14 yes yes 46,XX normal
43 m 80 choroid mixed 13 yes no* 45,X,-Y,del(1)(p22p32),+der(2;8)(q10;q10),+i(2)
(q10),-3,+4,der(6)t(6;15)(p22;q21),7?,-8,-8,del(9)
(p13),add(21)(p11)
45 m 61 choroid epithelioid 11 ND yes 46,XY (56%)/ 45,X,-Y (44%)
48 f 55 ciliary body spindle 10 no yes 43,XX,i(1)(q10),-3,-4,der(6)del(6)(q1?5q2?5)ins(6;?3)
(q1?5;?p12p22),der(13;22)(q10;q10),t(14;19)
(q22;?p13),der(16)t(3;16)(q21;p12),-18,+20
50 m 57 choroid epithelioid 6 no yes 45,X,-Y (18%)/ 45,X,-Y,add(13)(q14)(70%)/ 45,X,-
Y,der(10;15)(q10;q10),add(13)(q14)(12%)
53 m 68 choroid mixed 13 ND yes 46,X,-Y,dic(1;16)(p11;q11),inv(2)(p11p13),-3,+8[16]
55 f 38 choroid spindle 11 ND yes 46,XX(20%)/ 45,X,-X(20%)/ 88,XXXX,der(1)t(1;6)
(p12;p11)x2,+der(1)t(1;6)[1],add(2)(q36 of q37)
x2,-6,-6,+8,+8,-14,-15,-16,-21
62 f 21 choroid spindle 7 no no 46,XX,t(11;15)(q13.2;q13)(87.5%)/46,XX (12.5%)
63 f 73 choroid epithelioid 12 ND no* 46-48,XX,-3,i(6)(p10)[5],i(8)(q10),+i(8)(q10),+i(8)(q10)
x2[4],del(16)(q21)[5]
71 m 66 choroid mixed 10 no yes 45,X,-Y 
97 m 73 choroid spindle 8 no no* 45,X,-Y(57%).46,XY(43%)
102 m 76 choroid spindle 12 no no* 46,XY,add(9)(q34),add(22)(p11)[3]/46,XY,add(9)
(q34),add(9)(p24),add(22)(p11)[15]
107 m 76 choroid mixed 19 yes no* 43,X,-Y,dic(3;19)(q11;q13.2),-13,der(17)t(13;17)
(q13;p12),-21,add(22)(p11) [4]/43,X,-Y,dic(3;19)
(q11;q13.2),-13,der(17)t(13;17)(q13;p12),add(22)
(p11) [6]
121 m 49 choroid mixed 14 yes yes 46-47,XY,del(1)(p31p36),-3,der(4)t(1;4)
(q12;q21),+8,+21[cp3]/45,X,-Y[3]/46,XY[8]
123 m 58 choroid epithelioid 11 yes no 46,XY[22]
125 f 74 choroid mixed 18 yes no 72-76,XXX,dic(1;7)(p10;p14),+dic(1;7)
(p10;p14),-3,+4,+6,-7,+i(8)(q10),+9,-11,-
15,+16,+18,+20,+?21,+22[cp12]/49-54,idem[cp2]
130 f 57 ciliary body mixed 16 yes no 41-48,XX,der(1)t(1;6)(p11;p1?2),add(4)(q1?2),-5,-
6,+7,+8,+8,-9,add(11)(q13~14),+add(11)(q13~14),-
13,-16,+22,+mar.ish der(6)(wcp6+),+mar.ish der(16)
t(6;16)(wcp6+,wcp16+)[cp6]
131 f 60 choroid mixed 8 yes no 46,XX[11]
136 f 85 choroid mixed 15 no yes 41-44,XX,der(1;8)(q10;q10).ish der(1;8)(wcp8+,205
3b3+,p1.164+,D8Z2+,puc1.77+,wcp1+),-3,+der(8).
ish der(8)ins(8)(p?21q?23q?24.1)del(8)(q22q22)
(wcp8+,114C11+,105H8+,p1.164-,
2053b3+),-15,del(16)(q11q1?3).ish del(16)
(wcp16+,pHUR195-)[cp15]
141 m 54 choroid mixed 11 no no 46,XY,+2,dic(6;13)(q12;p10),dic(6;14)(q12;p10)[16]
147 m 56 choroid spindle 13 no no 44~47,XY,del(1)(p2?)[5],add(7)(p?2)
[4],+9[2],-15[4],add(19)(q1?3[3],+mar[2][cp6]/46,XY[3]
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148 m 59 choroid mixed 13 yes yes 45,X,-Y[3]/46,XY[10]/47,XY,+?der(2)[2]/46,XY,add(8)
(p),der(15)t(1;15)(q11;p11)[1]
150 m 42 choroid spindle 12 no no 46,XY[4]/47,XY,+9[3]/47,XY,+9,der(10)t(6;10)(p12;q26)[4]
151 f 48 choroid spindle 12 no no 46,XX[3]/46,XX,der(20)t(6;20)(p12;p12)[5]/47,XX,idem,+
8[4]/47,XX,idem,+8,psudic(17;15)(p13;p11)[3]
152 f 76 choroid epithelioid 15 yes yes 45~48,XX,-3,i(8)(q10),+i(8)(q10),+i(8)(q10)[cp5]/46,XX[4]
/47~49,XX,+3[3],+5[2],+6[2][cp4]
157 f 72 choroid mixed 13 yes no* 46,XX[10]/47,XX,+8[7]
158 m 61 choroid spindle 11 no yes 45,X,-Y[10]/46,XY[4]
159 f 37 choroid spindle 12 no no 40~46,XX,add(2)(q3?4).ish der(2)t(2;6)[6],der(5)t(5;6)
(q34;?)[9],del(6)(q?)[3],der(7)t(7;8)(p21;q?),add(10)
(p1?4).ish der(10)t(8;10)[2],add(11)(q1?4).ish der(11)
t(8;11)[9],der(16)t(8;16)(q?;q24)[7],
add(18)(q23)[1] [cp19][19]/46,XX[1]
160 f 72 choroid mixed 14 yes yes 46,XX[10]/40~42,XX,del(1)(p21),-3,-6,i(8)(q10)[1],-12,-18
[cp5]/47,XX,del(1q),der(1)t(1;8)(p;q),+7,-8,+9,del(11p)[1]
165 m 42 choroid spindle 12 no no 47,XY,add(6)(q21),der(7)t(1;7)(q12;q36),+8[20]
166 f 49 choroid mixed 18 no no 47,X,-X,-3,+7,i(8)(q10),+i(8)(q10)[1]/46,XX[4]
174 f 59 choroid spindle 19 no yes 75,XXY,1p+,-3,+i(6)(p),i(8)(q),9p+
177 m 59 choroid spindle 8 yes yes 45~47,XY,-5[2],+8[2],add(8)(p22),+add(8)(p22)
[4],-9[2],del(13)(?q14q21),der(17)ins(17;13)
(q12;?q14q21)del(17)(q22q23),-19[2],-22,+mar[cp7]
178 f 73 choroid mixed 17 yes no 45~47,XX,del(1)(p21),add(7)(q36),+8[2],-15,add(17)
(p12),+ring[1][cp5]/46,XX,del(1)(p21),der(5)t(5;14),add(7)
(q36),+8,-14,-15,add(17)(p12),+ring[5]
179 m 60 choroid spindle 11 no no 46,XY[15]
180 f 79 choroid epithelioid 16 no yes 43~45,X,-X,-3,i(8)(q10),+i(8)(q10),+i(8)(q10)
[2],der(16;21)(q10;q10),der(22)[1][cp5][5]
182 f 52 choroid spindle 14 no no 46,XX,der(6)t(6;6)(q16;p12),add(22)(p11),add(22)(q13)
[16]
187 m 65 choroid epithelioid 15 yes yes 45,X,-Y,-3,-4,i(8)(q10),+i(8)(q10),+mar
189 m 80 choroid mixed 14 yes yes 44,XY,-1,-2,-3,dic(1;6)(q10;q10),+ring[5]/45,XY,-1,-2,-
3,dic(1;6)(q10;q10),+8,+ring[12]/90,XXYY,idem,+8,+8[1]
191 f 46 choroid spindle 14 no yes 46,XX,add(1)(q42),add(4)(q3?2),del(6)(q1?4q2?5),der(8)
t(6;8)(p12;q24),-16,add(16)(q?2),add(17)(p13),add(21)
(p11),+mar1,+mar2 [19]
193 m 44 choroid epithelioid 16 yes yes 46, XY[16]
195 m 68 choroid epithelioid 16 no no 46, X,-Y,-3,+i(8)(q10),+i(8)(q10)[4]/47,idem,+add8(p?)
[12]
199 f 64 choroid spindle 17 yes yes 44~45,XX,der(1)t(1;6)(p12;p11),-3,+i(8)(q10),+i(8)(q10)
[1],der(14)t(14;22)(q13;q11),-16,-22[cp19]
205 m 46 choroid spindle 7 yes no 44,X,-X,der(22)t(12;22)(q12;p12) [3]/45,X,-X,I(12)
(q10),idic(22)(p12) [2]/46 XX [26]
207 m 76 choroid spindle 15 yes no 45,X,-Y,-3,i(6)(p10),+8[8]/46,XY[7]
211 f 66 choroid spindle 14 no yes 73,X,-X,-X,add(1)(q43),+2,-3,+7,+8,+i(8)(q10),+i(8)
(q10),-9,add(9)(q?13),-10,+11,+12,+13,+14,+15,-
17,+19,-21[1]/149,idemx2[1]
218 m 60 choroid spindle 17 no no 41,XY,-1,der(11)t(1;11)(q12;p15),add(12)
(p13),-15,-16,-21,-22[16]
219 m 69 choroid mixed 18 yes yes 45,XY,-3,i(8)(q10)[14]
226 m 27 choroid mixed 13 yes no 46,XY,-3,i(8)(q10),+i(8)(q10)[6]/47,XY,-3,i(8)(q10),+i(8)
(q10)[3]/46,XY[2]
237 m 77 choroid spindle 14 no yes 45,X,-Y,add(1)(p2),-3,+i(8)(q10)[4]
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240 m 52 choroid spindle 15 no yes 46,XY,-3,+i(8)(q10)[17]
241 f 84 choroid spindle 14 no no 46,XX[22]
242 f 47 choroid spindle 16 no no 46,XX,der(3)t(3;8)(q2?9;q11),der(6)add(6)(p?22)t(6;8)
(q16;q?21),+der(6)add(6)(p?22)t(6;13)(q11;q11),-
13,add(17)(p13)[10]
246 m 57 choroid epithelioid 15 no no 40-47,X,-Y,-3.?add(6)(q13),i(8)(q10),+i(8)(q10),+i(8)
(q10)[2],+i(8)(q10)[1][cp3][3]
253 m 74 choroid epithelioid 19 yes yes 77-86,XXYY,i(1)(q10),+der(1)i(1)(q10)t(1;17)(q21;p12)
or der(1)i(1)(q10)t(1;17)(q21;24)x3,-3[3],i(4)(p10),+i(4)
(p10)[3],-6[3],i(6)(p10),i(8)(q10)x2,-9,-9,-10,add(11)
(p14)x2,-13,-14[3],-15,-15,-16[3],
add(20)(q13)x2[cp4][4]/79-86,XXYY,i(1)(q10),+i(1)
(q10),+i(1)(q10)[6],+2[5],-3[5],-3[4],-4[4]i(4)(p10),+i(4)
(p10)[7],-5[8],-6,i(6)(p10)[8],-7[3],+7[3],i(8)(q10)x2,-9,-
10[8],-11[7],-12[6],-13[6],-14[5],-15[6],-15[3],-16[7],-
17[3],+18[3],-19[3],add(20)(q13)x2,+mar[2][cp9][9]
254 f 74 choroid mixed 18 yes yes 45,XX,der(1)t(1;16)(p22;p11),-3,+i(8)(q10),-16[16]
256 m 40 choroid spindle 12 no no 46,XY,der(19)t(6;19)(p23;p13.3)[18]
257 m 87 choroid spindle 12 no no* 46,XY,der(8)t(8;18)(p12;q12),der(21)t(6;21)(p11;p11)
[12]/46,XY,del(6)(q15q26),der(8)t(8;8)(p12;q12),der(21)
t(6;21)(p11;p11)[3]
261 m 40 choroid spindle 9 no no 55,XY,+2,+add(5)(q12),+der(5;17)(q10;q10),del(6)
(q12q27),+8,+8,+der(9)t(8;9)(q11;p12),+11,+20[16]
262 f 64 choroid epithelioid 13 yes yes 45-91,X,-X,-3,+i(8)(q10),inc.[6]/46,XX[8]
265 m 40 choroid spindle 13 no yes 46,XY,del(6)(q15q22)[2]/46,XY,del(6)(q15q22),add(14)
(q32)[1]/ 46,XY,del(6)q15q22),der(17)t(7;17)(q11.2;p13)
[5]/ 46,XY,del(6)(q15q22),add(14)(q32),der(17)t(7;17)
(q11.2;p13)[8]
270 m 65 choroid spindle 14.5 yes yes 46,XY,add(6)(q21),add(7)(q21),?del(9)
(p13p23),dup(10)(q26q23),del(11)(q22),add(14)
(p11),add(19)(13.4)[1]/46,XY,add(6)(q21),add(7)
(q21),?del(9)(p13p23),dup(10)(q26q23),del(11)(q22),
add(14)(p11),add(19)(13.4),der922)t(8;22)9q21;p10)
[13]/43,XY,add(6)(q21),add(7)(q21),add(8)(p11),?del(9)
(p13p23),-10,dup(10)(q26q23),del(11)(q22),add(14)
(p11),der(15;15)(q10;q10),add(19)(q13.4)[2]
271 f 55 choroid spindle 13 yes no 45,XX,-3,der(8)t(8;8)(p23;q13)[14]
272 f 52 choroid spindle 15 yes no* 46,XX,der(1)t(1;16)(p2?1;p11),-3,+(8)(q10),-16[16]
274 m 42 choroid spindle 17 no no 46,XY,del(11)(q2?2),der(18)t(6;18)(p21;q23),add(19)
(p13.3)[4]/ 46,XY,add(9)(q34),del(11)(q2?2),der(18)
t(6;18)(p21;q23),add(19)(p13.3)[19]
281 m 69 choroid spindle 16 no no 46,XY,der(7)t(6;7)(p22;p22)[20]
*Patients without metastases, death due to other causes
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Abstract
Purpose: Uveal melanoma is a highly malignant disease with a mortality of 50% at 10-15 years. 
Previous studies have shown that chromosomal changes are associated with a decreased survival 
of the patient. However, these studies analyzed small numbers of tumors that did not allow robust 
statistical analysis. Here we assess the independent value of numerical changes of chromosomes 
1, 3, 6 and 8 on the disease free survival (DFS) in a large series of uveal melanoma patients.
Patients and methods: 120 tumors from uveal melanoma patients were analyzed for numerical 
changes of chromosomes 1, 3, 6 and 8 with cytogenetic analysis, fluorescent in situ hybridization 
and/or comparative genomic hybridization. Data were correlated with disease outcome in 
univariate and multivariate analyses using Kaplan-Meier and Cox regression analyses. 
Results: At a mean follow-up time of 45 months, 42 patients had died or were suffering from 
metastatic disease. In the univariate analysis, loss of chromosome 3, gain of 8q, largest tumor 
diameter or the presence of epithelioid cells was associated with a decreased disease free survival. 
In the multivariate analysis, the effect of monosomy 3 on survival was largely modified by changes 
in chromosome 1p36. We found that, regarding all chromosomal changes, only concurrent loss 
of chromosome 1p and 3 was an independent prognostic parameter for DFS (p<0.001).
Conclusions: In uveal melanoma, concurrent loss of chromosomes 1p and 3 is an independent 
predictor of decreased disease free survival.
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Introduction
Uveal melanoma is the most common form of primary eye cancer in adults with a mortality 
rate of fifty percent after ten to fifteen years. 1 Metastases occur predominantly in the liver. 
Early identification of patients at high risk of metastases may allow detection of metastases at 
a stage in which adjuvant therapy can be justified. Several prognostic factors based on clinical 
and histological features are known, for instance gender, age at time of diagnosis, largest tumor 
diameter (LTD), involvement of ciliary body and presence of epithelioid cells.2 Nevertheless, none 
of these prognostic factors is specific enough for identification of patients at risk of metastatic 
disease.
Cytogenetic abnormalities are correlated with the clinical outcome of patients with leukemia 
and lymphoma. 3 Uveal melanomas are highly amenable for cytogenetic analysis and show 
mostly simple karyotypes in contrast to most other solid tumors. Non random chromosomal 
abnormalities, such as variation in chromosomes 1p, 3, 6 and 8 were detected in these 
tumors. 4, 5 Loss of chromosome 3 and gain of chromosome 8q have been associated with a high 
mortality rate, whereas abnormalities of chromosome 6 were found to correlate with a good 
prognosis. 6 However, these data were obtained from relatively small studies. Furthermore, the 
independent value of these chromosomal changes and the effect of chromosome 1p loss on 
survival remain to be determined. 
The purpose of this present study was to investigate the association between chromosomal 
changes and clinical and histological variables. Furthermore, we aimed to examine the independent 
effect and interactions of numerical changes of chromosomes 1, 3, 6 and 8 on disease free 
survival (DFS) of uveal melanoma patients. 
Patients and methods
Patients and tumor samples
From March 1992 to April 2003, we collected tumor material of 152 consecutive patients who 
underwent enucleation for ciliary body or choroidal melanoma. Informed consent was obtained 
prior to enucleation and the study was performed according to the tenets of the Declaration 
of Helsinki. Fresh tumor material was obtained within 1 hour after enucleation according to a 
standardized protocol; incision is made through the tumor leaving the optic nerve intact. The 
quantity of obtained tissue (5-8 mm3) depended on tumor size. A sample was taken from the side 
opposed to the optic nerve and divided into two; one part was processed for cytogenetic analysis 
and/or fluorescent in situ hybridization (FISH), whereas the other part was stored in liquid nitrogen. 
Until January 1995 only cytogenetic analysis was performed which was successful in 15 out of 46 
cases. From that time on tumors (n=106) were analyzed with FISH and, if metaphases could be 
obtained, with cytogenetic analysis. In the latter ones comparative genomic hybridization (CGH) 
analysis (n=30) was performed on tumor material that could not be completely analyzed by 
these two techniques. Conventional histopathologic examination was performed on all tumors 
and confirmed the origin of the tumor. Cytogenetic studies were also carried out on stimulated 
peripheral blood samples of each patient to exclude the presence of congenital chromosome 
abnormalities. Follow-up data from time of diagnosis till the end of the study in April 2004 were 
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obtained by reviewing each patient’s charts and contacting their general physician. Three patients 
were at that time lost to follow-up. From two of these patients, however, a late date of follow-up 
was obtained and they were therefore also included in the study. From the 120 patients included 
in the survival analysis, there were 67 men and 53 women. The age at time of diagnosis ranged 
from 21 to 87 years (mean 61). The mean duration of follow-up, from diagnosis to presence of 
metastases or end of study, was 45 months (range 6-142 months).
Histological findings 
The mean and median tumor diameter and thickness were 12.7 and 13.0 mm (SD 3.3; range 
4.5-19), and 7.8 and 8.0 mm (SD 3.7; range 1.5-22), respectively. Twenty tumors showed 
involvement of the ciliary body and 100 were located in the choroid. Cell type was classified as 
mixed/epithelioid in 69 tumors and spindle cell type in 51 tumors.
Cytogenetic, FISH and CGH analysis
Cytogenetic analysis
Chromosome preparations were made according to standard procedures and stained with 
acridine orange or atebrine to obtain R or Q banding. Cytogenetic abnormalities were described 
in accordance with the ISCN (1995).7 
FISH analysis
Dual color FISH on uncultured tumor material using centromeric and locus specific cosmid, 
P1 or YAC probes for chromosome 1, 3, 6 and 8 was performed as described previously. 8 
Seven probes were used: p1-79 (mapped to chromosome band 1p36), Pα 3.5 (centromere 3), 
YAC 827D3 (3q24), cos85 (6p21) and cos52 (6q23) (Prof. Y Nakamura, Tokyo, Japan), D8Z2 
(centromere 8) and ETO (8q22). The probes were validated on normal peripheral blood cell 
metaphase spreads and ten metaphases were analyzed for each probe. Cut-off limits were less 
than three percent. The concentration for centromeric probes was 5 ng per slide; for cosmids, 
P1 and YAC probes 50 to 75 ng per slide were used. After hybridization and washing, slides 
were counterstained with 4’, 6-diamidino-2-phenylindole and mounted in anti-fade solution 
(Dabco-Vectashield 1:1). Signals were counted in 300 interphase nuclei according to the criteria 
of Hopman et al. 9 Scoring for deletion (>15% of the nuclei with one signal) or amplification 
(>10% of the nuclei with 3 or more signals) were adapted from the available literature. 10 
CGH analysis
DNA from formalin-fixed paraffin-embedded tumor material was isolated from 40 10µm 
sections. The pigmented tumor was scraped off from the glass slides using a fine scalpel. Excised 
material was deparaffinized in xylene and ethanol and air-dried. Isolation of DNA was performed 
using the DNA tissue kit (Qiagen, Hilden, Germany). Concentration was determined using a 
fluorometer (Biorad, Veenendaal, The Netherlands), whereas molecular weight was estimated 
on ethidium-bromide stained agarose gels. Tumor DNA and reference DNA (0.5 µg) was labeled 
using the Bio-prime DNA labeling kit (Invitrogen, Breda, The Netherlands) with Spectrum Green 
(Vysis, Hoofddorp, The Netherlands) or Alexa 594 (Molecular Probes, Leiden, The Netherlands) 
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respectively. Equal probe mixture of tumor and reference DNA was denatured and hybridized 
in the presence of human cot-1 DNA to normal male metaphase chromosomes for three days 
at 37ºC. Samples were counterstained with DAPI in anti-fade solution. Images were acquired 
with a Zeiss axioplan microscope equipped with Isis software from Metasystems (Metasystems, 
Altlussheim, Germany). For each case ten metaphases were analyzed. Loss of DNA sequences 
was defined as chromosomal regions where the mean green: red ratio was below 0.8, while 
gain was defined as chromosomal regions where the ratio was above 1.2. Threshold levels were 
determined on basis of analysis of known chromosomal aberrations.
Data classification
We subdivided the variation in chromosomes 1p, 3, 6p, 6q and 8q using cytogenetic and FISH 
analysis into 3 categories: loss of one copy, normal copy numbers (two copies) and gain of one 
or more copies. Monosomy 3 was defined when, using FISH, there was only one signal seen for 
both the centromere 3 and 3q24 probe. Gains of 6p and 8q were scored when more than 2 
signals were found for both the 6p21 and 8q22 probe, and loss of 1p and 6q when the probes for 
1p36 and 6q23 showed only one signal.
When different subclones were identified, only the FISH findings of the largest clone were 
classified. Cytogenetic and CGH results were classified for those regions studied with FISH 
analysis. All major chromosomal changes detected by cytogenetic analysis could also be detected 
by FISH analysis. 
Statistical analysis
The primary end point for DFS was the time to development of metastatic disease from time of 
enucleation, whereby death due to other causes was treated as censored. The influence of single 
prognostic factors on DFS was assessed using the log rank test (for categorical variables) or Cox 
proportional hazard analysis (for continuous variables) and Kaplan-Meier curves were made to 
illustrate the differences in survival. Comparisons of the distributions of clinical and chromosomal 
variables were performed with Fisher’s exact test (for categorical variables) and the Mann-
Whitney test (for continuous variables). To identify the independent value of the prognostic 
factors on disease-free survival we used a multivariate Cox proportional hazard analysis and the 
likelihood ratio test. Possible prognostic factors were age at time of diagnosis, cell type (spindle 
cell vs. mixed / epithelioid cell), largest tumor diameter, mutual loss of chromosome 1p36 and 3, 
and gain of 8q. All tests were two-sided. An effect was considered significant if the p-value was 
0.05 or less. The statistical analyses were performed with the SPSS-11 software.
Results
Of the 152 uveal melanoma, 32 cases we could not be analyzed for chromosome 1p, 3, 6 and 
8 abnormalities. A total of 120 uveal melanoma cases were analyzed for chromosomal changes 
using cytogenetic, FISH and/or CGH analyses. Cytogenetic analysis was successful in 69 out of 120 
tumors. For 55 tumors cytogenetic and FISH data were available, while for 47 tumors only FISH 
was performed. Additionally, in 30 tumors CGH analysis was performed. Not all probes could 
be tested on all tumors because of lack of material. The mean number of probes successfully 
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used for FISH was 5.5. Combining cytogenetic, FISH and CGH data genomic abnormalities were 
found in 88 percent of the 120 tumors. Results for all chromosome regions (1p, 3, 6p, 6q and 8q) 
were obtained for 108 tumors (varying from 108-118 successful analyses per region, table 1). 
Thirty-eight patients had died from metastatic disease and four were suffering from metastases 
at time of evaluation.
Table 1. Univariate analysis of prognostic markers on disease free survival in uveal melanoma
Variable Mean p-value*
Age at time of diagnosis (yrs) 61 0.079†
Largest tumor diameter (mm) 12.7 0.011†
Tumor thickness (mm) 7.8 0.293†
Variable no. of patients (%) p-value*
Mixed/epithelioid cell type 69 (58) 0.003
Involvement ciliary body 20 (17) 0.521
Male gender 67 (56) 0.978
loss of 1p36 41/118 (35) 0.081
loss of chromosome 3 55/109 (50) <0.001
gain of chromosome 6p 34/111 (27) 0.497
loss of chromosome 6q 33/108 (31) 0.319
gain of chromosome 8q 69/110 (63) <0.001
* Log-rank test 
† Cox-regression analysis
* Chromosome locus at which the abnormality is absent (-) or present (+)
† The p-value is for the comparison among different subgroups within a chromosome aberration group and was calculated 
by Fisher’s exact test
‡ The p-value is for the comparison of means among different subgroups within a chromosome aberration group and was 
calculated by Mann-Whitney test
Significant p-values are indicated in bold
 
Univariate analysis of the single prognostic factors showed significantly lower DFS for patients with 
loss of chromosome 3, gain of 8q and with a mixed/epithelioid cell type in the tumor compared 
to patients without these chromosomal changes or with a spindle cell type (table 1). The largest 
tumor diameter was also significant in the univariate analysis. Other potential prognostic factors 
such as gender, age at time of diagnosis, tumor thickness and tumor location (i.e. involvement of 
ciliary body) did not reach significance. Also chromosomal changes such as loss of chromosome 
band 1p36, gain of chromosome 6p and loss of chromosome 6q were not significantly associated 
with disease free survival. 
To examine the possibility that other chromosomal variations may affect the prognosis of the 
monosomy 3 patients, we constructed Kaplan-Meier curves of chromosome 3 changes stratified 
for the other chromosomal changes and performed log rank tests (results not shown). We found 
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that the effect of monosomy 3 on DFS was substantially modified by changes in copy number 
of chromosome 1p36. In tumors with normal copy numbers of chromosome 1p36, a small 
difference in DFS was observed between those patients with and without loss of chromosome 
3 (p=0.064) whereas this difference was highly significant in patients with tumors with also 
loss of chromosome 1p36 (p<0.001). The interaction term between tumors with loss of 
chromosome 1p36 and 3 and the remaining patients (i.e. patients with tumors with normal 
copies of chromosome 1p36 and 3 or with either 1p36 or 3 loss) was highly suggestive (HR= 
3.61), but did not reach significance (p=0.155). In addition, we compared the DFS of patients 
with a concurrent loss of chromosome 1p36 and chromosome 3 with the remaining patients 
using the log rank test. The difference in survival was found to be highly significant (p<0.001) 
(figure 1). Remarkably, gain of chromosome 1p36 occurred in 5 patients, but this number was 
too small to perform statistical analysis.
Figure 1. Kaplan-Meier survival 
curve of loss of chromosome 
1p36 and/or 3
The dashed line represents the 
tumors with concurrent loss of 
chromosomes 1p36 and 3; the 
solid line represents the tumors 
with loss of only chromosome 
1p36, only monosomy 3 or loss of 
neither chromosomes 1p36 nor 3 
(p<0.001).
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Considering the strong interaction between chromosome 1p and 3 losses, we validated whether 
this concurrent loss is an independent parameter for DFS. Significant correlations between age at 
time of diagnosis, tumor diameter, cell type, chromosome 6p and 8q gains using Mann-Whitney 
and Fisher’s exact tests (table 2) were observed. Monosomy 3 was associated with age at time 
of diagnosis (p=0.050), cell type (p=0.013) and mean tumor diameter (p=0.002). Gain of 
chromosome 6p was correlated with cell type (p=0.008) and gain of chromosome 8q with 
mean tumor diameter (p<0.001). These chromosomal changes and confounding variables were 
analyzed in a multivariate model. After correcting for these variables, we found that patients 
with tumors with concurrent loss of chromosomes 1p36 and 3 have an almost 7.8 times higher 
chance of developing metastases compared to those without these losses or with either 1p36 or 
3 loss (p=0.039) (table 3). Gain of chromosome 8q (HR=2.43, p=0.054) and mixed/epithelioid 
cell type (HR=2.24, p=0.077) almost reached significance and the other variables (gain of 
chromosome 6p, largest tumor diameter and age at time of diagnosis) were not significant. 
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Furthermore, the interaction term between monosomy 3 and gain of chromosome 8q was not 
significant (HR=0.53; p=0.469). When analyzed in a multivariate model with the confounding 
variables, such as age at time of diagnosis, gain of chromosome 6p, cell type and mean tumor 
diameter, we found a hazard ratio of 0.67 with a p-value of 0.676 (data not shown).  
Discussion
Previous studies already demonstrated the non-random occurrence of cytogenetic abnormalities 
of chromosome 1, 3, 6 and 8 in uveal melanoma. Monosomy 3 and gain of 8q have been shown 
to be associated with poor survival after treatment for uveal melanoma. 6, 11, 12 Using univariate 
analysis we confirmed these findings. In addition, we demonstrated in the present study, which is 
the largest series described so far therefore allowing multivariate statistical analysis, that tumors 
with a concurrent loss of chromosomes 3 and 1p36 are at high risk of metastasizing (HR=7.81, 
table 3). The molecular genetic changes that underlie these chromosomal changes have not yet 
been determined. 
Chromosome 1p loss occurs frequently in many solid tumors like skin melanoma and 
neuroblastoma. In the latter tumor type, loss of chromosome 1p is known to be a predictor of 
unfavorable outcome of the patient. 13, 14 In uveal melanoma loss of chromosome 1p has been 
described, but any prognostic significance had not been determined up to now. Contrary to 
Sisley et al. 15 in our study loss of material of 1p36 was not associated with large ciliary body 
melanomas, but was rather detected in metastasizing tumors in agreement with Aalto et al. 16 
Eighty-nine percent of the metastasized tumors with chromosome 1p36 loss had concurrent 
monosomy 3. Concurrent loss affecting survival suggests an interaction of proteins encoded by 
genes located on these chromosomes, which may promote tumorigenesis, metastatic disease 
and consequently reduce survival. However, we cannot exclude that these sites encode for 
proteins that might independently promote tumorigenesis and metastasis.
Gain of chromosome 8q was a significant predictor of survival in the univariate analysis. In 
the multivariate analysis it did not reach statistical significance as an independent prognostic 
marker. Previous studies already suggested that acquisition of isochromosome 8q is a secondary 
event and that gain of additional copies is related to tumor size. 11, 17, 18 Moreover, monosomy 
3 seemed to predispose to isochromosome formation. 4 This may explain the correlation of 
gain of chromosome 8q with survival as observed in other studies. 6, 11 We demonstrated a 
strong correlation between the largest tumor diameter and the presence of chromosome 
8q abnormalities, suggesting that acquisition of additional copies of 8q may result in a growth 
advantage of the tumor. 
Similarly, the abnormalities of chromosome 6 were not independently associated with survival, 
in contrast to previous claims. 6 We found a strong correlation between the gain of chromosome 
6p and spindle cell type. Sisley and White and coworkers associated chromosomal changes, 
such as loss of chromosome 3, gain of chromosome 8q and abnormalities of chromosome 6 
with prognosis. 6, 15 However, as far as we know their findings were not corrected for tumor 
diameter or cell type as in the present study. This could have influenced their findings, leading 
to contradictory observations. Another known prognostic marker for a poor outcome of uveal 
melanoma patients is the presence of epithelioid cells. We found a strong correlation between 
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chromosomal aberrations (chromosomes 3, 6 and 8) and cell type (table 2). Even though 
epithelioid or mixed cell type was significantly associated with decreased DFS in the univariate 
analysis, it was not in the multivariate analysis. 
Although loss of an entire chromosome is a common change in uveal melanoma, partial deletions 
of chromosome 3 have been reported leading to the hypothesis that two regions, one on the 
p-arm and one on the q-arm, might be involved in metastasis. 19
Table 3. Prognostic markers for metastasis in 120 uveal melanoma patients*
Variable Hazard ratio p-value†
Loss of chromosome 1p36 with loss of 3 7.81 0.039
Gain of chromosome 8q 2.43 0.054
Mixed/epithelioid cell type 2.24 0.077
Gain of chromosome 6p 1.33 0.558
Largest tumor diameter 1.03 0.588
Age at time of diagnosis 1.00 0.900
* Multivariate analysis using Cox proportional hazard analysis
† Likelihood ratio test
Chromosome 1p36
loss*
Chromosome 3
loss*
Chromosome 6p
gain*
Chromosome 8q
gain*
Clinical data - + p-value - + p-value - + p-value - + p-value
    
Gender male 42 20 0.193† 32 29 0.311† 45 19 0.481† 24 39 0.498† 
female 29 21 22 26 32 15 17 30
     
Mean age (yrs)  61 61 0.345‡ 57 64 0.050‡ 61 59 0.298‡ 59 61 0.223‡
      
Cell type spindle 32 17
0.432† 
24 17
0.013† 
27 21
0.008† 
23 24
0.024† 
mixed/epithelioid 39 24 25 38 50 13 18 45
    
Mean tumor thickness 
(mm)  
7.8 8.0 0.355‡ 7.7 8.5 0.133‡ 7.8 8.6 0.135‡ 7.5 8.4 0.127‡
    
Mean tumor diameter 
(mm)  
12.5 13.0 0.186‡ 12.1 13.9 0.002‡ 12.6 13.6 0.059‡ 11.3 13.9 <0.001‡
    
Involvement 
of ciliary 
body
no 61 31
0.133†
48 43
0.106† 
62 30
0.239† 
34 57
0.592† 
yes 10 10 6 12 15 4 7 12
* Chromosome locus at which the abnormality is absent (-) or present (+)
† The p-value is for the comparison among different subgroups within a chromosome aberration group and was 
calculated by Fisher’s exact test
‡ The p-value is for the comparison of means among different subgroups within a chromosome aberration group and 
was calculated by Mann-Whitney test
Significant p-values are indicated in bold
Table 2. Correlation between chromosomal abnormalities and clinical data
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Seven patients in our study had a partial deletion of chromosome 3 (either one copy of the 
centromeric region or 3q-region) from whom 2 patients had died due to metastatic disease. In 
five tumors two signals for the centromere and only one signal for the 3q probe were observed, 
whereas two tumors had one copy of the centromere and two of the 3q-probe. Since these 
changes were observed with FISH analysis and karyograms of these tumors were not available, 
we were not able to identify any breakpoints. These and more subtle structural aberrations can 
be resolved with techniques with higher resolution, such as genomic arrays or LOH. However, 
changes such as base substitutions, very small deletions or insertions will still be missed. 
Our study on chromosomal abnormalities in uveal melanoma is, to our knowledge, the largest 
series reported in the literature. Our study may be biased because we examined only tumors 
from patients treated by enucleation, as no tumor material is available from patients treated 
with radiotherapy protocols. There is a need to stratify patients prospectively into low and high 
risk groups for metastases. Our findings suggest that chromosomal abnormalities may be useful 
in identifying patients at high risk of metastases. Previous studies by Sisley et al. have shown a 
correspondence between major clonal alterations in FNAB’s and the main tumor using cytogenetic 
techniques. 20 Furthermore, they showed that with short-term cultures of FNAB’s conventional 
cytogenetic analysis was possible in 60% of the cases. In addition, Naus et al. indicated that 
application of FISH on FNAB’s is a reliable method for assaying genetic prognostic parameters. 8 
Only in 0.8% a small variation that have could lead to a misclassification was found. 
There are at least two potential challenges involved in the application of our data to patients 
on a prospective basis. First, our study involves patient samples from relatively large tumors 
that were treated by enucleation. It remains to be seen that our data can be applied to smaller 
tumors that will be treated by radiation therapy. Second, despite correspondence between 
chromosomal abnormalities detected from FNAB samples and tissue retrieved at enucleation, 
there are no studies to date that confirm the uniform distribution of cytogenetic abnormalities 
in uveal melanoma, and it is at least theoretically possible that an FNAB might capture tissue 
that does not contain the cytogenetic markers of interest. Nevertheless, data from our study, 
the largest cohort of patients studied to date for cytogenetic abnormalities in primary uveal 
melanoma, suggests the feasibility of studying patients with uveal melanoma in prospective trials 
using samples retrieved by FNAB.
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Abstract
Purpose: Concurrent loss of chromosome 1p36 and chromosome 3 leads to decreased disease-
free survival in uveal melanoma patients. A candidate tumor suppressor gene APITD1 is located 
on the critical region on chromosome-arm 1p and it was therefore hypothesized that lower 
expression levels of this gene could lead to decreased survival in patients with concurrent loss 
of a region on chromosome-arm1p and chromosome 3. Using neuroblastoma cells, which, like 
uveal melanoma, originate from neural crest cells, Krona et al. showed that APITD1 has cell 
growth and/or cell death properties. In this study we analyzed if APITD1 expression corresponds 
with DNA copy number and is related with survival in uveal melanoma.
Methods: To detect whether copy number loss of APITD1 results in lowered mRNA expression 
of the gene, we combined FISH analysis with real-time PCR. In addition, the effect of APITD1 
expression on survival was studied using Kaplan-Meier survival analysis.
Results: Expression of APITD1 mRNA was not related to DNA copy number (p=0.956) or 
chromosome 3 status (p=0.958). Kaplan-Meier survival analysis showed very similar survival curves 
for tumors with high and low APITD1 expression with a log-rank significance value of p=0.9682. 
Conclusions: These results indicate that APITD1 is not the tumor suppressor gene on 1p36 
responsible for the negative prognostic effect in uveal melanoma with concurrent loss of 
chromosomes 1p36 and 3.
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Introduction
Uveal melanoma (UM) is the most common primary malignant intra-ocular tumor in the Western 
world, with a yearly incidence of 6 per million.1 Cytogenetic and molecular genetic studies 
revealed that over 80% of the UMs from sporadic cases have a nearly diploid character with 
simple non-random chromosomal aberrations, of which amplification of chromosome regions 
8q and 6p and loss of chromosome 3 and the chromosomal regions 6q and the distal part of 
1p are the most frequent.2,3 Loss of the chromosomal region 1p36 is also frequently observed 
in various other tumor types, including neuroblastoma and pheochromocytoma, which also 
originate from neural crest-derived cells. In neuroblastoma, loss of chromosome-arm 1p is 
known to be a predictor of unfavorable clinical outcome.4,5 In UM, loss of the tip of 1p, as was 
identified with FISH-probe RP11-48E9 located on 1p36, has been detected in metastasizing 
tumors3. Furthermore, concurrent loss of this region and chromosome 3 is associated with 
decreased survival of UM patients.2 This suggests that a tumor suppressor gene involved in 
UM is located on the distal region of 1p. In our own tumor set, we could not identify losses 
of the telomeric part of chromosome-arm 1p that were smaller than 1p34-pter and Hughes 
et al. identified a smallest region of overlap (SRO) ranging from 1p34-pter using array-CGH.6 
This region is still considerably large and is very gene-dense, which makes it hard to identify 
candidate genes. However, in neuroblastoma a 500kb region on 1p36.2-1p36.3 was reported,7 
which includes the promising candidate tumor suppressor gene APITD1 (APoptosis-Inducing, 
TAF9-like Domain 1) positioned at chromosome band 1p36.22. The protein, encoded by this 
gene contains a domain which is similar to the human TATA box binding protein-associated 
factor, TAFII31 (locus name TAF9). TAFII31 has been identified as a critical protein required 
for p53-mediated transcription activation.8 As p53 is associated with apoptotic cell death and 
growth arrest, APITD1 might be important in tumor suppression. Krona et al. showed that 
addition of APITD1 mRNA to neuroblastoma cells, results in a reduction of cell growth (up 
to 90%) compared to non-treated cells, suggesting that APITD1 does indeed have a role in 
the cell death pathway of neuroblastoma.9 Loss of function or downregulation of APITD1 can 
thus be a way for tumor cells to overcome the cell growth-regulating properties of the p53 
pathway. In UM, the p53 pathway is not affected through alterations in p53 protein levels.10 
Therefore, decreased expression of APITD1 could be implicated in UM by interfering with the 
p53 pathway. We have analyzed whether loss of chromosomal region 1p36 leads to decreased 
expression of APITD1 in UM. Furthermore, we evaluated whether lower expression levels of 
APITD1 were associated with a decreased patient survival. A relation between 1p36 loss and 
decreased expression would indicate APITD1 as a possible candidate tumor suppressor gene 
responsible for poor prognosis in UMs with concurrent loss of chromosomal region 1p36 and 
chromosome 3.
Methods
Patient samples and cell lines
Fresh tumor material was obtained from patients without prior radiation or chemotherapy 
within 1 hour after primary enucleation. Informed consent was given prior to enucleation and 
the study was performed according to the tenets of the Declaration of Helsinki. Tumors were 
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processed for FISH and cytogenetic analysis as described previously.11 Part of the tumor was 
snap-frozen and stored in liquid nitrogen. In addition, eleven UM derived cell lines were used. 
Mel270, Mel 202, EOM 3, OCM1 and 92.1 are cell lines derived from primary tumors. OMM 
1, OMM 2 and OMM 3 were established from metastases from different UM patients and 
OMM 2.2, OMM 2.3 and OMM 2.6 are all cell lines derived from different metastases of the 
same patient of whom also Mel 270 was derived.12-15 Also 2 cell lines obtained from normal eye 
melanocytes (MC), EMC 1 and EMC 4, were included as a control for expression in normal 
melanocytic cells.
Fluorescence In Situ Hybridization (FISH)
Dual color FISH on uncultured tumor material, using centromeric and locus specific cosmid, P1 
or YAC probes for chromosome 1p, 3, 6 and 8, was performed as described previously.16 Twenty 
tumors were selected from our UM database based on the FISH scores on chromosome 1p, ten 
with loss of 1p36.33 and ten with normal copy numbers of this region. All tumors were further 
analyzed with BAC probe RP11-199O1 mapping to the APITD1 gene sequence at 1p36.22, 
combined with BAC probe RP11-48E9, mapping to 1p36.33, as reference probe. Both probes 
were selected from the human genome browsers of UCSC (http://genome.ucsc.edu/cgi-bin/
hgGateway) and NCBI (http://www.ncbi.nlm.nih.gov/mapview/map_search.cgi). The probes 
were validated on normal peripheral blood cell metaphase spreads and interphase nuclei. For 
each probe ten metaphases and 100 interphases were analyzed. Abnormal copy numbers were 
detected in less than 3 percent of the scored interphase nuclei. In the tumors, signals were 
counted in 200 interphase nuclei according to the criteria of Hopman et al.17 Cut-off limits for 
deletion (15% of the nuclei with one signal) or amplification (>10% of the nuclei with 3 or more 
signals) were adapted from the available literature.18
RNA purification, cDNA synthesis and TaqMan assay
Five to eight sections with a thickness of 50 µm were made from fresh frozen tumor material, 
depending on the size of the tumor. RNA was isolated from the sections using RNA-Bee 
(TelTest Inc, Friendsweed, Texas USA) and cell line RNA was isolated with the RNeasy Mini 
Kit (Qiagen, Venlo, the Netherlands) according to the manufacturer’s protocol. RNA quantity 
was measured using the NanoDrop® ND-1000 Spectrophotometer (NanoDrop Technologies, 
Wilmington, Delaware USA) and the quality was assayed on the Bioanalyzer 2100 (Agilent, 
Palo Alto, California USA). From 1 µg of total RNA cDNA was synthesized using 2µl of a 
random hexamer primer (0,5 µg/µl) and 10 U of super RT (HT Biotechnology LTD, Cambridge, 
England) according to the manufacturers instructions. Solutions were diluted to 10 ng/µl for 
cDNA synthesis. 
For the TaqMan assay the TaqMan® Universal PCR Master Mix Kit (Applied Biosystems) 
was used. TaqMan Gene Expression Assays were selected for APITD1 and 3 reference genes, 
beta-2-microglobulin (B2M; 15q21-q22), beta-glucuronidase (GUSB; 7q21.11) and hypoxanthine 
phosphoribosyltransferase (HPRT1; Xq26.1). Each of these assays consists of two unlabelled 
primers and a probe labeled with the 5´  reporter dye FAM and the 3´  quencher TAMRA (ordered 
from the Applied Biosystems assays-on-demand platform). Every reaction contained 3.375 µl 
H2O, 12.5 µl Master Mix (2x) (without AmpErase® UNG), 2.5 µl TaqMan Gene Expression 
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Assay and 1 µl of cDNA. The reactions were run on the ABI PRISM™ 7700 Sequence Detection 
System (Applied Biosystems). The solution was subjected to a protocol of subsequently 50 °C 
for 2 min., 95 °C for 10 min. and 45 cycles of 95 °C for 15 s, followed by 60 °C for 1 min. 
The efficiency of the TaqMan assay was determined by assaying a control pool of human RNA 
extracted from three lymphoblastic cell lines in dilutions of 10, 20, 100, 200 and 1000 times. 
With the ΔRn (threshold) set at 0.1, a standard curve of mean Ct for three replicates at each 
dilution versus log10 amount of cDNA was determined. The efficiency of the reaction was 
calculated from the slope of this standard curve using the formula Etarget = 10−1/slope. These 
efficiencies were 1.9991, 1.9956 and 1.9996 for the reference gene TaqMan assays B2M, GUSB 
and HPRT1 respectively. APITD1 had an efficiency of 1.9833. Of the three endogenous control 
genes tested, GUSB and HPRT1 showed the least intra-tumor variation and GUSB expression 
levels came closest to APITD1 expression (data not shown). Therefore GUSB was chosen as 
the endogenous control in APITD1 relative expression measurements. To estimate the relative 
expression of APITD1 the difference in Ct value of APITD1 and the chosen endogenous control 
gene, ΔCt, was determined for each sample. This ΔCt value was transformed by 2- ΔCt x 1000 to 
correct for the logarithmic nature of the Ct value. The differences in amplification efficiency 
between the assays, approximately 2 in all assays, were insignificant and therefore not taken 
into account in the calculations.
Statistical analysis
Relative expression of APITD1 mRNA in a group of 10 tumors with loss of one copy of the 
APITD1 region was compared with relative expression in a group of 10 tumors without loss 
of this region in a two-sample t-test. The relative expression of APITD1 was also compared 
between groups of tumors with and without monosomy of chromosome 3, consisting of 10 and 
9 samples respectively (the chromosome 3 status of one patient was uncertain). The tumors 
were divided into a group with high and low expression to analyze the influence of APITD1 
expression levels on disease-free survival, with 12 (the geometric mean of all samples) chosen 
as the highest value for 2- ΔCt x 1000 in the group of low expression, thereby dividing the patients 
in two groups of ten each. Kaplan-Meier survival analysis and the log rank test were performed 
to determine the influence of APITD1 expression on survival. Disease-free survival is the time 
from enucleation to the development of metastatic disease or disease-related death. All tests 
were two-sided. Statistical analyses were performed using SPSS-11 software. 
Results
FISH
Twenty tumors were selected from our UM database on the basis of routine FISH scores on 
chromosomal region 1p36. Ten showed loss of one copy of 1p36.33 and ten had normal copy 
numbers of this region. All tumors were analyzed using FISH with BAC probes RP11-199O1 
(1p36.22) and RP11-48E9 (1p36.33). Results are presented in table I. The results found with 
the diagnostic probe RP11-48E9 were not different from the results obtained with the APITD1 
probe RP11-199O1, indicating that the region of loss detected in routine FISH encompassed at 
least the APITD1 gene in all cases. 
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Real-time PCR
APITD1 expression was analyzed using Quantitative Real-Time PCR. APITD1 was not differentially 
expressed in melanocytic and UM derived cell lines. Independent sample t-test showed a 4.1 
times higher expression in cell lines compared to expression in the primary tumors (p<0.001) 
(fig.1). There was no significant difference in APITD1 expression levels between tumors with 
and without loss of 1p36, irrespective of chromosome 3 status (p= 0.956). Irrespective of 
chromosomal 1p36 status APITD1 expression levels were also not significantly different 
between tumors with and without loss of chromosome 3 (p=0.958) and between tumors with 
concurrent loss of 1p36 and chromosome 3 and tumors without loss of chromosome-arm 1p 
and chromosome 3 (p=0.764). To test for a significant difference between APITD1 expression 
and patient survival, the samples were separated into groups of high and low APITD1 expression. 
Kaplan Meier survival analysis showed very similar patterns of patient survival in both groups, 
with a resulting log rank p-value close to 1 (0.9682) (fig.2).
Table 1. Relative expression of APITD1 compared to GUSB with DNA copy number and follow-up data
Tumor Relative expression of
APITD1 (2- ∆Ct x 1000)
DNA Copy number1 Survival 
(years)
Event2
RP11-48E9
1p36.33
RP11-199O1
APITD1
RP11-64F6
Chromosome 3
1 3.01 1 1 1 3.14 0
2 2.52 1 1 1 1.31 1
3 7.71 1 1 1 1.62 1
4 13.33 1 1 1 6.02 0
5 8.28 1 1 1 3.05 1
6 38.01 1 1 1 0.43 1
7 16.08 1 1 2 7.83 0
8 17.03 1 1 2 4.03 1
9 11.54 1 1 2 5.97 0
10 13.17 1 1 2 4.97 0
11 9.58 2 2 1 8.41 0
12 15.13 2 2 1 2.13 1
13 22.82 2 2 1 7.31 0
14 11.90 2 2 1 3.42 1
15 18.24 2 2 2 8.74 0
16 13.97 2 2 2 2.26 0
17 12.62 2 2 2 2.87 1
18 5.98 2 2 2 6.56 0
19 8.66 2 2 2 4.05 0
20 9.80 2 2 NA 5.63 0
1The reported copy numbers were scored in 72% of the counted nuclei in one case and 
over 80% in all other cases; NA= data not available. 20: no event has occurred; 1: event 
(melanoma-related death).
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Figure 2. Kaplan-Meier 
survival analysis of APITD1 
expression in 20 uveal 
melanoma patients. Dashed 
line: tumors with high APITD1 
expression; solid line: tumors 
with low APITD1 expression. 
p-value is indicated.
Figure 1. APITD1 expression in UM and MC cell lines and primary UMs. Results of the primary UMs are divided 
into two groups, based on the number of APITD1 DNA copies. The Y-axis indicates the relative expression of APITD1 
compared to the GUSB housekeeping gene, calculated with 2- ΔCt x 1000. The identity of each sample is indicated along 
the X-axis.
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Discussion
A frequent characteristic of UM is deletion of the distal part of chromosome 1p. In combination 
with the loss of chromosome 3, loss of 1p36 leads to decreased disease free survival.2 
This implicates 1p36 as a location of a UM prognosis-related related suppressor gene. In 
neurblastoma, also originating from neural crest-derived cells, a small cluster of genes in a 
500kb SRO was reported. The genes in this cluster, APITD1, UBE4B/UFD2, KIF1B, PGD, DFFA 
and PEX14, are all downregulated in high-stage neuroblastomas and are all candidate tumor 
suppressor genes. For APITD1, UBE4B/UFD2 and DFFA a relation with high stage neuroblastoma 
was reported. Besides a lower expression in high-stage neuroblastomas, a splice site mutation 
was detected in UBE4B/UFD2 in a high-stage neuroblastoma with a fatal outcome and there 
are also some coding mutations found in the DFFA gene in neuroblastoma. The DFFA gene has 
essential functions in the final stage of apoptosis. This altogether suggests a role of these genes 
at least in high-stage neuroblastoma. 7,10,19-22 In UM, the p53 pathway is not affected through 
alterations in p53 protein levels.9 Therefore, interference of the p53 pathway could be caused 
by another mechanism. Kilic et al. suggested that p73, a p53 homologue located on 1p36, might 
be a possible prognosis-related suppressor gene (unpublished data). Another candidate gene, 
located on 1p36 is CHD5, which encodes a protein that functions in the p53 pathway, was 
recently shown to function as a tumor suppressor in vivo.23 The APITD1 gene in the reported 
neuroblastoma gene cluster is associated with p53 activity and has been shown to inhibit cell 
growth.7,10 Since expression of APITD1 is almost absent in a variety of tumors10 and because of 
its is relation with p53 activity, down-regulation of APITD1 could provide an alternative way to 
interfere with the p53-mediated pathway in tumors without alterations in p53 protein levels. 
Therefore, we characterized expression and copy number of the APITD1 gene in UM.
We combined FISH analysis with real-time PCR to assess if copy number loss of APITD1 results 
in lowered expression of the gene. A Kaplan-Meier survival analysis was performed with 
APITD1 expression as a discriminator to study the effect of APITD1 expression on survival. We 
analyzed APITD1 expression in 10 tumors with and 10 tumors without chromosomal loss of 
1p36, using a FISH probe mapping to 1p36.33. In all cases, loss of this region concurred with the 
loss of one copy of the APITD1 region, whereas retention of two copies of 1p36.33 was always 
combined with two copies of the APITD1 region. There was no difference found in APITD1 
expression between tumors with and without loss of 1p36. Similar results were obtained for 
tumors with and without loss of chromosome 3 and for tumors with and without concurrent 
loss of 1p36 and chromosome 3. In addition, in Kaplan-Meier survival analysis based on high and 
low expression of APITD1, the two groups showed very similar survival curves with a log-rank 
significance value of 0.9682 (fig.2). This indicated that downregulation of APITD1 is probably not 
the mechanism for immortality of those cell lines We showed that expression of the APITD1 
transcript is generally elevated in both melanocyte and UM derived cell lines, compared to 
primary UMs. This finding is in concordance with the earlier report on APITD1 expression in 
neuroblastoma in which APITD1 expression was also considerably lower in primary tumors 
compared to neuroblastoma-derived cell lines.10 
The negative effect on prognosis of loss of chromosome-band 1p36 in tumors with monosomy 
of chromosome 3 is most probably caused by decreased expression of a tumor suppressor 
gene located on this region as a result of the chromosomal loss. Following the data in table 1 
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we could verify for this group of cases that concurrent loss of chromosomal region 1p36 and 
chromosome 3 has an adverse effect on patient outcome (Log Rank significance p-value of 
0.0259), which shows that that this cohort has the correct size and composition to evaluate 
this adverse survival effect. In the present study, APITD1 mRNA levels alone are not associated 
with survival. Furthermore, we could not find differential expression for APITD1 in tumors with 
and without loss of the 1p36 region. From these results we conclude that APITD1 is not the 
suppressor gene on 1p36 responsible for the poor prognosis in UMs with concurrent loss of 
chromosome 1p36 and chromosome 3.
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Abstract
Purpose: Loss of chromosome 3 is frequently observed in uveal melanoma and is associated with 
poor prognosis. In about 50% of the uveal melanomas one copy of chromosome 3 is lost. Using 
comparative genomic hybridization (CGH) we have detected a chromosome 3q13-3q21 deletion 
in a uveal melanoma cell line, Mel270, which is derived from a primary tumor. The aim of the 
present study is to demarcate this region, which could harbor a tumor suppressor gene (TSG). 
Methods: Genomic DNA was extracted from four uveal melanoma cell lines, established from one 
primary tumor, Mel270, and its metastases. Subsequently, loss of heterozygosity (LOH) analysis 
was performed. LOH studies were complemented with fluorescent in situ hybridization (FISH). 
Results: LOH and FISH studies revealed a chromosome 3q deletion ranging from 3q21.2-3q24 in 
two cell lines, Mel270 and OMM2.3, derived from the primary tumor and one of its metastases, 
respectively. In addition, a region of allelic loss, mapping to 3p24, was found in these cell lines. 
In contrast, FISH probes mapping to 3p24 revealed the presence of two copies. In OMM2.2, 
established from a different metastasis that originated from the same primary tumor from which 
OMM2.3 was also derived, LOH was detected at most of the loci that were analyzed. This 
finding is consistent with isodisomy of chromosome 3 in OMM2.2. 
Conclusions: We have fine-mapped structural deletions located at chromosome 3q and a 
hemizygous region at chromosome 3p in uveal melanoma cell lines. These results contribute to 
a further demarcation of a candidate region for tumor suppressor genes.
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Introduction
Uveal melanoma, the most common malignant intra-ocular tumor in adults, affects 6 per million 
adults of the Western population yearly. 1 Uveal melanomas originate from neural crest derived 
melanocytes of the uvea and can be located posterior in the choroid and anterior in the ciliary 
body or in the iris. In the past the only treatment available was enucleation of the eye, while 
nowadays eye-conservative treatments like brachytherapy, external beam irradiation and 
stereotactic radiotherapy have become the first choice of treatment. Only 2% of the cases have 
clinically detectable metastasis at presentation and despite improved primary tumor treatment 
protocols, 50% of the patients die from distant metastasis that most often disseminate to the 
liver (90% of all cases with metastasis). 2
Cytogenetic and molecular genetic studies revealed that the larger part of the uveal melanomas 
from sporadic cases have a nearly diploid character with simple non-random chromosomal 
aberrations. Loss of chromosomes 1 and 3, structural abnormalities of chromosome 6, and gain 
of chromosome 8q are most frequently observed. 3-8 Chromosome 3 loss is a prognostic marker 
for decreased survival of the patient 4-6, 9 and several studies indicated gain of chromosome 8 as 
an independent prognostic marker of poor survival. 5, 6 Furthermore, loss of chromosome 1p was 
observed in primary tumors that had metastasized and in metastases. 8, 10
Involvement of chromosome 3 is considered a primary event. 3, 11 In uveal melanomas that are 
characterized by different sub-populations, loss of chromosome 3 is a constant event, whereas 
a variable number of copies of the long arm of chromosome 8 can be observed. In many uveal 
melanomas an entire chromosome 3 is lost 8, 12, 13 and in some cases with two apparently 
normal chromosomes 3, acquired isodisomy has been observed. 12 It is generally believed 
that loss of a tumor suppressor gene (TSG) located at chromosome 3 plays a role in uveal 
melanoma development. Only a few melanomas with structural abnormalities of chromosome 
3 or translocations involving chromosome 3 have been reported up to now, which complicates 
mapping of putative TSGs. However, a study by Tschentscher et al. 14, who investigated uveal 
melanomas with structural abnormalities of chromosome 3, revealed two regions of allelic 
loss on chromosome 3, i.e. 3p25 and 3q24-3q26. Moreover, they concluded that tumors that 
metastasized showed loss of both regions. Parrella et al. defined a minimal region of allelic loss, 
ranging from 3p25.1-3p25.2 in a set of uveal melanomas. 15
The present study aimed at further delineation of a chromosome 3q deletion, previously detected 
with conventional comparative genomic hybridization (CGH) in Mel270, a uveal melanoma cell 
line established from a primary tumor that metastasized. 16 LOH analyses were performed on 
Mel270 and a series of metastasis-derived cell lines, obtained from liver metastasis, originating 
from the primary tumor from which Mel270 was derived. These analyses were complemented 
by FISH analyses, allowing identification of chromosomal aberrations on a single cell level. In 
addition, we have analyzed the p-arm of chromosome 3 for the presence of allelic loss. Our 
results are discussed in the context of other published structural chromosome 3 deletions found 
in uveal melanomas.
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Materials and methods
Cell Lines
For the present study uveal melanoma cell lines were used. Mel270 was established from a primary 
uveal melanoma. 17 OMM2.2, OMM2.3 and OMM2.6 are metastatic cell lines that originated 
from three different liver metastases of the same patient from whose primary tumor Mel270 was 
established. 18 All cell lines were grown in HEPES and glutamate containing RPMI 1640 culture 
medium, supplemented with 10% fetal calf serum, 1% penicillin and 1% streptomycin. Cells 
were passaged, depending on growth rate.
Comparative Genomic Hybridization
Comparative genomic hybridization on metaphases was performed according to Naus et al. 16
Loss of Heterozygosity
Polymorphic microsatellites for LOH studies were selected using the UCSC Genome Bioinformatics 
website (http://www.genome.cse.ucsc.edu) and synthesized by Life Technologies (Breda, The 
Netherlands). An overview of the markers that we used is given in Table 1 (chromosome 3q) and 
Table 2 (chromosome 3p). Primer sequences and locations are available upon request. Genomic 
DNA was isolated from the cell lines using standard techniques. Amplification reactions were 
performed in a 50 µl mixture, containing 50 pmoles of each oligonucleotide, 10 mM of each 
dNTP, 0.25 units Supertaq polymerase (HT Biotechnology Ltd., Cambridge, England), Supertaq 
buffer and about 100 ng genomic DNA. Reactions were denatured at 95ºC and subjected to 
30 cycles of denaturation at 95ºC for 1 minute, annealing for 1.5 minutes at 55ºC (except for 
marker D3S1580: annealing temperature 57ºC ) and elongation at 72ºC for 2 minutes, followed 
by 10 minutes final extension at 72ºC. Obtained polymerase chain reaction (PCR) products were 
purified using Qiaquick PCR purification system (Qiagen, Westburg, Leusden, The Netherlands). 
Subsequently, 1 µl purified PCR product was radioactively end-labeled, using 5 U polynucleotide 
kinase (Roche Molecular Biochemicals, Almere, The Netherlands) and 2 µCi [γ-32P] ATP 
(Amersham Pharmacia Biotech UK Ltd., Little Chalfont, United Kingdom). Denaturing stop mix 
(95% deionized formamide, 20 mM EDTA, 0.02% xylene cyanol FF, 0.02% bromophenol blue) 
was added in an equal volume. After heating for 5 minutes, the samples were quickly chilled and 
3 µl samples were loaded on a 6% denaturing polyacrylamide gel, which was run at 60 W. After 
electrophoresis the gel was dried on Whattman paper and a Fuji super RX film was exposed. 
Autoradiograms were visually analyzed. Since cell lines were used, marker patterns specific for 
the uveal melanoma cell lines could not be compared with that of a corresponding control. 
Therefore, results obtained for Mel270 were compared to those achieved for the corresponding 
metastases. Furthermore, DNA samples extracted from other uveal melanoma cell lines and 
human placenta DNA from a healthy individual were taken along. 
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Fluorescent in Situ Hybridization
Dual color interphase FISH was performed on cultured Mel270 cells as described previously by 
Naus et al. 19 The probes that we used are locus-specific bacterial artificial chromosome (BAC) 
clones, selected from the Roswell Park Cancer Institute database (http://genomics.roswellpark.
org/human/overview.html) and obtained from CHORI-BACPAC Resources (Oakland, CA, United 
States). An overview of the BAC probes that we used is given in Tables 1 and 2. Some of them 
Table 1. Results of chromosome 3q analysis of Mel270, using FISH and LOH 
Position# BAC Copy number Marker Number of alleles
3q21.1 D3S1267 2
3q21.2 RP11-95H16 2 D3S1269 2
3q21.2 D3S1589 1
3q21.2 RP11-205A6 1
3q21.3 RP11-59J16 ? D3S3606 1
3q22.1 - D3S1587 1
3q22.1 - D3S1292 1
3q22.1 - D3S1273 1
3q22.2 RP11-220J13 ? D3S1615 1
3q22.3 D3S3528 1
3q22.3 RP11-162J10 1 D3S1576 1
3q23 RP11-166D18 1 D3S3554 1
3q23 - D3S1309 1*
3q23 - D3S3694 1
3q23 RP11-160A13 1 D3S3546 1
3q24 RP11-165M11 ? D3S1569 2
3q24 RP11-72E23 1 D3S1557 1
3q24 - D3S1593 1
3q24 RP11-88H10 1 D3S1608 1*
3q24 - D3S3627 1
3q24 - D3S196 1*
3q24 - D3S2440 1
3q24 - D3S3618 1*
3q24 - D3S1306 1
3q24 - D3S3626 2
3q24 RP11-229G6 2 -
3q25.1 RP11-145F16 ? D3S1299 1
3q25.1 RP11-64F6 2 D3S1279 2
3q25.1 RP11-65L11 2 -
3q25.2 RP11-80I14 2 D3S1280 2
3q26.1 - D3S3702 2
3q26.31 - D3S2421 1
3q28 - D3S1580 1*
3q28 - D3S1294 2
3q28 - D3S1601 2
3q29 - D3S1272 1
Corresponding FISH clones and markers are presented at the same line. ?: presence of a subclone, *: presence of a weak 
second allele.
# position according to the Humane Genome Browser (March 2006) (http://genome.cse.ucsc.edu/).
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correspond to the markers that we selected for LOH analysis. Five ng of centromeric probe 
Pα3.5 was used per slide, 100 ng of telomeric probe B47A2 (kind gift of L. Kearney and J. Flint) 20 
and 75 ng probe in case of BAC clones. The probes were validated on normal peripheral blood 
cell metaphase spreads and ten metaphases were analyzed for each probe. Cut-off limits were 
less than three percent. For deletion mapping, signals in 300 interphase nuclei were counted 
according to the criteria of Hopman et al. 21 The cut-off values used for monosomy (only one 
signal in more than 15% of the nuclei) or polysomy (more than 10% of the nuclei with 3 or more 
signals) were adapted from available literature. 22 In case subclones were identified, only findings 
concerning the largest clone were used for analysis.
Table 2. Results of chromosome 3p analysis of Mel270, using FISH and LOH.
Position# BAC Copy number Marker Number of alleles
3p26.3 D3S3050 2
3p26.1 RP11-28P14 2 D3S1304 1*
3p26.1 - D3S3728 2
3p26.1 - D3S3591 1
3p26.1 - D3S1537 2
3p26.1 - D3S4545 2
3p25.3 RP11-128A5 2 D3S3691 2
3p25.3 - D3S1597 2
3p25.1 - D3S3693 1
3p25.1 - D3S3608 2
3p24.3 RP11-255O19 2 D3S1286 2
3p24.3 - D3S1293 1
3p24.3 RP11-208G16 2 -
3p24.3-24.2 RP11-41F5 2 -
3p24.1 - D3S1266 1
3p24.1 RP11-11L6 2 -
3p24.1 D3S3727 1
3p22.3 D3S2432 2
3p22.3 D3S3518 2
3p22.3 D3S1619 2
3p22.2 RP11-209O16 2 -
3p21.32-3p21.31 RP11-189H19 2 -
3p13 D3S2406 2
Corresponding FISH clones and markers are presented at the same line. *: presence of a weak second allele.
# Position according to the Humane Genome Browser (March 2006) (http://genome.cse.ucsc.edu/).
Results
Loss of Heterozygosity
We have previously shown a deletion of chromosome 3q13-3q21 in Mel270, using conventional 
CGH (fig. 1). 16 For a further demarcation of this region of loss, LOH studies were performed. 
For the LOH analyses microsatellite markers were selected in and around the deletion region 
3q13-3q21 in Mel270. Using this set of markers, loss of heterozygosity was identified for Mel270 
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but only with markers, mapping to chromosome 3q22.1. Therefore, we extended our marker 
set with markers mapping between chromosome band 3q22 and the 3q telomere. Cell lines 
from corresponding metastases, i.e. OMM2.2, OMM2.3, and OMM2.6 were analyzed along 
with Mel270. Mel270 and OMM2.3 showed LOH with consecutive markers, mapping to loci at 
3q21.2-3q23 (fig. 1 and fig. 2). In OMM2.6 our results were indicative of loss at loci from 3q13.31 
to the 3q telomere, whereas OMM2.2 showed loss at most loci tested along the q-arm. 
In uveal melanomas that metastasized, another region of LOH, mapping to chromosome 3p25, 
has been observed . 14, 15 To establish whether chromosome 3p deletions could also be detected 
in Mel270 and related cell lines OMM2.2, OMM2.3 and OMM2.6, eighteen different markers, 
mapping between chromosome band 3p26.2 and 3p13, were analyzed (fig. 1). In Mel270, 
OMM2.3 and OMM2.6 loss of heterozygosity was detected with successive markers D3S1293, 
D3S1266 and D3S3727, representing loci at 3p24.1-3p24.3. Results obtained for OMM2.2 were 
again indicative of isodisomy. 
Fluorescent In Situ Hybridization
Complementary to the LOH studies, interphase FISH was performed on Mel270 cells, using 
fifteen BAC clones mapping to 3q21.1-3q25.2. Twelve of these clones corresponded to the 
polymorphic markers we used (see Table 1). Results obtained from LOH analysis and FISH 
studies were not in complete accordance. While FISH clone RP11-88H10 showed loss of one 
copy, the corresponding microsatellite marker D3S1608 showed the presence of a weak second 
allele (fig 3A and Table 1). With FISH clone RP11-165M11 unclear results were obtained and 
the corresponding marker D3S1569 showed presence of 2 alleles. Markers D3S1309, D3S196 
and D3S3618 also revealed a weak second allele while flanking FISH probes and markers were 
indicative of loss. Marker D3S3626 showed no allelic loss and could demarcate the telomeric 
border of the deletion. Results obtained with markers D3S1299, D3S2421 and D3S1272, located 
at the telomeric site of the deletion border, showed the presence of one allele and marker 
D3S1580 the presence of a weak second allele.
The p-arm of chromosome 3 was studied with a panel of eight FISH clones, mapping from 
3p21.32-3p26.1. Although microsatellite analysis was indicative of allelic loss at four consecutive 
loci ranging from 3p24.1-3p24.3, interphase FISH revealed the presence of two copies of 
chromosome 3p at all the loci studied (table 2 and fig. 3B). Signals obtained with probe RP11-
11L6 were not specific enough, using interphase FISH. Therefore, metaphases were analyzed; in 
33 out of 36 metaphases two copies were detected.
Discussion
Cytogenetic studies revealed that Mel270 exhibits the most important chromosomal aberrations, 
i.e. loss of chromosome 3 and gain of chromosome 8, which are consistently observed in 
uveal melanoma. 16 Therefore, we believe that Mel270 can safely be used as a model system, 
guaranteeing an unlimited supply of material, which is very helpful in the search of putative 
TSGs. Loss of heterozygosity analysis on cell lines is complicated by the fact that corresponding 
normal DNA of the patient is not available. In case only one allele is observed it is not possible 
to discriminate between loss of one allele and lack of heterozygosity of the used microsatellite. 
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Figure 1. CGH, FISH and microsatellite analyses 
on Mel270 and 3 metastatic cell lines. On the 
right of the chromosome 3 ideogram the results of 
respectively, CGH, FISH and microsatellite instability 
analyses are shown. The deleted region in CGH on 
nine metaphases is indicated with an open bar. For 
both FISH and microsatellite analysis the positions 
and results are indicated with circles. Filled circle: no 
copy number change was observed; open circle: copy 
number loss (FISH); loss of heterozygosity (LOH). 
The LOH analysis results of the three metastatic cell 
lines OMM2.2, OMM2.3 and OMM2.6 are shown 
next to the LOH data of Mel270.
Figure 2. Microsatellite 
analysis of several cell lines 
with different primer sets. 
Representative results obtained 
with chromosome 3q markers 
D3S3546 and D3S1280 are shown.
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However, since we were able to compare a cell line derived from a primary tumor (Mel270) 
and three metastatic cell lines (OMM2.2, OMM2.3 and OMM2.6), obtained from three different 
liver metastases from this same primary tumor, we were able to differentiate possible LOH. 
Furthermore, in case of Mel270, FISH was performed, complementary to LOH analysis. 
Combining the data obtained with microsatellite analysis and FISH revealed allelic loss at 
chromosome 3q21.2-3q24 in Mel270 (Table 1). Cell line OMM2.3 showed LOH at the same loci. 
Results obtained with microsatellite analysis and FISH were not always corresponding. Markers 
D3S1309, D3S1608, D3S196 and D3S3618 showed the presence of a weak second allele. This 
might be the result of the presence of an extra homologous binding site in the genome, giving 
rise to an extra product, since FISH data obtained with probe RP11-88H10, corresponding to 
D3S1608, clearly showed loss of one allele. Markers D3S1309 and D3S1608, for example, are 
both attributed to two STSs, as was found with the web-based NCBI e-PCR tool. Unknown 
second target sites could also be present for the other markers. Weak extra alleles might 
also be explained by the presence of a subclone in the tumor. Marker D3S3626, showing two 
Figure 3. FISH analysis of Mel270.
A: representative results of dual color FISH on Mel270 cells, hybridized with a combination of a chromosome 3q probe 
(red) and a centromere 3 probe (Pα3.5) (#3) (green), except for probe RP11-95H16 (green) that was combined with a 
3pter probe (B47A2) (red). Panel A: 3pter probe and RP11-95H16; #3 and RP11-88H10; and #3 and RP11-229G6.
B: representative results of dual color FISH on Mel270 cells, hybridized with a combination of a chromosome 3p probe 
(red) and a centromere 3 probe (Pα3.5) (#3) (green). Panel B: #3 and RP11-208G16, #3 and RP11-255O19, and #3 
and RP11-41F5.
Color figure can be found on page 144.
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alleles, marks the end of LOH region. But also at the telomeric site of this deletion border some 
inconsistencies were observed. Markers D3S1299, D3S2421 and D3S1272 showed the presence 
of one allele and marker D3S1580, which is also attributed to two STSs, showed only a weak 
second allele. Inconsistencies like this can also be explained by lack of heterozygosity for these 
markers. Furthermore, it is also known from literature that LOH analysis is not always a reliable 
technique. 23 
While CGH analysis previously revealed a deletion at 3q13-3q21 16, our fine-mapping studies 
pointed to a deletion ranging from 3q21.2-3q24. This discrepancy can be explained by the fact 
that the resolution of conventional CGH on metaphases is limited. 24 
Along the p-arm allelic loss was detected in Mel270 and corresponding cell lines OMM2.3 
and OMM2.6 with three consecutive markers, mapping to 3p24.1-3p24.3. Since FISH analysis 
revealed two copies in this region, this could point to a hemizygous region. However, false 
positive results, due to lack of heterozygosity, cannot be excluded. CGH analysis and karyotyping 
(results not shown) were not indicative of any chromosome 3 loss in OMM2.2 and OMM2.6, but 
the LOH analysis points to isodisomy of whole chromosome 3 in OMM2.2, and a large part of 
the long arm of chromosome 3 in OMM2.6.
Although in a large part of the uveal melanomas monosomy of chromosome 3 is found 13, several 
studies revealed structural abnormalities of chromosome 3p and or 3q in uveal melanomas. A 
partial duplication, involving the long arm of chromosome 3 with a breakpoint at 3q25 has been 
described by Prescher et al. 25 Scholes et al. 13, who performed LOH studies, reported a 3q 
deletion, ranging from a region between marker D3S1589 (3q21.2) and D3S1605 (3q25.32) to the 
telomere. A LOH study by Tschentscher et al. 14, performed on uveal melanoma with structural 
abnormalities, allowed definition of a smallest region of overlap (SRO) at chromosome 3q24-
3q26. (D3S196-D3S1763). At the telomeric site the SRO is flanked by marker D3S1763, mapping 
to 3q26.1, and marker D3S2425 located at 3q26.31, showing loss and retention, respectively. 
At the centromeric site the SRO is flanked by marker D3S196 (3q24) showing LOH and marker 
Mdf2 at the RHO locus (3q21.3) showing retention of both alleles. In the present study, a deletion, 
starting at marker D3S1589 at 3q21.2 and ending at marker D3S3626 (3q24) at the telomeric 
site, was found. Combining our data with data from Tschentscher et al. 14 yielded an overall SRO, 
ranging from 3q21.3-3q24. Furthermore, these data corroborate with a study by Dahlenfors et 
al. pointing to the 3q23 region as a possible TSG location, based on a rearrangement found in one 
UM. 26 As far as we know, UM specific TSGs mapping to 3q21.3-3q24 have not been identified 
to date. A candidate tumor suppressor gene in uveal melanoma, tp63, is located outside this 
region, on 3q27. 27 In other tumor types loss of chromosome 3 has also been described. Loss of 
chromosome 3q seems to be an early event in pheochromocytomas as well. 28
Aberrations of the p-arm of chromosome 3 have also been described. In one uveal melanoma 
a translocation with a breakpoint at 3p13 was found. 29 Tschentscher et al. suggested that in 
metastasized uveal melanoma two regions on chromosome 3 (a region on the q-arm and a 
region on the p-arm) harbor TSGs. 14 This could explain the frequently observed loss of an 
entire chromosome 3 in those tumors. Although our CGH and FISH analysis did not reveal a 
chromosome 3p deletion in Mel270, microsatellite analysis pointed to a region of allelic loss, 
ranging from 3p24.1-3p24.3. This possible hemizygous region is flanked by marker D3S1293 
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(3p24.3) showing LOH and marker D3S1286 (3p24.3) showing retention of two alleles at the 
telomeric site. The border of the centromeric site is defined by marker D3S3727 (3p24.1) and 
D3S2432 (3p22.3), showing allelic loss and retention of two alleles, respectively. This region 
does not overlap with the SRO’s defined by Tschentscher et al. (3p25.3-3p26.1) and Parrella et 
al. (3p25.1-3p25.2) (14, 15). However, in an earlier study by Sisley et al. allelic loss of the Thyroid 
Hormone Receptor B (THRB) locus was observed in 60% of the uveal melanoma investigated. 30 
The human THRB locus, which maps to chromosome 3p24.2 (human genome draft, version May 
2004), acts as a transcriptional activator and silencer. Aberrant expression and/or mutations in 
THR genes could be associated with carcinogenesis. 31 Another candidate TSG that is located 
in the hemizygous region is Retinoic Acid Receptor β2 (RARβ2) (3p24.2). Decreased levels of 
this receptor are associated with malignancies, like breast tumors, lung cancer and squamous 
cell cancer of head and neck. 31 Other possible TSGs on 3p like the Von Hippel Lindau (VHL) 
gene (3p25.3), Ras association domain family 1 (RASSF1) (3p21.31) and the Fragile Histidine 
Triad (FHIT) (3p14.2) map to regions outside the hemizygous region, detected in the present 
study. 31 Interestingly, gene expression profiling studies of Tschentscher et al. (2003) and Onken 
et al. (2004) described gene expression classifiers predictive for tumor class, monosomy of 
chromosome 3 and prognosis, that harbor a number of genes that are located on the regions on 
chromosome 3 delineated in this study. The respective genes are NR1D2 and RPL15 on the 3p 
region and PIK3R4, EIF2A and KIAA0678 on the 3q region. 32,33 This supports our statement that 
it is likely that one or more genes on those regions function as tumor suppressor genes in poor 
prognostic uveal melanoma. For further reduction and localization of putative TSG loci, high-
resolution analysis, focusing on those regions in a set of tumors with a short DFS is required.
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Abstract
Objectives: Uveal Melanoma (UM) is the most common primary intraocular malignancy of the 
eye in adults. Certain chromosomal aberrations serve as excellent prognostic markers for UM. 
Monosomy of chromosome 3 is the most frequently found non-random chromosomal aberration 
in UM strongly correlating with poor prognosis. This loss is considered a primary event that is not 
commonly seen in other tumor types. Chromosome 3 is believed to harbor tumor suppressor 
genes (TSGs) that are important in UM development. Until now, only a few UMs with partial 
aberrations on chromosome 3 or translocations involving chromosome 3 have been described. 
We have searched UMs for a common deleted region on chromosome 3 to reduce the candidate 
TSG region. 
Methods: Our database, consisting of 120 UMs with cytogenetic, pathological and follow-up 
data, contained two patients with a deletion of the entire long arm of chromosome 3 and only 
one UM with a partial 3q deletion. We demarcated this deletion using Comparative Genomic 
Hybridization and Fluorescence In Situ Hybridization. 
Results: The delineated region spans from the centromere to approximately 3q26.2. The 
patients with either 3q or partial 3q deletions did not suffer from metastatic disease during 11 
years of follow-up. 
Discussion: Apparently, these partial chromosome 3 deletions do not lead to the development 
of metastases. The hypothesis that loss of both a region on 3p and 3q leads to decreased survival 
in UM and that loss of only 3q is not the sole event leading to a poor prognosis is supported by 
these findings.
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Introduction
Uveal melanoma (UM) is the most common primary intraocular malignancy. Several prognostic 
parameters, among which some are cytogenetic, are available to select patients at risk of 
developing metastases. Those parameters have been selected from the non-random chromosomal 
aberrations occurring in uveal melanoma. Amplification of chromosome 8q, amplification of 6p, 
loss of 6q and loss of 1p36 frequently occur in UM. 1-6 However, monosomy of chromosome 3 is 
the most frequently found non-random chromosomal aberration that highly correlates with poor 
prognosis. This effect becomes even stronger when besides 3 also 1p36 is lost. 7 Involvement 
of chromosome 3 is considered to be a primary event; loss of chromosome 3 is a constant 
event in UMs that are characterized by different sub-populations, in contrast to the variable 
number of copies of chromosome 8q that can be observed. 1, 8 In many uveal melanomas an 
entire chromosome 3 is lost, or isodisomy of this chromosome is acquired. 4, 6, 9 Monosomy 
of chromosome 3 is not commonly observed in other tumor types and it is widely believed 
that chromosome 3 harbors tumor suppressor genes that play an important role typically for 
uveal melanoma development. Until now, only a few melanomas with partial aberrations on 
chromosome 3 or translocations involving chromosome 3 have been described, which obviously 
makes it difficult to map the putative tumor suppressor genes. In a loss of heterozygosity (LOH) 
study on UM, Tschentscher et al. found two regions of allelic loss on chromosome 3, one located 
at 3p25 and one ranging from 3q24-q26. 10 In all metastasized tumors both regions were lost. In 
the UM cell line Mel270, we have also demarcated two candidate regions for tumor suppressor 
genes on chromosome 3 (van Gils et al., manuscript submitted for publication). The results 
suggested a region of LOH at 3p24, and on the long arm of chromosome 3 a deletion was 
observed from 3q21.3 until 3q24, overlapping with the region found by Tschentscher et al. [10]. 
To determine whether loss of a specific region on chromosome 3q is involved in UM development 
and progression, and to further delineate this region, we searched for more UMs with partial 3 
deletions. In our patient cohort we identified two patients with a deletion of 3q and one case with 
a partial deletion of 3q. We have subsequently demarcated the borders of this deletion, using 
Fluorescence In Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH).
Methods
Patient material
UMs from patients who underwent enucleation of the tumor-containing eye for ciliary body or 
choroidal melanoma, at the Erasmus MC Rotterdam and Rotterdam Eye Hospital were collected. 
Informed consent was given prior to enucleation and the study was performed according to the 
tenets of the Declaration of Helsinki. Fresh tumor material was obtained within 1 hour after 
enucleation and processed for FISH and cytogenetic analysis as described. 11
The remainder of the eye was embedded in paraffin immediately after enucleation at the 
department of Pathology. A set of 120 tumors were selected from our database, and included in 
this study, based on the availability of cytogenetic, pathological and follow-up data.
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Selection of patients
From these 120 tumors, we selected those tumors suspect of partial losses of chromosome 
3, based on the outcome of CGH or routine FISH analysis using probes on centromere 3 and 
3q24. In total 5 patients with a partial loss of chromosome 3 could be identified. Three tumors 
were included in this study because routine FISH showed two copies of centromere 3 and only 
one copy of 3q (Case 1, 3 and 4). Tumor 2 was included based on cytogenetic findings indicating 
loss of 3q (FISH on 3q was not informative). For tumor 5 routine FISH showed one copy of 
centromere 3 and two copies of 3q.
CGH
CGH was performed as described by Kiliç et al. 7 Images were acquired with a Zeiss axioplan 
microscope equipped with Isis version 5 software, MetaSystems (Ohio, USA). Ten metaphases 
were analyzed. Loss of DNA sequences was defined as chromosomal regions where the mean 
green: red ratio was below 0.8, while gain was defined as chromosomal regions where the ratio 
was above 1.2. Threshold levels were determined on basis of analysis of known chromosomal 
aberrations. 
FISH
Dual-color FISH was performed on uncultured tumor material fixed directly after enucleation as 
described previously. 13  If directly fixed material was not available, nuclei isolated from paraffin 
embedded UMs were used. Tumor cells were deparaffinized and the nuclei were isolated and 
fixed with ethanol/acetic acid (3:1). Nuclei were spotted on slides using the Cytofuge (Nordic 
Immunological Laboratories B.V., Tilburg, The Netherlands) and subsequently treated according 
to the procedure described by Van Dekken et al. 14 The concentration for centromeric probes 
was 5 ng per slide; for Bacterial Artificial Chromosome (BAC) probes 50 to 75 ng per slide was 
used. When nuclei isolated from paraffin embedded UMs were used, the samples were analyzed 
with the routine FISH probes as previously described by Naus et al. (2000). 15 For additional 
FISH, BAC probes were selected from the human genome browsers of UCSC (http://genome.
ucsc.edu/cgi-bin/hgGateway) and NCBI (http://www.ncbi.nlm.nih.gov/mapview/map_search.
cgi). CTD-probes were obtained from Invitrogen (Carlsbad, USA) and RP-probes from CHORI-
BACPAC Resources (Oakland, USA). Signals were counted in 300 interphase nuclei according to 
the criteria of Hopman et al. 16 Cut-off limits for deletion and amplification were adapted from 
the available literature.
Results
All enucleated UMs were karyotyped if metaphase spreads could be obtained. Karyotyping 
results from 3 of the 5 selected tumors were available (Table 1).
Material of all five cases was analyzed with CGH and, if possible, with FISH using diagnostic 
probes hybridizing to chromosomes 1, 3, 6 and 8 (data not shown). To control for ploïdy status 
and to confirm regions of loss, additional FISH was performed on material of four of the included 
cases. Data of additional FISH analyses are summarized in Table 2.
CGH showed that the tumor from case 3 had two copies of chromosome 3. Since diagnostic 
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FISH with probe RP11-64F6 (3q25.1) showed that only 15.5% of the nuclei contained one signal, 
the subclone of nuclei containing the deletion is probably too small to be detected with CGH. No 
additional FISH was performed on this tumor. The tumor derived from case 5 showed complete 
monosomy of chromosome 3, with differences in the extent of the loss for certain regions on 
both the p and q arm in its CGH profile. To find out whether this pattern was specific and not 
due to label preference, fluorescent labels of patient and control DNA were swapped during the 
random prime labeling and CGH was repeated. The same pattern was obtained, suggestive of a 
specific signal, probably caused by more than one region of loss along the q-arm of chromosome 
3 in this tumor. However, all FISH probes analyzed along chromosome 3, indicated a loss. A 
partial loss of chromosome 3 was observed in the tumors derived from cases 1, 2 and 4 using 
CGH analysis. The tumors of cases 2 and 4 showed deletion of the entire 3q-arm, whereas the 
tumor derived from case 1 showed a partial deletion of the long arm of chromosome 3. CGH 
revealed a deletion, ranging from the centromeric region of chromosome 3 to approximately 
3q26.2 (fig. 1A and B). Thus, the tumor, obtained from case 1, was the only tumor with a clear 
partial deletion on chromosome 3q in this study. This tumor had two copies of 1p36, gain 
of chromosome 6p, loss of 6q and normal copies of chromosome 8. The deleted region on 
chromosome 3q was further defined using FISH. Probes were selected in both border regions. 
At the telomeric border of the deletion, loss of one signal was found with probe RP11-478O19 
(3q26.1), whereas two signals were found at 3q26.2 with RP11-816J6 (fig. 1C). In routine FISH, 
two copies of the centromere were detected. To find out whether the breakpoint of the deletion 
was at the centromere or whether it was located in a region beneath it, FISH was performed with 
probes, mapping to 3q11. RP11-449F7 showed one signal with a percentage of 78% (fig. 1D). 
Two other probes, CTD-2007O24 and CTD-2005N19 revealed loss of one copy at 3q11 as 
well. In conclusion, the 3q deletion in the tumor of this patient ranges from the centromere until 
at least 3q26.1, possibly until 3q26.2 (Figure 2). 
Discussion
It is generally thought that loss of chromosome 3 would result in loss of two or more distinct 
TSGs located on the short and long arms of chromosome 3. Concurrent loss of the candidate 
regions on 3p and 3q seems to be essential in uveal melanoma development, as was hypothesized 
by Tschentscher et al. 10 Loss of an entire chromosome 3 would therefore be favorable and could 
explain the high frequency of monosomy 3 observed in UM. The finding that loss of chromosome 
3 is an early event in UM development is also in support of the hypothesis that this chromosome 
harbors on both its arms TSGs that are involved in UM. This explains why partial abnormalities 
on chromosome 3 are rare and in most cases of UM with chromosome 3 aberrations a complete 
monosomy is found. CGH and micro-satellite analysis has been used to delineate these regions 
further and the different studies are summarized in figure 2. Aalto and coworkers used CGH 
analysis on 29 primary tumors and revealed one tumor with a partial deletion on chromosome 3q, 
ranging from 3q25 to 3q26.3. 6 In one study, a chromosome 3q translocation (t(3;14) (q23;q32)) 
was reported. 18 With microsatellite analysis with a low-resolution marker set Scholes et al. 
identified a region of LOH from at least 3q25.1 and possibly from 3q21 until the telomere. 9 
Parrella et al. reported three partial deletions with LOH of more than one marker, in their LOH 
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study on 21 UMs that did not show monosomy of chromosome 3 in earlier allelotyping. Two 
of these tumors had a common region of loss ranging at most from 3q13.31 to 3q22.2. 19 
Tschentscher et al. applied CGH and LOH on UMs and UM derived cell lines and rapport a 
common deleted region from 3q24 to 3q26.10 This shortest region of overlap (SRO) overlaps 
with the 3q21.3-3q24 region deleted in the UM cell line Mel 270 and its metastasis OMM2.3. as 
we observed using FISH and LOH analysis (W.van Gils et al., manuscript submitted). 
When combining the data of the different studies with our data, we find a new SRO with its 
proximal border at 3q24 and a distal border at 3q26.2. This candidate region on chromosome 
3q in UM harbors many possible TSGs. One of those genes in the breakpoint region is the 
ectopic viral integration site 1 (EVI1) gene that is frequently deregulated in hematological 
malignancies, often through translocations. 20, 21 A second candidate in this region is telomerase 
RNA component (TERC), required as the template in telomeric repeat synthesis. 22 Deregulation 
of telomere synthesis might contribute to tumorigenesis by circumventing terminal growth arrest 
and apoptosis following unacceptable short telomeres. A third candidate gene is Programmed 
Cell Death 10 (PDCD10). Mutations within this apoptosis related gene cause cerebral cavernous 
malformations. Intriguingly, 5% of patients with familial cerebral cavernomas develop retinal 
cavernoma. 23 
Whether loss of this particular region of chromosome 3 contributes to the development of 
metastasis is not clear. The three patients in our database of which the UMs only showed a 
(partial) loss of the q-arm of chromosome 3, did not develop metastatic disease during 5 to 
11 years of follow-up. Deletion of this region is apparently not enough for UMs to develop 
metastases, which also supports the hypothesis that loss of both a region on 3p and 3q leads to 
a poor signature in UM. Previously, we have observed that concurrent loss of chromosome 1p 
and chromosome 3 significantly predicts for decreased disease-free survival in uveal melanomas 
patients. 7 Thus in addition to chromosome 3 genes, genes on other chromosomal regions could 
contribute towards the development of metastasis. 
Examination of more uveal melanomas with partial 3q deletions could possibly further narrow 
down the region of interest. To increase chances to further demarcate the SRO, it would be 
interesting to include uveal melanomas from patients with a short survival, for which no deletions 
were observed on chromosome 3 in diagnostic cytogenetics and classical CGH, and to analyze 
those tumors with high resolution techniques like array-CGH and SNP analysis.
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Table 1. Tumor selection indicative of partial losses with corresponding karyotype* 
Uveal melanoma Karyotype (ISCN 2005) Initial FISH results on chr. 3 (copy nr.)**
#3 3q
Case 1 NA* 2 1
Case 2 43,X,-Y,dic(3;19)(q11;q13.2),-13, 
der(17)t(13;17)(q13;p12),add(22)
(p11)[6]/43,idem,-21[4]
2 NA
Case 3 NA* 2 1
Case 4 46,XX,der(20)t(6;20)(p12;p12)
[5]/47,idem,+8[4]/ 47,idem,+8,psu 
dic(17;15)(p13;p11)[3]/46,XX[3]
2 1
Case 5 45~48,XX,-3,i(8)(q10),+i(8)
(q10),+i(8)(q10)[cp5]/ 
47~49,XX,+3[3],+5[2],+6[2]
[cp4]/46,XX[4] 
1 2
*NA = data not available
** Cut-off limits for deletion (>10% of counted nuclei with one copy) were adapted from the available literature.17
Table 2. FISH results of chromosome 3 deletion analysis 
Tumor Probe Chromosomal 
position* 
Copy number
(Percentage)**
Case 1 CTD-2005N19 3q11.2 1 (70.0)
CTD-2007O24 3q11.2 1 (82.3)
RP11-449F7 3q11.2 1 (77.7)
RP11-64F6 3q25.1 1 (78.7)
RP11-117L15 3q25.31 1 (83.7)
RP11-90M7 3q26.1 1 (68.5)
RP11-478O19 3q26.1 1 (67.5)
RP11-816J6 3q26.2 2 (95.3)
RP11-54L9 3q28 2 (96.3)
Case 2 RP11-632N21 3p24 2 (87.0)
Pα 3.5 Centromere 3 2 (97.0)
CTD-2005N19 3q11.2 1 (83.5)
RP11-64F6 3q25.1 1 (67.5)
RP11-147L6 3q26 1 (91.5)
RP11-54L9 3q28 1 (84.5)
Case 3*** --- --- ---
Case 4 RP11-384L8 3p22.3 3 (15.0)
Pα 3.5 Centromere 3 3 (25.0)
RP11-64F6 3q25.1 1 (93.0)
Case 5 RP11-632N21 3p24 1 (82.5)
Pα 3.5 Centromere 3 1 (78.5)
CTD-2005N19 3q11.2 1 (77.5)
RP11-64F6 3q25.1 1 (81.5)
* UCSC Genome Browser on Human March 2006 Assembly.
** The copy number of the largest clone (percentage between brackets) is given.
*** No FISH chromosome 3 deletion analysis was performed on Case 3.
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Figure 1. CGH and FISH on case 
1. A) Metaphase spread after com-
parative genomic hybridization with 
tumor DNA labeled in green, refer-
ence DNA labeled in red. The ar-
rowheads point to the red regions 
on the q-arm of chromosomes 3 
indicating a loss. B) CGH results on 
chromosome 3 of ten metaphase 
spreads processed with Isis version 
5 software. The thick line repre-
sents the average signal of the ten 
metaphases. The lower limit was 
set as green-to-red ratio 0.8, the 
upper limit as a ratio of 1.2. The 
partial deletion is indicated with a 
red bar alongside of the chromo-
some image. C) and D) are images 
of FISH. C) FISH on isolated nuclei 
with probes RP11-816J6 (labeled 
in red) and RP11-54L9 (labeled 
in green) showing the presence 
of two copies of regions 3q26.2 
and 3q28, respectively. D) Probes 
RP11-449F7 (red) and RP11-64F6 
(green) showed loss of one copy 
of chromosome 3 in the regions 
3q11.2 and 3q25.1 respectively.
Color figure can be found on page 144
Figure 2. Summary of previous-
ly described partial deletions 
in UM on one of the arms of 
chromosome 3 together with 
the partial deletion found in 
patient 1. Chromosome band-
ing pattern is designated on the 
left according to ISCN (2005). On 
the right of the ideogram, regions 
of deletion found in different stud-
ies are represented by the vertical 
bars, translocation regions by open 
circles. The region identified in this 
study is designated by a grey bar. 
The different studies are indicated 
by letters under the respective 
bar. A) Partial deletion found in 
this study in patient 1; B) Deletion 
found with CGH by Aalto et. 
al. [6].; C) Deletion identified by 
Scholes et al. [9] with microsatellite 
markers; D) Translocation (t(3;14)
(q23;q32)) identified in UM derived 
cell line by Dahlenfors et al. [18].; E) 
Common region of deletion in mi-
crosatellite analysis by Parrella et 
al. [5].; F) Smallest region of overlap 
identified by Tschentscher et al. [10] 
with microsatellite analysis; G) Par-
tial deletion found in an LOH study 
by Van Gils et al. on UM derived 
cell line Mel 270.
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Abstract
Objectives: Uveal Melanoma (UM) is the most common primary intraocular malignancy in 
adults. Loss of the long arm and gain of the short arm of chromosome 6 are frequently observed 
chromosomal aberrations in UM, together with loss of chromosome 1p36, loss of chromosome 
3 and gain of chromosome 8. This suggests the presence of one or more oncogenes on 6p and 
tumor-suppressor genes at 6q that are involved in UM development. However, both regions 
have not been well defined yet. Also in other neoplasms gain of 6p and loss of 6q are frequently 
occurring events. In this case report, we describe the delineation of a partial gain on chromosome 
6p and a partial deletion on 6q in a UM with the objective to pinpoint smaller candidate regions 
on chromosome 6 involved in UM development. 
Methods: Conventional cytogenetics, CGH and FISH were used to delineate regions of loss and 
gain on chromosome 6 in this UM patient. 
Results: With conventional cytogenetics a deleted region was found on chromosome 6q that 
was further delineated to a region ranging from 6q16.1 to 6q22 using CGH and FISH. A region 
of gain from 6pter to 6p21.2 was also demarcated with CGH and FISH. No other deletions or 
amplifications on recurrently involved chromosomes were found in this patient. 
Conclusions: This study indicates the presence of one or more tumor suppressor genes on 
chromosomal region 6q16.1-6q22 and the presence of one or more oncogenes on chromosomal 
region 6pter-6p21.2, which are likely to be important in uveal melanoma and other tumors.
Chapter 8106
Introduction
Uveal melanoma (UM) is the most common primary malignancy in the eye with an incidence of 
about 6 per million people every year in the western world. 1 Several prognostic parameters are 
available to identify patients at risk of developing metastases. Among these are the cytogenetic 
parameters loss of chromosome 1p36, loss of chromosome 3, gain of chromosome 8 and 
abnormalities on chromosome 6. Abnormalities on chromosome 6 have also been described in 
other types of tumors. Gain of the short arm of chromosome 6 is a frequently occurring event 
in many other neoplasms, including lymphoid tumors, sarcomas, retinoblastoma and cutaneous 
melanoma. 2-7 This suggests the presence of a common oncogene in this chromosomal region. 
Correlation of gain of 6p with decreased survival was found in certain types of sarcoma and 
cutaneous melanoma. 3,8,9 Deletion of the long arm of chromosome 6 also occurs in many 
neoplasms, including carcinomas of the prostate and breast and melanomas. 10-13  In several 
studies on different types of tumors the relation of chromosome 6q loss with survival was 
investigated. In cutaneous melanoma and acute lymphoblastic leukemia loss of 6q is correlated 
with a poor clinical signature. 14,15 This suggests the presence of a tumor-suppressor gene or 
genes at 6q. In UM, aberrations of chromosome 6 also occur frequently and a correlation with 
increased survival has been described. 16  In contrast to this, Aalto et al. showed that loss of 
chromosome 6q is associated with decreased survival. 17 Although these findings are contradictory 
and a possible relation between abnormalities on chromosome 6 and prognosis is difficult to 
determine, it seems very likely that there are genes on regions on both arms of chromosome 
6 involved in tumor development and progression. In UM, the deletion of 6q appears to be 
a late event resulting from tumor progression. 18  Although in certain tumor types a smaller 
candidate region or regions for oncogenes on 6p and tumor suppressor genes on 6q have been 
identified, in UM the regions of interest have not been well defined yet. In this report, a UM case 
with gain of chromosome 6p and loss of chromosome 6q and without numerical aberrations on 
chromosomes 1, 3 and 8 is investigated in detail. The fact that not the complete chromosome 
arms of chromosome 6, but only a smaller region of both the q-arm and the p-arm are involved, 
offers the opportunity to demarcate the regions of loss and amplification on chromosome 6, 
involved with UM development, further.
Methods
Case history
A 39-year-old male without a relevant medical history, no use of any medication nor any 
intoxication, presented with painful irritation and decreased visual acuity in his left eye starting six 
weeks before his initial visit. The right eye had a visual acuity of 1.0 without correction, whereas 
the left eye had a visual acuity of 0.6 without correction and stenopeic 1.0. On fundoscopic 
examination the patient appeared to have a large pigmented tumor with small superficial 
hemorrhages located in the temporal posterior pole of his left eye with an exsudative retinal 
detachment. Fluorescence angiography showed tumor vascularization with minimal leakage 
in the late phase. Ultrasound examination showed a solid homogeneous tumor with a largest 
tumor diameter of 13.2 mm, a sereous retinal detachment, no choroidal excavation, and low to 
Regional deletion and amplification on chromosome 6 in a uveal melanoma case 107
middlehigh internal reflectivity. Subsequently the affected eye was enucleated. After 48 months of 
follow-up the patient is still alive without signs of metastatic disease. Family history was negative 
for UM or other tumors.
Patient sample
Informed consent was given prior to enucleation and the study was performed according to 
the tenets of the Declaration of Helsinki. Permits were granted by the local medical ethical 
committee. Fresh tumor material (designated EOM 265) was obtained within 1 hour after 
enucleation and processed for FISH and cytogenetic analysis as described. 19
Cytogenetic analysis
Chromosome preparations were made following standard cytogenetic procedures and stained 
for R and Q banding. Cytogenetic abnormalities were described according to the International 
System for Human Cytogenetic Nomenclature (ISCN). 20 
Fluorescence In Situ Hybridization (FISH)
Dual color FISH on uncultured tumor material using centromeric and locus specific cosmid, 
P1 or YAC probes for chromosome 1, 3, 6 and 8 was performed as described previously. 21 
For further analysis, suitable bacterial artificial chromosome (BAC) probes were selected from 
the human genome browsers of UCSC (http://genome.ucsc.edu/cgi-bin/hgGateway) and NCBI 
(http://www.ncbi.nlm.nih.gov/mapview/map_search.cgi). 
Comparative Genomic Hybridization (CGH)
CGH was performed as described by Kilic et al. 21 Images were acquired with a Zeiss axioplan 
microscope equipped with Isis version 5 software, MetaSystems (Ohio, USA). Ten metaphases 
were analysed. Loss of DNA sequences was defined as chromosomal regions where the mean 
green: red ratio was below 0.8, while gain was defined as chromosomal regions where the ratio 
was above 1.2. Threshold levels were determined on basis of analysis of known chromosomal 
aberrations. 22
Results
Histopathological examination
The pigmented tumor originated from the choroid with a spindle cell morphology. The 
histopathological largest tumor diameter was 13 mm with a prominence of 12 mm. The tumor 
showed no invasion through Bruchs’ membrane or into the retina. No invasion of the sclera was 
seen and also the optic nerve was free of tumor. Vascular loops could not be identified and the 
mitotic figures were rather low with 2/15 HPF. 
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Cytogenetic and FISH analysis
EOM 265 presented with karyotype: 46,XY,del(6)(q15q22)[2]/46,XY,del(6)(q15q22),add(14)
(q32)[1]/ 46, XY, del(6)(q15q22), der(17)t(7;17)(q11.2;p13)[5]/ 46,XY,del(6)(q15q22),add(14)
(q32), der(17)t(7;17)(q11.2;p13)[8] (fig. 1).
FISH analysis showed no copy number abnormalities on chromosomes 1, 3, 6 and 8 other than 
gain of a region of chromosome 6p (two extra signals). Probe cos52 on 6q23 showed normal 
copy numbers.
CGH analysis of EOM 265 showed a deletion was on chromosome 6 between 6q14 and 6q23 
with signals close to the threshold level with a significant deleted region on 6q21-6q22.1. CGH 
also indicated amplification of 6p22-6p25 (fig. 2). No abnormalities of chromosome 14 were 
found in CGH. It could well be that the extra material on this chromosome as seen in the 
karyotype was caused by chromosome 6p material translocated to the tip of chromosome 14q 
(fig. 1). This translocation could however not be confirmed by FISH due to scarcity of metaphase 
spreads in the sample. A just significant gain of chromosome 7q was also seen. this gain is 
probably the result of extra material of chromosome 7q on the derivative chromosome 17 in 
subclones of the tumor. These subclones are less numerous present in the karyotype (13 of the 
16 methaphases) compared to the abnormalities on chromosme 6q. However the finding in the 
karyotype do not necessary reflect the situation in vivo since in vitro specific clones could have 
a growth advantage. CGH analysis did not show copy number abnormalities on chromosomes 
1, 3 and 8. (fig. 1). Disomy of chromosome 3 was confirmed in MLPA with kits P070 and P036B 
that cover all subtelomeric regions, revealing normal copy numbers for both distal regions of 
chromosome 3 (data not shown). 
Figure 1. Representative karyogram for EOM 265. The karyogram (QFQ banding) shows the following karyotype: 
46,XY,del(6)(q15q22),add(14)(q32), der(17)t(7;17)(q11.2;p13). Structural abnormalities are indicated by arrowheads. 
Loss of 21 is a non-clonal event, and therefore not indicated in the karyotype.
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The regions found on chromosome 6 in CGH were further investigated using FISH with the 
probes presented in figure 2, covering regions from 6pter to 6p21.2 and from 6q14 to 6q22.33. 
Probe RP11-215O12 on 6p21.3 and all probes located more distal on the chromosome showed 
presence of 3 (28-31%) to 4 copies (10-52%) of this region, whereas normal copy numbers 
were found with probe RP11-375E1, located more proximal on 6p21.3. This results in an 
amplified region of 35 Mb ranging from 6p21.3 to 6pter. The presence of a subclone with 4 
copies of this region explains the strong amplification signal of the region as was observed in 
CGH.Probe RP1-154G14 mapping to 6q16.1 and all probes mapping to more proximal region on 
6q, showed presence of two copies, while all probes in this region located more distal, showed 
loss of one signal in almost all nuclei. Of the probes surrounding the distal border of the deleted 
region, RP11-358H7 located on 6q22.32 as well as the probes located more proximal all showed 
clear losses in more than 40% of the interphase nuclei, whereas probes located distal from this 
probe showed no loss. These experiments confirmed the deletion and further delineated the 
deletion to a region of 32 Mb ranging from 6q16.1 to 6q22, to which interesting candidate tumor 
suppressor genes are mapped (fig. 2).
Figure 2. Regions of deletion and amplification on chromosome 6 in EOM 265. On the left of the chromome 6 
ideogram a CGH plot of the complete chromosome 6 is shown, with the thick black line representing the average signal 
of ten metaphases. The lower limit (the vertical line indicated by a gray arrow) was set as green-to-red ratio 0.8, the 
upper limit (indicated with an open arrow) has a ratio of 1.2. Deletions are indicated with a gray bar on the left and gains 
are indicated with an open bar on the right of the plot. Right to the ideogram of chromosome 6 the results of respectively 
karyotyping, CGH and FISH are shown. Losses found in karyotyping and CGH are indicated with grey boxes, gain in a 
white box. FISH probes with increased copy numbers are indicated with open dots, FISH probes that showed loss are 
indicated with open dots with a horizontal line. FISH probes that showed normal copy numbers are indicated with black 
dots. The chromosomal location in megabasepairs of each probe is indicated between brackets.
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Discussion
Inactivation of tumor suppressor genes by homozygous deletions, mutations or epigenetic events 
such as methylation of promoter regions is a common event in human cancers. However, in UM 
the molecular pathogenesis is largely unknown. Several chromosomal aberrations do occur in 
these tumors, like monosomy 3, loss of 1p and 6q, and gain of 8q and 6p. In this patient gain 
6p21.3-6pter and loss of 6q16.1-6q22 were observed as the only recurrent aberrations in those 
regions. Although Aalto et al. found that loss of chromosome 6q is associated with decreased 
survival 17, it is described that abnormalities on chromosome 6 resulting in a relative increase of 
6p material are associated with a better prognosis. 16 Also the clinical characteristics indicated a 
relatively good prognosis. Choroidal localization, spindle cell type, absence of vascular patterns 
and low mitotic activity all correlate with a better prognosis. 23-25 Only gender of the patient 
and the relatively large size of the tumor contribute negatively to prognosis. This is, overall, 
in agreement with the fact that the patient is still alive after 4 years of follow-up whereas UM 
mortality peaks at 2-3 years after treatment. 26 Furthermore, in gene expression profiling, the 
tumor showed a gene expression profile corresponding to Class 1, described by Onken et al. 
and Tschentscher et al. 27,28 to be the UM class related with a better prognosis and disomy of 
chromosome 3 (data not shown). It is very likely that an oncogene involved in UM development 
is located on the demarcated region on 6p ranging from 6p21.3 to the telomeric region and that 
one or more tumor suppressor genes likely to be important in UM development are located in the 
region of 6q16.1 to 6q22. Apparently, genes on the both regions are involved in tumor intitiation 
and development rather than with progression. This possibility is supported by the findings on 
three other tumors in our archive. These UMs, described by Naus et al. (2002) as EOM 141, 
EOM 150 and EOM 182, have gains and losses of considerably larger regions of chromosome 
6 compared to the subject of this study, with no numerical abnormalities on chromosomes 1, 
3 and 8 and until now, none of these patients did develop metastatic disease. 29 Also in other 
studies UMs with large structural abnormalities on chromosome 6 without abnormalities on 
chromosomes 1p, 3 and 8 are described. 30-32  
The region on 6p spans approximately 35 megabasepairs and is therefore too large to point out 
candidate oncogenes. HLA genes, which are located on this region of chromosome 6p, have 
been described to play a role in UM. 33,34 In addition, the gene expression signature reported by 
Tschentscher et al. (2003), that was based on classification of UMs in classes with and without 
monosomy of chromosome 3 respectively, contains 3 genes located in of the region on 6p that 
we describe in this report, namely HCGIV.8, ALDH5A1 and TFAP2A, all with a higher expression 
value in tumors with disomy of chromosome 3. 27 Interestingly, the developmentally regulated 
activator of transcription TFAP2A (transcription factor AP2-Alpha), was also present in the micro 
array classifier created by Onken et al. (2004). 28 Gain of 6p in tumors has not previously been 
described to correlate with increased survival. In other malignancies gain of 6p correlates with 
decreased survival. 35 In UM, the frequently occurring event of 6p gain most likely contributes to 
tumorigenesis and not progression.
This study indicates that one or more tumor suppressor genes likely to be important in UM 
development are located in the region of 6q16.1 to 6q22. Partial or complete deletions of 
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chromosome 6q are also frequently found in other types of tumors. The region found in this 
study partially overlaps with smaller regions found in prostate cancer, ovarian cancer and more 
than one region found in breast cancer and lymphoproliferative disorders. 12,13,36-41 In malignant 
cutaneous melanoma a large region with highest frequency of LOH ranging from 6q22 to 6q27 
was identified and this loss is significantly associated with poor prognosis. 11,14 In contrast, in 
prostate cancer, ovarian cancer and breast cancer 6q loss occurs with a high frequency, but no 
relation with prognosis is observed, indicating a role in tumor development but not in tumor 
progression. The region of 32 Mb demarcated in this study is still considerably large and contains 
numerous genes, for example EphA7, AIM1 and CCNC that could function as tumor suppressor 
genes. The Eph tyrosine kinase receptor Epha7 is found to be downregulated in colorectal 
cancers 42 and is shown to be part of a regulatory system for apoptosis in neural progenitors. 
Loss of Epha7 expression caused a reduction of apoptosis in vivo. 43 AIM1, absent in melanoma 
1, was found not to be expressed in tumorigenic cell lines, but highly expressed in suppressed 
melanoma cell lines. 44 CCNC, the cyclin C gene active in the G1-phase, is frequently deleted in 
leukemias and described to have decreased expression in papillary carcinoma. 45,46 
In addition to the even smaller regions of overlap on chromosome 3p identified by Cross et 
al. (2006) 47, the partial deletion on chromosome 6q is the smallest demarcated region on 
chromosome 6 in UM until now and will be very helpful in the search for candidate tumor 
suppressor genes involved in development and progression of UM, which also accounts for 
candidate oncogenes in the amplified region on chromosome 6p. Both regions will help to get a 
better understanding of UM development. 
In addition to the even smaller regions of overlap on chromosome 3p identified by Cross et 
al. (2006) 47, the partial deletion on chromosome 6q is the smallest demarcated region on 
chromosome 6 in UM until now and will be very helpful in the search for candidate tumor 
suppressor genes involved in development and progression of UM, which also accounts for 
candidate oncogenes in the amplified region on chromosome 6p. Both regions will help to get a 
better understanding of UM development.
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Objectives of this work
In uveal melanoma a number of clinical and histopathological prognostic parameters have been 
described. 1, 2 Furthermore, certain chromosomal aberrations were found to have a prognostic 
value. 3-5 However, none of these factors were discriminative enough and the described 
prognostic chromosomal regions were relatively large, containing numerous genes. The aim of 
this thesis is to tackle both issues by developing a more reliable prognostic set of parameters 
based on a further delineation of prognostic relevant chromosomal regions complemented with 
gene expression analysis. 
Prognostic signature of Uveal Melanoma based on gene-expression profiling 
data
Micro array-based gene expression analysis is an important tool in current cancer research that 
can be used to predict prognosis and for improved understanding of the genetic pathways leading 
to tumor development and progression. We and others have used this approach to develop 
classifiers to discriminate tumors with for example a high risk of systemic tumor spread.6, 7 These 
studies, including our own analysis described in chapter 2, indicate the existence of two distinct 
molecular classes in primary uveal melanomas and we developed gene expression classifiers for 
disease-free survival and for unsupervised tumor class. The tumor class signature correlates with 
known prognostic markers and has strong prognostic value, outperforming all known prognostic 
indicators for uveal melanomas (HR 7.7, p<0.001). Despite the fact that in the comparable 
studies different gene-sets were identified, we were able to show that with our gene-set of 
32 genes we could identify the same two separate tumor categories Class 1 correlates with a 
better prognosis and class 2 with a poor prognosis; (Class 1: sensitivity 1 and specificity 0,94; 
class 2: sensitivity 0,93 and specificity 1, respectively). The genes that are most differentially 
expressed in the micro-array classifier, predictive of tumor class, can be used in rapid diagnostic 
screening with Real-Time PCR. With this method, a small number of genes can be analyzed 
in high-throughput screening.8 This will allow the application of recently collected micro-array 
knowledge in a diagnostic setting. Since it has been shown that tumor class can be predicted 
from fine-needle aspirate biopsies (FNAB)s, a more accurate and possibly eye-sparing prognostic 
screening has now become possible.9
Pathway analysis of Uveal Melanoma based on gene-expression profiling data
To unravel the molecular basis of uveal melanoma development and progression the differential 
expression between sub-groups was estimated in Significance Analysis of Micro arrays (SAM) 
implemented in Omniviz according to the principles of Tusher. 10 All comparisons were made 
using our extensive patient database containing follow-up, histo-pathological, clinical and 
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cytogenetic data. The data were explored using Ingenuity Pathways Analysis, a Web-based 
application that enables the discovery, visualization, and exploration of interaction networks with 
significantly changed gene expression in micro array data sets. When looking at the significance 
of functions and diseases, we did not find any significant functions in the SAM dataset based 
on tumor micro array class. The groups that were analyzed originated from unsupervised 
hierarchical clustering, resulting in two groups that have the most opposing gene expression 
profile, Therefore, there are many different genes in many different pathways and functions 
that discriminate between the two groups, irrespective of biological functions and pathways. 
Ingenuity function analysis compares the percentage of associated genes in each specific function 
group with the percentage of associated genes in total, which makes it unlikely that one specific 
function will reach significance.
However, when we looked at the most significant functions in the data of SAM analysis on 
disease-free survival with 4 years as the cut-off value, the most significant deviant biological 
functions are cell cycle, cellular assembly and organization, embryonic development, DNA 
replication, recombination and repair, lipid metabolism and small molecule biochemistry, all with 
a –log(significance) value of 0.0015. 
This indicates that tumors in the poor DFS group in general have higher mitotic and metabolic rates, 
an up-regulated DNA-repair mechanism and upregulation of a number of apoptosis mediating 
genes and also have a number of unregulated genes that are involved in the development of 
metastases, like Col18A1, HTATP2, MAPK1, PTPRA and STAT6. This is in line with what could 
be expected from tumors in a poor prognosis group, and it partly explains why these tumors 
are more prone to develop metastatic disease than tumors in the better prognosis group. The 
data are indicative of faster tumor growth, a higher incidence of chromosomal aberrations and 
up regulation of genes involved in migration and the development of metastases in the poor 
prognosis group, all typical for a more aggressive phenotype. The initiation of this aggressive 
signature, however, remains concealed with this approach. 
Prognostic parameters
In this thesis, we have re-assessed a number of clinical and histopathological known predictors 
of UM survival in a prognostic analysis that also included chromosomal changes. The single 
prognostic factors were analyzed in a univariate and a multivariate setting. Loss of chromosome 
3, largest tumor diameter, gain of chromosome 8q and a mixed/epitheloid cell type were the 
only significant predictors of poor survival in univariate analysis. The significance of monosomy of 
chromosome 3, largest tumor diameter and cell type did not alter when correcting for possible 
confounders. Of this set of prognostic markers, loss of chromosome 3 is widely accepted as 
the most reliable prognostic parameter. One of the findings described in this thesis is that when 
this loss is accompanied by loss of chromosome 1p, disease-free survival chances are further 
decreased, with a HR of 7.8 (p<0.001) of developing metastatic disease. Micro array classification 
has a HR of 7.7 (p<0.001). The major difference between the parameters micro array class 
and concurrent loss of chromosomes 1p and 3 is that with micro array classification the poor 
prognosis group encompasses 50% of all patients, instead of only one fifth of all patients with the 
chromosomal predictor. In other words, micro array classification has a strong predictive value 
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for a highly increased risk in a larger number of patients. The combination of concurrent loss of 
chromosome 3, epitheloid cell type and micro array class 2, the three most significant individual 
predictors for poor prognosis, results in an almost ten times higher risk of developing metastatic 
disease for 37% of all patients in the analyzed cohort. When additional parameters are added 
to the analysis, like loss of chromosome 1p, the relatively small size of the total cohort of 46 
patients that were analyzed on micro-arrays results in rather small sub-groups of patients that 
lack statistical power. It would therefore be of great interest to use the expression based classifier 
gene set to determine array class in an additional series of patients, preferably by micro-array 
analysis of more UMs, which will also lead to more data on affected pathways, or by analysis with 
the relatively cheap and fast technique of Quantitative Real-Time PCR. This will lead to a larger 
patient cohort, in which more prognostic parameters can be combined, resulting in a very strong 
prognostic prediction for groups of patients. In that context, the finding that we could classify 
all patients in our study to the correct class with only the top four predicting genes opens great 
perspectives for a rapid prognostic class prediction using real-time PCR. 
Chromosomal regions
Earlier studies have revealed prognostic significant chromosomal regions of gain and loss in uveal 
melanoma. The most frequently affected chromosomes are chromosomes 1, 3, 6 and 8. We and 
other research groups have published data on the smallest recurrently affected chromosomal 
regions, (summarized in fig. 1-4 of the introduction) and together with the experimental research, 
described in chapters 2-8 of this thesis, a few remarkable observations can be made. 
Improvement of diagnostic FISH probe set
Loss of chromosome 3 is the most frequent adverse event in uveal melanoma. Combined 
delineation studies revealed smaller regions of deletion on both arms. The combined results 
of different studies, including our studies described in chapters 6 and 7 of this thesis, show 
different demarcated regions. However, a region ranging from 3q25.1 to 3q26.1 is involved 
in most studies and our routinely used diagnostic FISH probe RP11-64F6 maps to this region. 
Two regions on the p-arm of chromosome 3 showed decreased expression in UMs with short 
survival, 3p12-3p14.1 and 3p23-3p25.3 (chapter 2). These regions overlap with the regions 
described by Cross et al. and Parrella et al.11, 12, resulting in common regions of 3p12-3p14.1 and 
3p25.1-3p25.2. Because of the strong relation of gene expression on those regions with survival 
and the finding that these regions of significantly decreased gene expression overlap with SROs 
of frequently deleted genomic regions in UM, it is important to include these 3p regions in the 
routine diagnostic FISH-panel in our laboratory, which currently only includes the q-arm and the 
centromere of chromosome 3. 
The FISH probe that we currently use as a diagnostic probe on chromosome-arm 6q, 
RP11-787I22, is located in the middle of the smallest region of overlap (SRO) ranging from 
6q16.3 –6q23 that results from different studies on uveal melanoma, together with the region 
described in chapter 8. The diagnostic probe on chromosome-arm 6p, RP11-356B3, is located 
slightly outside the smallest overlapping region of amplification described in chapter 8 of this 
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thesis (6p22.3 –p25.3). Since amplifications on chromosome-arm 6p in almost all cases include 
the tip of the chromosome, extension of the diagnostic FISH set with a more telomeric probe on 
chromosome-arm 6p is urgently needed.
The findings described above have lead to a proposal for a renewed set of diagnostic FISH probes, 
including probes on chromosome-arm 3p and a new 6p probe, mapping to the subtelomeric 
region of chromosome-arm 6p. The locations of the current and suggested probes for FISH for 
routine diagnostic screening of UMs are listed in table 1. This improved FISH panel will increase 
the sensitivity since it includes the analysis of additional important regions.
Chromosomal location Current diagnostic 
probe set
New diagnostic 
probe set
Chromosome 1 1p36 1p36
Chromosome 3
3p25.1
3p13
#3 #3
3q24 3q24
Chromosome 6
6p22 6pter
6q21 6q21
Chromosome 8
8p11 8p11
#8 #8
8q24 8q24
Table 1. Current and suggested locations for the diagnostic FISH probes
Role of chromosome 8 alterations 
Our expression studies showed that genes on the whole long arm of chromosome 8 were 
expressed at higher levels and genes on 8p were expressed at lower levels in tumors with a short 
survival time. In our genomic studies we observed that both loss of 8p and gain of 8q are strongly 
related to loss of chromosome 3, whereas gain of 8p is not related with loss of chromosome 3 
(chapter 3). Apparently, iso-chromosome formation of the long arm of chromosome 8, and not 
gain of an entire chromosome 8 copy contributes to a poorer prognosis of UM patients. As a 
validation of this hypothesis, Kaplan Meier survival analysis of patients in our database showed 
a significant poorer survival for patients with either iso-8q formation, or, when karyotyping was 
not possible, concurrent loss of chromosome-arm 8p and gain of 8q, when compared with gain 
of an entire chromosome 8. The log-rank significance of this difference was 0.029 (fig.1). This 
suggests that both loss of chromosome-arm 8p and gain of chromosome-arm 8q are important 
in tumor progression.
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Candidate genes in common deleted and or amplified regions 
In this thesis the strong negative effect on prognosis of concurrent loss of chromosome region 
1p36 and chromosome 3 is described (chapter 3). In the search for a possible candidate gene 
responsible for the adverse effect of chromosome 1p loss in uveal melanoma, we have studied 
expression and performed copy number analysis of one particular gene in this region, APITD1. 
Although expression of this gene, that contains an apoptosis-inducing domain, is affected 
in neuroblastoma, its expression is not related with survival or DNA copy number in uveal 
melanoma. Therefore, another gene must be responsible for the adverse effect of 1p loss. The 
gene TP73, also located on chromosome 1p36, was studied in a differential expression study and 
revealed increased expression of the dominant negative p73∆ex2 transcript in tumors with loss 
of chromosome 1p. This suggests a role of this gene in uveal melanoma (Kilic et al., submitted). 
13 Other interesting candidates could be UBE4B, IF1B, PGD, DFFA and PEX14, which are down-
regulated in neuroblastomas with poor prognosis and belong to the same cluster of genes to 
which APITD1 belongs. 14
The affected regions on chromosome 3, described in chapter 6 of this thesis, harbor potential 
tumor suppressor genes. Candidates on the 3p region are THRB and RARβ2. The human THRB 
locus acts as a transcriptional activator and silencer. Aberrant expression and/or mutations in 
THR genes could be associated with carcinogenesis. Decreased levels of the receptor RARβ2 are 
associated with malignancies, like breast tumors, lung cancer and squamous cell cancer of the 
head and neck.15 As addressed in chapter 2, also MITF is a promising candidate gene since it is 
located in one of the regions on chromosome-arm 3p with lower expression in UMs of patients 
with a short survival time.
Figure 1. Kaplan-Meier survival analysis of UM patients with tumors presenting with gain of chromosome 8 
or isochromosome formation of chromosome-arm 8q. Dashed line: tumors with gain of an entire chromosome 8; 
solid line: tumors with presence of 8q iso-chromosomes.
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In addition, the gene expression classifiers described by Onken et al. and Tschentscher et al. 
harbor two genes mapping to the 3p region, NR1D2 and RPL15, and three genes mapping to the 
3q region, PIK3R4, EIF2A and KIAA0678. 6, 7 In particular, these 3p genes are excellent candidates 
for future analysis. 
The deleted region on chromosome-arm 6q described in chapter 8 of this thesis contains many 
genes, with among them the candidate tumor suppressor genes EphA7, AIM1 and CCNC. In 
addition, three genes of the gene expression classifiers described by Onken et al. and Tschentscher 
et al. map to the amplified 6p region described in chapter 8, namely HCGIV.8, ALDH5A1 and 
TFAP2A. 6, 7 
Abnormal expression of genes in poor prognosis uveal melanomas could, besides chromosomal 
aberrations, also be caused by epigenetic mechanisms like methylation of gene promoter regions. 
Blocks of genes with lower expression in particular chromosomal regions without deletions could 
indicate epigenetic mechanisms of regulation of gene expression in uveal melanoma. Previously, 
promoter methylation has been identified as the mechanism responsible for lower expression 
of the classifier gene TIMP3 in uveal melanoma. 16 In addition, methylation of RASSF1A has been 
shown to be a sensitive prognostic marker for prognosis in uveal melanoma. 17 Therefore it is 
interesting to look at the methylation status of genes in prognostic relevant regions of uveal 
melanoma in tumors of patients with a poor survival and without chromosomal aberrations 
of those regions. It could well be that the promoter regions of genes in those regions have 
abnormal methylation patterns in these tumors. Epigenetic studies would, therefore, lead to 
a better understanding of the genetic and epigenetic mechanisms underlying decreased and 
increased expression of genes associated with poor prognosis in uveal melanoma.
Future developments and new directions
Global screening of the tumors with high resolution techniques will provide more knowledge 
on the involved chromosomal areas in uveal melanoma. In particular the development of Single 
Nucleotide Polymorphism (SNP) micro arrays is very promising, since it allows a rapid high 
resolution screening of both copy number and the number of different alleles in one single 
run. In a recent SNP analysis study from Onken et al. it was shown that loss of heterozygosity 
screening provides a stronger prognostic marker for uveal melanoma than monosomy of this 
chromosome. 18 The combination of screening for the presence of different allelic variants and 
screening for copy number using SNP micro arrays offers the opportunity to further delineate 
the critical chromosomal regions in UM. This approach has already proven its advantages in a 
large scale study on childhood acute lymphoblastic leukemias, in which the frequent mutation 
of genes encoding transcription factors important for B cell development, was detected by SNP 
micro array analysis.19 Also, the findings in a large breast cancer study, in which SNPs in five novel 
independent loci that exhibited strong and consistent evidence of association with breast cancer 
were found, underline the value of large-scale SNP analysis in tumors. 20 Although for this kind of 
studies large numbers of case and control samples have to be included to identify true candidate 
SNPs, these findings open wide perspectives for high resolution SNP analysis in other types of 
tumors.
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About 5 years ago another new high-throughput method has been developed for genetic 
screening. This method, called Multiplex ligation-dependent probe amplification or MLPA, 
allows determination of copy number presence of up to 60 sequences in one reaction, thereby 
enabling a rapid screening of a series of DNA samples.21 The technique is very promising for 
UM, now that the prognostic relevant regions become more and more specified. There are 
also possibilities for MLPA to be applied in tumor gene expression screening and tumor DNA 
methylation. 22, 23 Methylation of cytosines in CpG dinucleotides forms the main epigenetic 
modification in humans.24 In cancer the amount of methylated CpG dinucleotides is often aberrant 
compared to normal tissues, resulting in uncontrolled gene expression levels.25, 26 As mentioned 
above, in uveal melanoma hypermethylation plays a role in abnormal expression of the p16 gene, 
as well as for RASSF1 and TIMP3. 16, 17, 27 It would be interesting to look at the methylation status of 
genes in uveal melanomas of patients with a poor survival and without chromosomal aberrations 
of the prognostic relevant regions. 
However, with regard to these high-throughput methods one has to keep in mind that an 
average signal of the specimen is measured. It is known that there are interesting UM cases that 
display a heterogenic pattern of morphological and chromosomal abnormalities. With respect 
to chromosomal abnormalities, in our tumor collection, there are UM cases found that display 
monosomy of chromosome 3 in one region, whereas retention of both alleles is found in other 
parts of the same tumor (unpublished data, personal communication H.W. Mensink). It would be 
interesting to further investigate to what extent intratumoral heterogeneity plays a role in UM 
and to study the prognostic value of smaller sub clones with loss of chromosome 3. If smaller sub 
clones are indeed important for patient survival chances, the new micro array-based techniques 
and multiplex analysis, in spite of their impressive high-throughput capacities, cannot replace the 
established karyotyping and FISH techniques, which allow analysis of single nuclei and thereby 
also smaller tumor subclones. However, a retrospective study has indicated that UMs can be 
classified correctly from the gene expression profile obtained from FNABs. 9 Although these 
findings have to be confirmed in a prospective study, this suggests that gene expression profile 
is relatively constant throughout the tumor. This opens doors for diagnostic and prognostic 
screening on FNABs.
In the gene-expression profiling study described in chapter 2, LAP analysis was successfully used to 
identify chromosomal regions with differential expression. Next to the regions on chromosomes 
3 and 8, a number of smaller regions were identified on chromosomes less frequently involved 
in UM. These regions might provide interesting starting points for future investigations. LAP 
analysis can be applied relatively easy to existing micro-array datasets to pinpoint chromosomal 
regions that are critical in malignant processes, both for tumor initiation and tumor progression. 
Therefore, LAP analysis could also be very useful in studies on other types of tumors.
Complementary to the screening at the DNA and RNA level, gene expression profiling has offered 
a number of candidates for immunohistochemistral approaches in UM, both for diagnostic/
prognostic and for therapeutic purposes. In our tumor-class prediction signature, there are 9 
genes of which the protein products are located at the plasma membrane. This makes it possible 
to screen for expression of those proteins and to assay their possible use as therapeutical targets 
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when their protein expression is found to be tumor specific and high enough for detection. A 
very promising pathway to study therapeutical purposes is the interaction of MSH with the RAS 
pathway. MSH, that also induces expression of the MITF1 gene described in chapter 2 of this 
thesis,28 binds to the MC1 receptor on melanocytes. This leads to accumulation of cAMP and PKA 
dependent activation of BRAF. Eventually, Ras/raf signaling results in ERK activation. Subsequently, 
ERK is able to activate transcription factors that in turn regulate various functions under which cell 
cycle control and proliferation and pigment synthesis. Since cutaneous melanoma is characterized 
by loss of the p16 encoding gene (CDKN2A) and activation of the RAS pathway,29, 30 it could well 
be that in uveal melanoma this pathway is critical in tumor development and thereby becomes 
a potential target for tumor treatment. In the pathway analysis of our gene expression data, Erk 
expression was found to be upregulated in both tumors classes, however only in class 2 tumors 
also Braf expression is increased. Perhaps activation of BRAF, plays a critical role in the poor 
survival of patients suffering from class 2 tumors specific. 
The importance of the work described in this thesis is not only the development of a new 
prognostic parameter and the delineation of already known prognostic relevant regions, but it 
also provides new opportunities for rapid prognostic screening as well as possible targets for 
anti-cancer therapy. Furthermore, the data generated by gene expression profiling provides new 
insights in the molecular biological behavior of uveal melanoma, which will ultimately lead to a 
better treatment of this disease. 
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Chapter 10
Summary
Uveal melanoma (UM) is the most common primary tumor in the eye with an incidence of 
approximately 7 per million every year in the Western World. The clinical outcome of patients 
with uveal melanoma depends on the development of metastases. A number of clinical and 
histopathological parameters have been described to predict for outcome of the disease. Also 
cytogenetic prognostic factors are reported. Previous studies from our group and others have 
shown that the most frequent aberrations, seen in UM, are loss of 1p36, loss of chromosome 3, 
abnormalities of chromosome 6 and gain of chromosome 8 or 8q. The use of only clinical and 
histopathological parameters is not conclusive enough; even in combination those parameters 
cannot provide a sound estimation of prognosis. Therefore it is of great importance that also 
cytogenetic prognostic factors are included in the establishment of a patients’ prognosis. Several 
studies have focused on the delineation of commonly affected regions on chromosomes 1, 3, 
6 and 8 in UM. This thesis describes different genomic and cytogenetic approaches to make 
advances in prognostic screening of UM and to provide new insights in the search for candidate 
genes, responsible for tumor initiation and development, and possible targets for therapy. 
In the first part of this thesis (chapter 2), a gene expression study of uveal melanoma performed 
with micro array technology is described. The existence of two distinct molecular classes in 
primary uveal melanomas is confirmed and the development of two gene-expression classifiers 
that predict for disease-free survival and for micro-array class is described. The results indicate 
that micro-array classification outperforms known prognostic indicators for uveal melanomas, 
such as cytogenetic abnormalities. In addition, two regions on chromosome-arm 3p were found 
to have decreased gene expression in tumors with shorter disease-free survival. Those regions 
likely harbor genes responsible for the poor prognosis of UM patients with chromosome 3 loss. 
In the second part, described in chapters 3 and 4, studies on different clinical and cytogenetic 
analyses of uveal melanoma and findings on correlations of a range of parameters with prognosis 
are described.
Chapter 3 describes a study in which the cytogenetic changes were correlated with clinical and 
histopathological parameters. The karyotypes of 74 primary uveal melanomas were analyzed, 
resulting in identification of the most frequent chromosomal abnormalities involved in uveal 
melanoma: chromosome 8 (53%); loss of chromosome 3, p-arm (41%) and q-arm (42%); 
partial loss of chromosome 1, p-arm (24%); and abnormalities in chromosome 6 that resulted in 
gain of 6p (18%) and/or loss of 6q (28%). In univariate analysis, monosomy 3 and largest tumor 
diameter were the most significant in determining survival of patients with uveal melanoma in 
this study, in which gene expression-based uveal melanoma class was not included. 
Chapter 4 describes the investigation of independent numerical changes in chromosomes 1, 
3, 6, and 8 on disease-free survival (DFS) in tumors of 120 uveal melanoma patients. Univariate 
analysis, loss of chromosome 3, gain of 8q, largest tumor diameter and the presence of epitheloid 
cells were associated with a decreased DFS. Multivariate analysis showed that the effect of 
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monosomy 3 on survival was strongly affected by changes in 1p36. Of all chromosomal changes, 
only the concurrent loss of the short arm of chromosome 1 and all of chromosome 3 was 
an independent prognostic parameter for disease-free survival (P < 0.001). Therefore, the 
conclusion of this part is that in uveal melanoma, concurrent loss of the short arm of chromosome 
1 and all of chromosome 3 is an independent and strong predictor of decreased DFS.
The third part of this thesis focuses on studies of critical regions and genes in uveal melanoma, 
aiming on further delineation of the critical regions in uveal melanoma, which will lead to the 
identification of genes that are critical in uveal melanoma. 
Chapter 5 focuses on a candidate tumor suppressor gene called APITD1 that is located on 
the critical region on chromosome-arm 1p. It was hypothesized that lower expression levels 
of this gene could lead to decreased survival in patients with concurrent loss of a region on 
chromosome-arm1p and chromosome 3. We have found that expression of APITD1 mRNA 
was not related to DNA copy number (p=0.956) or chromosome 3 status (p=0.958). Kaplan-
Meier survival analysis showed very similar survival curves for tumors with high and low APITD1 
expression with a log-rank significance value of p=0.9682. These results indicate that APITD1 is 
not the tumor suppressor gene on 1p36 responsible for the negative prognostic effect in uveal 
melanoma with concurrent loss of chromosomes 1p36 and 3.
Delineation studies of chromosome 3 in uveal melanoma are described in chapters 6 and 7. 
Chapter 6 outlines the demarcation of partial losses of chromosome 3 in a uveal melanoma 
cell line, Mel270, which is derived from a primary tumor. LOH and FISH studies revealed a 
chromosome 3q deletion ranging from 3q21.2-3q24 in Mel270 and the cell line OMM2.3 that 
was derived from one of the metastases of the same primary tumor. In addition, a region of 
possible allelic loss, mapping to 3p24, was found in these cell lines. Since allelic loss could not 
be confirmed by FISH, this could point to a hemizygous region. These results contribute to a 
further demarcation of candidate regions for tumor suppressor genes on chromosome 3 in uveal 
melanoma.
Chapter 7 considers a delineation study of chromosome 3 by investigating tumors with partial 
chromosome 3 losses using FISH and CGH. This study led to demarcation of a region that spans 
from the centromere to approximately 3q26.2. Interestingly, all patients in our cohort with UMs, 
presenting with partial deletions of chromosome 3, involving the q-arm only, did not die from the 
disease. Apparently, poor prognosis in UM patients is not caused by loss of the 3q region only.
Chapter 8 describes a delineation study on chromosome 6. In an interesting UM case, karyotyping 
and FISH analysis revealed a deleted region on chromosome 6q that was further delineated to a 
region ranging from 6q16.1 to 6q22 using CGH and FISH analysis. Furthermore, a region of gain 
spanning from 6pter to 6p21.2 was also demarcated with CGH and FISH. No other deletions 
or amplifications on recurrently involved chromosomes were found in this patient. This study 
indicates the presence of one or more tumor suppressor genes on chromosomal region 6q16.1-
6q22 and the presence of one or more oncogenes on chromosomal region 6pter-6p21.2, which 
are likely to be important in uveal melanoma and probably also in other tumors. 
In chapter 9 the findings of this thesis and future directions of uveal melanoma research are 
discussed. The work described in this thesis has led to a further delineation of chromosomal 
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regions that are of importance in uveal melanoma development. In addition, it is shown that 
molecular class based on gene expression profile and concurrent loss of chromosome-arm 1p 
and chromosome 3 are the most significant predictors for poor prognosis in UM patients.
Samenvatting
Oogmelanomen zijn de meest voorkomende primaire tumoren in het oog met een incidentie 
van ongeveer 7 per miljoen per jaar in de Westerse wereld. De klinische afloop van de ziekte 
hangt af van de ontwikkeling van metastasen. Een aantal klinische en histopathologische 
parameters zijn beschreven waarmee de prognose voor een oogmelanoom patiënt bepaald kan 
worden. Ook van enkele cytogenetische parameters is een prognostische waarde beschreven. 
Eerder onderzoek door onze en andere onderzoeksgroepen heeft aangetoond dat de meest 
voorkomende chromosomale afwijkingen in oogmelanomen bestaan uit het verlies van 
chromosoom-arm 1p36, verlies van chromosoom 3, afwijkingen op chromosoom 6 en winst 
van chromosoom-arm 8q. Het gebruik van enkel klinische en histopathologische parameters is 
niet conclusief genoeg, aangezien met deze parameters zelfs in combinatie niet met voldoende 
zekerheid de overlevingskansen voor een oogmelanoom patiënt kunnen worden voorspeld. Het 
is daarom van belang dat ook cytogenetische factoren worden meegenomen in de bepaling van de 
prognose voor een patiënt. Verscheidene eerdere studies hebben zich gericht op de afbakening 
van gemeenschappelijk betrokken chromosomale regio’s op de chromosomen 1, 3, 6 en 8. Dit 
proefschrift beschrijft verschillende genomische en cytogenetische benaderingen om vooruitgang 
te boeken in de prognostische screening van oogmelanomen en het verwerven van nieuwe 
inzichten in de zoektocht naar kandidaat-genen, welke verantwoordelijk zijn voor de initiatie van 
oogmelanomen en de ontwikkeling ervan, en naar mogelijke targets voor behandeling.
In het eerste gedeelte van de thesis (hoofdstuk 2), wordt een gen expressie studie op 
oogmelanomen beschreven, waarbij gebruik is gemaakt van micro array technologie. Het bestaan 
van twee verschillende moleculaire klassen bij oogmelanomen wordt bevestigd en de ontwikkeling 
van twee gen expressie classifiers indicatief voor ziekte vrije overleving en moleculaire micro 
array klasse wordt beschreven. De resultaten geven aan dat micro array classificatie een betere 
prognostische marker vormt dan andere bekende prognostische markers bij oogmelanomen, 
zoals cytogenetische parameters. Verder zijn twee regio’s op chromosoom-arm 3p gevonden 
waarvan de genexpressie significant verlaagd is in tumoren met een kortere overleving. Deze 
regio’s bevatten waarschijnlijk genen die verantwoordelijk zijn voor de slechte prognose van 
oogmelanoom patiënten met verlies van chromosoom 3.
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Het tweede gedeelte van dit proefschrift, beschreven in hoofdstukken 3 en 4, beslaat studies 
naar verschillende klinische en cytogenetische factoren in oogmelanomen en de bevindingen 
over correlaties van een reeks parameters met de prognose.
Hoofdstuk 3 beslaat een studie waarin cytogenetische veranderingen worden gekoppeld aan 
klinische en histopathologische parameters. De karyotypes van 74 primaire tumoren zijn 
vergeleken, wat heeft geresulteerd in de identificatie van de meest voorkomende chromosomale 
afwijkingen in oogmelanomen, namelijk chromosoom 8 (53%), verlies van chromosoom 
3, namelijk de p-arm (41%) en de q-arm (42%), verlies van een deel van chromosoom 1 op 
de p-arm (24%) en afwijkingen op chromosoom 6 resulterend in winst van 6p (18%) en/of 
verlies van 6q (28%). In univariate analyse is gevonden dat monosomie van chromosoom 3 
en de grootste tumor diameter de meest significante predictors vormen voor overleving van 
oogmelanoom patiënten in deze studie, waarin tumor classificatie op basis van genexpressie 
profiel niet is opgenomen.
Hoofdstuk 4 beschrijft een onderzoek naar de invloed van onafhankelijke numerieke veranderingen 
op de chromosomen 1, 3, 6 en 8 op ziektevrije overleving in de tumoren van 120 oogmelanoom 
patiënten. In univariate analyse werd gevonden dat verlies van chromosoom 3, winst van 8q, 
grootste tumor diameter en de aanwezigheid van epitheloid cellen geassocieerd waren met 
een verminderde ziektevrije overleving. Multivariaat analyse toonde aan dat het effect van 
monosomie van chromosoom 3 op de overleving versterkt werd door verlies van 1p36. Van alle 
chromosomale afwijkingen, was gezamenlijk verlies van chromosoom 3 en chromosoomregio 
1p36 de enige onafhankelijke prognostische marker voor ziektevrije overleving (P<0.001). De 
conclusie van dit gedeelte is dan ook dat het gecombineerde verlies van chromosoom 3 en de 
korte arm van chromosoom 1 een onafhankelijke en sterk voorspellende prognostische marker 
voor oogmelanomen vormt.
Het derde gedeelte van dit proefschrift bestaat uit studies naar kritische regio’s en genen in 
oogmelanomen, met als doel de voor oogmelanomen kritische regio’s te verkleinen, wat zal 
leiden tot de identificatie van genen die kritiek zijn voor oogmelanomen.
Hoofdstuk 5 richt zich op een kandidaat tumor suppressor gen, genaamd APITD1, dat is 
gelokaliseerd in het kritische gebied op chromosoomregio 1p. De hypothese was dat verlaagde 
expressie van dit gen zou kunnen leiden tot een verslechterde overleving bij patiënten met 
gezamenlijk verlies van de kritische regio op 1p en chromosoom 3. We vonden dat expressie van 
APITD1 mRNA niet gerelateerd is aan het aantal DNA kopieën (p=0.956) of chromosoom 3 
status (p=0.958). Kaplan-Meier overlevingsanalyse liet zien dat tumoren met een hogere en een 
lagere APITD1 expressie een vergelijkbare overleving hadden, met een log-rank significantie van 
p=0.9682. Deze resultaten geven aan dat APITD1 niet het tumor suppressor gen is op 1p36 dat 
verantwoordelijk is voor het negatieve effect op de prognose in oogmelanomen met gezamenlijk 
verlies van chromosoom 3 en chromosoomregio 1p36.
Hoofdstukken 6 en 7 behandelen delineatie studies op chromosoom 3 in oogmelanomen.
In hoofdstuk 6 wordt een afbakeningsstudie beschreven van partiële deleties op chromosoom 3 
in een oogmelanoom cellijn, genaamd Mel270, welke is verkregen uit een primaire tumor. LOH 
en FISH analyse duidden op een chromosoom 3q deletie van 3q21.2 tot 3q24 in Mel270 en de 
cellijn OMM2.3, welke is afgeleid van één van de metastasen van dezelfde primaire tumor. 
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Ook werd een regio van mogelijk allelisch verlies gevonden in beide cellijnen, gelokaliseerd op 
3p24. Omdat het allelisch verlies niet bevestigd kon worden met FISH, zou het een hemizygote 
regio kunnen betreffen. Deze resultaten dragen bij aan een verdere afbakening van kandidaat-
regio’s voor tumor suppressor genen op chromosoom 3 in oogmelanomen.
Hoofdstuk 7 betreft een delineatie studie van chromosoom 3 waarbij tumoren met partiële 
verliezen op chromosoom 3 onderzocht zijn met FISH en CGH. De studie heeft geleid tot 
de afbakening van een regio vanaf het centromeer tot ongeveer 3q26.2. Opvallend is dat alle 
patiënten in het cohort met oogmelanomen welke een partiële deletie van chromosoom 3 
bevatten die enkel de q-arm beslaat, niet overleden zijn ten gevolge van metastasen. Het lijkt 
erop dat de slechte prognose in oogmelanoom patiënten niet veroorzaakt wordt door verlies 
van de 3q regio alleen. 
Hoofdstuk 8 beschrijft een delineatie studie op chromosoom 6. In een interessante oogmelanoom 
casus, werd met karyotypering en FISH analyse een gedeleteerde regio aangetoond welke verder 
is afgebakend tot een gebied van 6q16.1 tot 6q22 met CGH en FISH analyse. Ook werd een regio 
van winst van 6pter tot 6p21.2 afgebakend met CGH en FISH. Verder werden geen deleties of 
amplificaties gevonden op vaak in oogmelanomen betrokken chromosomen waargenomen in 
deze tumor. Deze resultaten duiden op de aanwezigheid van één of meer tumor suppressor 
genen in het gebied 6q16.1-6q22 en de aanwezigheid van één of meer oncogenen op de 
chromosomale regio 6pter-6p21.2, welke waarschijnlijk van belang zijn voor oogmelanomen en 
wellicht ook in andere tumoren.
In hoofdstuk 9 worden de bevindingen van deze thesis en mogelijke nieuwe onderzoeksrichtingen 
volgend uit dit proefschrift besproken. Het werk wat wordt beschreven in deze thesis heeft geleid 
tot een verdere afbakening van chromosomale regio’s die van belang zijn in de ontwikkeling 
van oogmelanomen. Verder is in dit werk aangetoond dat moleculaire klasse gebaseerd op gen 
expressie profiel en gemeenschappelijk verlies van chromosoomgebied 1p36 en chromosoom 3 
de meest significante voorspellers zijn van een slechte prognose voor oogmelanoom patiënten.
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List of abbreviations
CGH  Comparative Genomic Hybridization
DFS  Disease-Free Survival
FISH  Fluorescence In Situ Hybridization
FNAB  Fine-Needle Aspiration Biopsy
HR  Hazard Ratio
LAP  Locally Adaptive statistical Procedure
LOH  Loss Of Heterozygosity
LTD  Largest Tumor Diameter
MM  MisMatch
MLPA  Multiplex Ligation-dependant Probe Amplification
PAM  Predictive Analysis of Micro-arrays
PM  Perfect Match
SKY  Spectral KarYotyping
SNP  Single-Nucleotide Polymorphism
SRO  Shortest Region of Overlap
TSG  Tumor Suppressor Gene
UM  Uveal Melanoma 
VSN  Variance-Stabilizing Normalization
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Figure 3, Chapter 2. Whole genome plot of the differentially expressed genes in LAP analysis at a q-value of 
<0.05. The colored perpendicular lines represent the exact chromosomal locations, orientations, and up- (red) or down-
regulation (green) states of the differentially expressed genes, while the white bars indicate locations and orientations 
of all probe sets in the microarray. Positions for both the sense and antisense strands are expressed in numbers of base 
pairs measured from the p (5’ end of the sense strand) to q (3’ end of the sense strand) arms; upper and lower bars 
stand for genes on sense and antisense strands, respectively. A) Differential expression of tumors with monosomy of 
chromosome 3 compared to tumors with normal copy numbers of chromosome 3. B) Differential expression of tumors 
in class 2 compared to tumors in class 1. C) Differential expression of tumors from patients with DFS ≤ 4 years compared 
to tumors from patients with DFS >4 years.
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Figure 3, Chapter 6.
FISH analysis of Mel270.
A: representative results of 
dual color FISH on Mel270 
cells, hybridized with a com-
bination of a chromosome 3q 
probe (red) and a centrom-
ere 3 probe (Pα3.5) (#3) 
(green), except for probe 
RP11-95H16 (green) that was 
combined with a 3pter probe 
(B47A2) (red). Panel A: 3pter 
probe and RP11-95H16; #3 
and RP11-88H10; and #3 and 
RP11-229G6.
B: representative results of 
dual color FISH on Mel270 
cells, hybridized with a com-
bination of a chromosome 
3p probe (red) and a cen-
tromere 3 probe (Pα3.5) 
(#3) (green). Panel B: #3 
and RP11-208G16, #3 and 
RP11-255O19, and #3 and 
RP11-41F5.
Figure 1, Chapter 7. CGH and FISH on case 1. A) Metaphase spread after comparative genomic hybridization with 
tumor DNA labeled in green, reference DNA labeled in red. The arrowheads point to the red regions on the q-arm 
of chromosomes 3 indicating a loss. B) CGH results on chromosome 3 of ten metaphase spreads processed with Isis 
version 5 software. The thick line represents the average signal of the ten metaphases. The lower limit was set as 
green-to-red ratio 0.8, the upper limit as a ratio of 1.2. The partial deletion is indicated with a red bar alongside of the 
chromosome image. C) and D) are images of FISH. C) FISH on isolated nuclei with probes RP11-816J6 (labeled in red) 
and RP11-54L9 (labeled in green) showing the presence of two copies of regions 3q26.2 and 3q28, respectively. D) 
Probes RP11-449F7 (red) and RP11-64F6 (green) showed loss of one copy of chromosome 3 in the regions 3q11.2 and 
3q25.1 respectively.
